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Abstract 
Glioblastoma multiforme are the most challenging of cancers to treat and even with recent 
advances in therapeutic approaches, the prognosis following diagnosis remains poor. Novel 
therapeutic approaches able to target such tumours without resulting in significant toxicity are 
needed. Micronutrients have been shown to exert potential therapeutic effects in cell culture 
and animal models which include anti-cancer activity and other functional properties such as 
anti-microbial and anti-oxidative effects. The aim of thi research was to investigate the anti-
cancer properties of curcumin (77% pure, derived from the ground rhizome of turmeric) and 
LycoRed powder (containing 10% lycopene from tomato extract) on four primary brain 
tumour-biopsy derived cell cultures (glioblastoma multiforme malignant cells) using a normal 
brain cell line as control (CC2565; passage 10 and above).  
The morphological appearance of the normal brain cell line and glioblastoma cell cultures 
was compared under phase contrast microscopy. The cytotoxicity of curcumin and Lycored 
was determined using a DRAQ 7 cell viability assay. Expression of antigens linked to 
invasive, angiogenic and apoptotic potential was studied using immunocytochemistry and 
flow cytometry. Induction of apoptosis was investigated using flow cytometry via Annexin-V 
staining. Anti-invasive and anti-angiogenic potentials were studied using a FluoroBlok 
invasion and angiogenesis assay (co-culture method) in vitro, respectively.  
Brain tumour-biopsy derived cell cultures incubated for 24h with increasing concentrations of 
curcumin showed significant decreased in cell viability (IC75,50,25 values 14.2 to 19.5µg/ml). 
LycoRed was not found to affect the cell viability of tumour cells ad no IC values could be 
established; only curcumin was therefore investigated in subsequent assays (using IC75 
concetration). Neither curcumin nor LycoRed showed toxicity to normal brain cells.  
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No significant induction of apoptosis by curcumin was observed in the primary brain tumour 
cells studied. However, three of the primary brain tumour cell cultures investigated were high 
in invasive capacity and curcumin treatment at IC75 concentration reduced the percentage of 
invasion after only 24 hours of incubation. In addition, curcumin was found to have anti-
angiogenic properties in vitro. In the normal brain cell culture, each parameter (number of 
nodes, junctions and branches) was maintained when treated with increasing concentrations 
of curcumin (0 to 40µg/ml). When all glioblastoma cell cultures and normal brain cells 
showed strong positivity for GFAP confirming that they are astrocytic in origin, expression of 
other antigens studied (Beta-1-integrin, CD44, VEGF, MMP-14, NG2, GD3) varied  between 
the primary brain tumour cell cultures. This suggests that the invasive or angiogenic capacity 
of the gliobalstoma cell cultures investigated may not be attributable to one common factor as 
has been reported before, but perhaps an integration of many factors with overlapping 
functions.  
In conclusion, the results indicate that curcumin may have anti cancer properties through  
inhhibition of invasion and angiogenesis in these malignant glioblastomas. Further studies are 
necessary to establish whether LycoRed possesses therapeutic potential.  
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CHAPTER 1: Introduction 
1.1 Classification of brain tumour 
The World Health Organisation (WHO) classification of gliomas recognizes three 
histological types of infiltrative tumours: the astrocytomas, oligodendrogliomas and mixed 
gliomas tumours (Kleihues, Burger and Scheithauer, 1993; Louis et al., 2007).  They are 
classified histologically according to their degree of malignancy with grades that correlate 
well with survival times.  Derived from glia, malignant gliomas are heterogenous and 
invasive.  Louis et al., (2007) have classified astrocytomas on the basis of histological 
features into four prognostic grades: I (diffuse astrocytoma), II (pilocytic astrocytoma), III 
(anaplastic astrocytoma) and IV (glioblastoma).  This was also described in the Daumas-
Duport grading system (Daumas-Duport et al., 1988) which is based on the histopathologic 
features of the tumour. 
    Tumours are graded from I to IV in increasing malignancy as determined by histological 
appearance.  Four features are assessed: nuclear atypia, mitosis, necrosis and endothelial 
hyperplasia.  Accordingly, Grade 1 lesions have none of these features, Grade 2 lesions have 
1 feature and so on.  Histological classification of gliomas is also based on perceived cell of 
origin plus the suffix “oma”, thus astrocytes give rise to astrocytomas, oilgodendrocytes to 
oligodendrogliomas or ependymal cells to ependymomas.  Neuronal derived tumours, 
however, are less frequent but generally seen in paediatric patients.  Thus, in adults, 
glioblastoma has the most common occurrence and is the most malignant of the gliomas.  
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1.2 Classification of astrocytoma  
60% of all primary brain tumours are neuroepithelial in origin and most of those arise from 
astrocytes.  Also known as gliomas, 75% of astrocytomas are diffusely infiltrative tumours 
and vary from low grade diffuse astrocytomas (grade II) to high grade tumours such as 
anaplastic astrocytomas (grade III) and glioblastoma multiforme (grade IV), the latter having 
the worst prognosis.   
    Pilocytic astrocytoma and pleomorphic xanthoastrocytoma have a more favourable 
prognosis due to their limited invasive capacity and lower capacity for anaplastic progression.  
Glioblastoma is the most common primary brain tumour to occur in adults and results in a 
median survival of less than a year, despite extensive multi-modality approaches in diagnosis 
and management of the patients.  
1.3 Glioblastoma Multiforme  
Gliomas are the most frequently diagnosed central nervous system tumours, representing 
50% of all gliomas.  The most common type of glioma is glioblastoma multiforme (GB) and 
is classified as grade IV (WHO classification).  A glioblastoma, technically known as 
glioblastoma multiforme, is the fastest growing type of astrocytoma, spreads quickly, invades 
nearby normal brain tissue and contains areas of dead cells (necrosis) in the center of the 
tumour.   
    GB is thought to arise from an astrocytic lineage, with the possibility that it originates from 
progenitor cells (Fan, Salford and Widegren, 2007).  Apart from the four features described 
previously all being present, these malignant neoplasms are also characterized by having a 
highly active mitotic rate, being pleomorphic in cellularity and exhibiting the presence of 
multinucleated giant cells.  In GB, pseudopalisade is a constant feature, surrounding the 
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necrotic areas as a result of hypoxia within the tumour bed.  Cells with pseudopalisades may 
serve to promote angiogenesis of the tumour (Pilkington, 2001; Rong et al., 2006; Jain et al., 
2007) by secreting vascular endothelial factor (VEGF). 
1.4 Types of Glioblastoma Multiforme: Primary (de novo) and secondary  
There are 2 forms of GB that are thought to exist biologically.  One of them is the astrocytic 
tumour which progresses from a lower to higher grade, known as secondary GB, and which 
occur in younger patients.   
     The, de novo (primary) form of GB appears in older patients without first presenting as the 
lower grade astrocytic tumour.  Unlike secondary GB, de novo type may involve progenitor 
cells of oligodendrocytes or astrocytes (Gupta, Djalivand and Brat, 2005; Ohgaki and 
Kleihues, 2013; Huang et al., 2014).  For both evolutions, genetic alteration and mutation 
may be involved in the pathways (Fig.1). 
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*Astrocytes (terminally differentiated)        *Oligodendrocyte/astrocytes(progenitor cells) 
17p loss (leads to p53 mutation)                     EGFR amplification and/or over expression 
PDGF-A, PDGFR-a over expression             MDM2 amplification and/or over expression 
 
                                   LOH of 10p and10q, PTEN/MMAC-1 mutation 
• 19q loss 
• 13q, 9p and Rb alteration 
 
 
                                                                                        p16 deletion, Rb alteration 
• LOH of 10p and q 
• DCC loss of expression 
• PDGFR-a amplification 
 
 
Figure 1: Two biological forms of glioblastoma that exist, each with different pathways of 
pathogenesis and possible genetic evolution. Adapted from Pilkington, 2001. 
 
1.5 Incidence of Glioblastoma Multiforme 
Glioblastomas account for 60-70% of malignant gliomas and the incidence has increased over 
the past 3 decades.  Approximately 3,500 cases are reported in UK each year and they 
Low	grade	
astrocytoma	
Anaplastic	astrocytoma	
Secondary	GBM																																																														
Primary	or	de	novo	GBM																																																														
Younger	patients	 Older	patients	
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represent 50-60% of all primary brain tumours.  The incidence in England and Wales is 4 per 
100,000 of the population (NHS, 2001) compared with approximately 5 cases per 100,000 
people in the United States (Wen and Kesari, 2008).  
GB is most commonly observed in adults aged 50 to 70 years and the median age of 
patients with glioblastomas at the time of diagnosis is 64 years, as reported by Wen and 
Kesari, (2008).  Glioblastoma multiforme tends to occur more frequently in males than 
females by a ratio of about 3:2 in America; in the United Kingdom approximately 55% of 
patients with GBs are males.  Burnet (2004) has emphasized life years that are lost, and has 
drawn a picture of the burden of the person affected person by a tumour.  Tumours of the 
central nervous system were reported to account for approximately 20 years of life lost, the 
highest among any other adult tumour type studied.  
1.6 Pathophysiology of Glioblastoma Multiforme 
Arising from glial cells or their precursors within the central nervous system, the tumour 
occurs in the subcortical white matter of the cerebral hemispheres within the corticotemporal 
region of the brain.  In terms of pathophysiology, GB is high in cellularity with poorly 
differentiated and pleomorphic cells (variation in the size and shape of cells or their nuclei) 
with occasional multinucleated cells and presence of mitotic activity.  Besides nuclear atypia, 
GB cells are anaplasic by means of reversion of cells to an immature or a less differentiated 
form, as occurs in most malignant tumours.  A GB also contains areas of microvascular 
proliferation, or necrosis, or both, which differentiates GB from anaplastic astrocytomas 
(AA).   
Furthermore, a GB is extremely complex due to the genetic mutations that occur (Table 1).  
Variants of the tumour include gliosarcomas, giant cell glioblastomas, small cell 
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glioblastomas and glioblastoma with oligodendroglial features. All of these are uncommon 
glioblastoma which, respectively, contain a prominent sarcomatous element, multi-nucleated 
giant cells, are associated with amplification of epidermal growth factor receptor (EGFR) and 
may have better prognosis than standard glioblastomas (Wen and Kesari, 2008).  Of all 
genetic mutations that occur, upregulation of vascular endothelial growth factor (VEGF) 
appears to be of utmost importance. Implicated in angiogenesis (formation of new blood 
vessels), VEGF ligands and receptors exist in extremely high concentrations compared to 
those in lower-grade tumours and even normal brain tissue (Pilkington, 2001; Popescu et al., 
2013). Hence, rapid growth of the tumour is permitted as a result of an increase in vascular 
permeability, endothelial gaps, and fenestrations. 
Table 1: Genetic mutations identified in glioblastoma 
 EGFR: epidermal growth factor, VEGF: vascular endothelial growth factor, MDM2: murine 
double minute, MGMT:methylguanine methyltransferase (Wen and Kesari, 2008). 
 
Mutations Implications  
EGFR Affecting cell proliferations; upregulated in GBM  
VEGF Role in angiogenesis; upregulated in GBM 
p53 deletion Lack in tumour suppression 
MDM2 amplification Binding to p53 thus reducep53 tumour suppressor activity 
MGMT amplification Upregulation in expression contribute to more DNA repair 
activity thus assists tumour to resistance in chemotherapy 
Loss of heterozygosity on 
chromosome 10q 
Associated with poor survival and appears to be  a likely aids 
the development of GBM 
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1.7 Diagnosis of Glioblastoma Multiforme 
A convincing diagnosis is highly dependent on the morphological assessment of the stained 
tissue sections but should also be strengthened by other important perspectives which include 
the clinical presentation, imaging and molecular genetics.  Glioblastoma is rarely seen in the 
spinal cord but frequently seen in the cerebral hemispheres of older adults.  A variety of 
symptoms could be presented clinically and include headaches, seizures, memory loss and 
neurological deficits.  
Neuronal imaging aids in providing essential information for a diagnosis such as the 
tumour site and details of the tumour characteristics.  Thus, knowing about the exact locus of 
the tumour permits appropriate approaches for consideration.  Moreover, enhancement in 
tumour characteristics may raise concerns about the true biological potential of the lesion 
which may not be assessed by other means.  Thus, an ample representative nature of the 
biopsy could be determined and correlates with the histological feature or its microvascular 
proliferation (Kleihues and Cavenee, 2000).   
Imaging techniques such as Magnetic Resonance Imaging (MRI) helps to show a 
heterogeneoustumour mass such as a glioblastoma when the central area of necrosis is 
surrounded with extensive oedema when compared to anaplastic gliomas.  MRI is also 
increasingly used as a diagnostic tool in monitoring the response to therapy as it capable of 
measuring vessel permeability and relativity of cerebral blood volume and hence aid in 
planning of surgery.  Indeed, neuronal imaging reveals the best set of anatomical, 
biochemical and molecular information on a specific tumor and, hence, its use in 
management of patients increases the understanding of the complex mechanism of glioma 
formation, behavior and migration. (Kleihues and Cavenee, 2000).   
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Genetic analysis could be distinctive in showing the genetic subtypes in tumours with the 
same morphology and reveal the probable pathways in tumour progression.  Sequential 
accumulation of genetic aberrations and the deregulation of signaling pathways of growth 
factors could separate glioblastomas into 2 main subtypes and hence aid in the diagnosis.  For 
example, as shown in figure 1, primary and secondary glioblastomas manifest different 
combinations of genetic mutations, and/or amplifications, despite being indistinguishable in 
morphology.   
1.8 Aetiology of Glioblastoma Multiforme 
An increase in the incidence of brain tumours over the past three decades has provoked the 
search for risk factors.  Genetic alterations may permit cells to elude destruction by the 
immune system and evade the regulatory systems.  Apart from molecular mechanisms, other 
sources such as chemical, physical or biological insults may exacerbate glioma-genesis.  
Genetic factors 
A number of familial syndromes are documented which may be associated with an increased 
incidence of brain tumours.  Such inherited syndromes include neurofibromatosis types 1 and 
2, Li Fraumeni syndrome and syndromes involving adenomatous polyps.  Both types of 
neurofibromatosis are associated with GBs other than astrocytomas, but Li Fraumeni 
syndrome is mainly associated with astrocytic tumours and is involved with TP53 mutation 
on the long arm of chromosome 17 (Collins, 2004; Perfister, Hartmann and Korshunov, 
2009).  Indeed, the majority of human cancers are connected to mutation of this tumour 
suppressor gene.  The p53 gene is important in guarding genome stability.  It induces the cell 
cycle arrest at G1 (RNA and protein synthesis) by inhibiting retinoblastoma (RB) 
phosphorylation in the presence of cyclin dependent kinase 4 (CDK4).   
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    p53 also stimulates bax and Fas protein expression in apoptosis induction.  In GBs, about 
30% of the genetic material was found to be lost on 17p.  The allelic loss seems to occur at 
the initial stages of astrocytic tumour development as grade II and III were found to have 
higher genetic loss (Von Deimling et al., 1992; Ohgaki and Kleihues, 2007).  Thus, it was 
suggested that alteration of the p53 gene may have provoked the initial steps of astrocytoma 
tumourigenesis.  
Neurocarcinogens 
Other known risk factors are potential neurocarcinogens such as ionizing radiation, mobile 
phones, dietary additives, immune factors and chemicals.  Radiation has long been suspected 
of increasing cancer incidence but no solid evidence has yet been provided to link radiation 
exposure with brain tumour development (Pilkington, 2001; Yasova et al., 2009).  The use of 
mobile phones has been brought up as a causative role in brain tumour aetiology in the past 
few years.  However, increased risk was only found with the older analogue system; i.e. 
Nordic Mobile Telephony (NMT) system, and not the Global System for Mobile 
communication (GSM), but this remains to be confirmed (Hardell et al., 1999). 
    In addition, attention has focused on aspartame (L-aspartyl-L-phenylalanine methyl ester), 
an artificial sweetener that is widely ingested and present mainly in our diet (soft drinks, 
confectionary etc.).  Aspartame breakdown results in four main components which include 
methanol and formaldehyde, phenylalanine, aspartic acid and diketopiperazine (DKP).  
Nitrosation of aspartame, hence its components, was thought to cause an elevation in brain 
tumour risk by the nitroso-derivative products, by increasing aspartame’s potential 
carcinogenic properties through inducing mutation of tumour suppressor genes.  Pilkington 
(unpublished data) used the Comet assay to show that aspartame does not have an effect on 
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normal brain cells, thereby suggesting that aspartame may not cause tumours.  However, if a 
pre-existing lesion is present, aspartame may speed up the progression of the tumour.   
    In addition, N-nitroso compounds are a group of neurocarcinogens that are present in cured 
meats and other food that have been preserved with nitrite and nitrosamides (Pilkington, 
2001; McKinney, 2004).  Such compounds are also found in green vegetables due to the use 
of crop fertilizers and pesticides.  
Viruses 
A number of viruses have been shown to cause brain tumours in animals but with the 
exception of studies in human immunodeficiency virus (HIV)-related brain lymphomas 
(Gavin and Yogev, 1999; Taiwo, 2000), only a few (Kouhata et al., 2001;  Ceballos-
Salobrena et al., 2000; Corallini et al., 1987b; Ka-Wei et al., 2013) have been reported in 
humans.  In addition, Pilkington (2001) has reported that SV40 (simian virus 40) was 
implicated in brain tumour aetiology in the 1950-1960s but that it was due to SV40 that 
contaminated the polio vaccine being administered.  Indeed, McKinney (2004) reported that 
no virus has been consistently associated with or found in brain tumour tissue.  Therefore, it 
is not definitely proven whether a virus can induce glioma in humans, and this is therefore an 
area that warrants further research. 
1.9 Mortality/Morbidity caused by Glioblastoma Multiforme 
There are many factors which account for the poor survival length for patients diagnosed with 
GB.  Based on biological conditions and prognostic value, patients with GB have an average 
survival of between 9 to 11 months (despite intensive, multimodal treatment), much less than 
with low grade astrocytomas (Grade I-III); i.e. 3 -7 years (Fine, 2006).  Hence, while other 
subtypes give a better prognosis, GB results in the poorest survival for all age groups.  In 
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addition, the survival is known to differ by geographical region and between countries, e.g. in 
England, tumours that are classified as benign would not be registered in cancer registration 
schemes in the same way as they are in the USA.  This results in lower rates of survival being 
recorded in the UK (McKinney, 2004).   
1.10 Biological features of Glioblastomas at a molecular level 
The biological properties of cell populations of intrinsic brain tumours, such as cellular 
heterogeneity and angiogenesis, have made effective treatment of gliomas challenging. 
Multiple processes of differentiation and anaplasia give rise to a heterogeneous cell 
population. Differences in morphology, genetics and immunological characteristics arise 
from the same neoplasm, rendering the tumour mass highly resistant to both radiotherapy and 
chemotherapy (Zhang and Barres 2010).   
    Solid tumour survival is dependent on angiogenesis which is the formation of new blood 
vessels to provide nutrients and oxygen and occurs in the presence of angiogenic factors such 
as VEGF.  Proposed as a primary stimulant, VEGF at even nanomolar concentrations can 
induce microvascular permeability (Folkman and Haudenschild, 1980).   
    The most significant biological feature of GBs that preclude successful therapy is invasion, 
the process by which tumour cells infiltrate the normal brain in a complex way, thereby 
rendering all current forms of therapy ineffective (Bellail et al., 2004).  Various components, 
including cell adhesion molecules (Cluster of differentiation 44, CD44), proteases (such as 
matrix metalloproteinases –MMPS), extracellular matrix (ECM) components and growth 
factors are involved in this multi-step process and are studied as parameters of brain tumour 
invasion.  
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1.10.1 Invasion 
A primary brain tumour is unique in its invasive behaviour as it does not metastasize outside 
of the brain but invades anywhere within the brain as single cells.  In addition, unlike other 
systemic malignant tumours (carcinomas), they have the tendency to infiltrate the blood 
vessels walls along the periphery (but not into the blood vessels walls), subpial glial space or 
white matter tracts (corpus callosum) (Burger and Scheithauer, 1994; Kleihues and Cavenee, 
2000).  There are two important requisites for a malignant neoplasm of haematogenous origin 
(cancers originated from the blood) which allow metastasis and give the cells the capacity to 
invade through blood vessel walls and the lymphatic system for transportation.  However, 
these are absent within the brain, thus may explain the reason why a primary brain tumour 
does not metastasise in nature.  Moreover, primary brain tumours do not invade the bony 
calvarium (bones forming the convexity of the skull, periosteum, and soft tissue coverings) 
unlike other metastatic tumours which invade the calvarium and are also more sharply 
delineated from surrounding brain tissue (Bigner, McLendon, Brunner, 1998).  Primary brain 
tumours are also short distance in invasive capacity and invade as a group of cells rather than 
as single cells.  As a result, invasion is one of the critical prognostic factors for brain tumours 
(besides heterogeneity and angiogenesis) as this is associated with complications in surgical 
excision of the tumour mass in the brain (Bellail et al., 2004).  
    In general, there are 3 steps in the model of invasion described for a variety of malignant 
cell types (Bellail et al., 2004).  Tumour cells (front) detach from the growing primary 
tumour mass and adhere to the extracellular matrix (ECM) via specific receptors.  Tumour 
cells are believed to have the ability to degrade ECM components via matrix 
metalloproteinases, which are secreted by the tumour cells into the microenvironment.  This 
will permit the neoplastic cells to migrate through the ECM and into the adjacent tissue.  
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However, the pathways created by glioma cells may be specific due to the unique 
composition of ECM of the brain (Bellail et al., 2004).  
Glycosaminoglycan hyaluronan is the major component of ECM within the brain, and 
attracts Na+ and other cations required for osmotic influx of water.  A variety of distinct 
proteoglycans are also present within the brain and have functions which include acting as 
de-adhesive proteins, growth factor modulators and cell cycle inhibitors.  However, in the 
brain tumour microenvironment, hyaluronan and many other ECM components are 
upregulated in expression (Bellail et al., 2004).  Changes in proteoglycans such as 
vitronectin, osteopontin, tenascin-C, secreted protein acidic and rich in cystein (SPARC) and 
brain enriched hyaluronic acid binding protein (BEHAB) may modulate the growth, 
proliferation and invasive activity of the tumour mass, but the exact mechanism(s) is yet 
unclear (Higuchi et al., 1993; Zagzag et al., 1996; Shi et al., 2007).  For instance, tenascin –
C, SPARC and thrombospondin were found to be upregulated both within and surrounding 
the blood vessels walls hence suggesting that it has an impact on angiogenic activity (Higuchi 
et al., 1993; Zagzag et al., 1996). 
Moreover, invasion in vivo and migration in vitro was found to be facilitated by an increase 
in hyaluronan (approximately 4 fold) through high expression of CD44 and RHAMM 
(Koochekpour, Pilkington and Merzak, 1995; Akiyama et al., 2001; Kim and Kumar, 2014).  
Indeed, for the invasion to take place, it is critical for the neoplastic cells to interact with the 
ECM via specific receptors expressed on the cell surface (Hood and Cheresh, 2002).  CD44 is 
the principal receptor for hyaluronan and plays a significant role in glioma cell-matrix 
adhesion, cell migration and regulation of tumour growth and metastasis (Ponta, Sherman and 
Herrlich, 2003).  As a transmembrane glycoprotein belonging to the superfamily of 
immunoglobulin receptors, CD44 also has an additional role, a hyaluronan-independent role 
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in cell migration, as it can act as a cell surface anchor for matrix metalloproteinase 9 (MMP-
9) (Yu and Stamenkovic, 1999; Wiranowska et al., 2010).  MMP-9 is one of the significant 
MMPs involved in proteolytic degradation of the ECM in brain tumours and has been 
strongly implicated in glioma invasion by several studies (Rao et al., 1993; Kondraganti et 
al., 2000; ; Murray, Morrin and McDonnell 2004; Hagemann et al., 2010; Kenig et al., 2010; 
Wiranowska and Rojiani, 2011) 
It is necessary for malignant neoplasms to have specific extracellular matrix proteases that 
can degrade the ECM and thus allow invading tumour cells to get through to adjacent sites, 
hence tumour progression.  MMPs are a large, diverse family of endopeptidases and are 
classified based on preferential substrate activity, protein domain similarity and sequence 
homology (Lee and Murphy, 2004).  However, they do not necessarily have the substrate 
specificity as the proteolytic functions may overlap.  Consisting of 25 members, they are 
produced in cells as pro-enzymes and require proteolytic cleavage for activation either by 
MMPs or serine protease (e.g. plasmin). They act as regulators to their inhibitors, tissue 
inhibitor of matrix metalloproteinases (TIMPs).   
Over expression of MMPs has been widely documented in both in vivo and in vitro studies  
in numerous malignancies and are highly critical for invasion and metastasis (Egeblad and 
Werb, 2002; Brand, 2000; Rooprai et al., 2007; Sohail et al., 2008).  MMP-2 and MMP-9 are 
the most debated and hence investigated for their roles in glioma invasion.  Mechanisms on 
how MMPs are upregulated and activated in glioma include genetic, hypoxic and stromal 
contributions.  Epidermal growth factor receptor variant III (EGFR vIII) amplification has 
appeared to promote the highest level of activated MMP-9 following constitutive EGFR 
tyrosine kinase activity (Choe et al., 2002; Ohka, Natsume and Wakayabashi, 2011).  
Hypoxic GB cells in vitro were shown to secrete pro-MMP-2 in high levels which activated 
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MMP-2.  This increased migratory properties by up to 60% more than normoxic cells (Brat et 
al., 2004; Brat and Van Meir, 2004).  In addition, the urokinase pathway of plasminogen 
activation also led to activation of MMPs besides other cell surface receptors that transduce 
intracellular signaling for migration.   
Known as urokinase-type plasminogen activator (uPA), it also includes urokinase receptor 
(uPAR) and plasminogen (Blasi and Carmeliet, 2002; Rao, 2003).  uPA is first secreted as an 
inactive pro-enzyme that is activated once cleaved post binding to uPAR.  Becoming an 
activated uPA, it then converts plasminogen to plasmin (a serine protease).  Plasmin degrades 
ECM proteins, activates other MMPs (such as MMP-2, -3 and -9) and cell surface receptors 
that transduce intracellular signaling for migration as shown in figure 2 (Bellail et al., 
2004)(Fig.2). 
 
Figure 2: Schematic representation of the mechanism of glioma cell interaction with 
astrocytes for invasion. Taken from Bellail et al., 2004. 
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1.10.2 Heterogeneity 
The idea that astrocytes are a homogeneous group of cells was based historically on their 
appearance as star shaped (Greek root word ‘astro’) and is perhaps not appropriate as their 
morphology is extremely diverse. In the late 19th century and early 20th century the 
heterogeneity of astrocytes was documented but the function of astrocytes has only begun to 
be understood in the past 20 years.  Astroyctes are heterogeneous across the brain regions as 
well as within the same regions of the brain.  These cells differ in morphology, 
developmental origin, gene expression, physiology, functions and response towards injury 
and disease and are highly important in tumour occurrence which yet still in its rudimentary 
phase (Zhang and Barres, 2010) hence needs further investigation.  
Astrocytes are found throughout the central nervous system but whether they originate 
from the same pool or distinct groups of progenitor cells is something that needs better 
understanding (Zhang and Barres, 2010).  However, the spinal cord is at least one of the 
production sites of astrocytes although 3 positions of distinct groups of white matter 
astrocytes in the spinal cord derive from different progenitor domains (Hochstim et al., 2008).    
    In addition, astrocytes differ in proliferation activity based on locations in the brain.  A 
population of astrocytes may appear homogenous but may contain hidden heterogeneity. The 
molecular mechanism that differentiates proliferative activity among astrocytes subtypes 
remains unclear (Fukuda et al., 2003; Ghashghaei et al., 2007).  
    Additionally, astrocytes are an extremely diverse group of cells with respect to gene 
expression and physiological properties (Sofroniew and Vinters, 2010).  Diversity in the 
functionality of the astrocytes (astrocyte-neuron interactions or between astrocytes 
interactions) is due to the differences in surface glycoprotein expression.  However, to date 
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heterogeneity in astrocytes is largely unexplored in vitro and warrants further research.  In 
terms of connectivity of the networks, astrocytes were also thought to be uniform in negative 
resting membrane potential and extensive gap junctions with low input resistance.  However, 
it has now been shown that they are diverse in gap junction coupling, calcium dynamicity and 
electrophysiological properties (Zhang and Barres, 2010).  
Regional heterogeneity and diversity in immunoreactive surface markers and in chemokine 
and cytokines expressed (different brain regions cultured) implies differences in response 
towards disease and injury.  Thus, heterogeneity must play additional roles in tractability 
(responsiveness to chemotherapy) of the tumour mass (Morga, Faber and Heuschling, 1999; 
Fitting et al., 2010).  In fact, cultured astrocytes, in comparison with solid tumours, may 
become more sensitive to cytotoxic drugs due to external factors such as medium 
composition, inadequate growth factors and temperature which may not resemble the in vivo 
environment exactly (Szaakacs and Gottesman, 2004).  
1.10.3 Angiogenesis 
One of the features that are required for the tumour to grow and metastasize (for all solid 
tumours) is the formation of new blood vessels from the existing ones, a process known as 
angiogenesis.  Brain tumours are particularly angiogenic and it has been reported that patients 
with high tumour microvascular densities have shorter post-operative survival durations in 
comparison with patients with low microvascular densities (Leon, Folkerth and Black, 1996; 
Carmeliet, 2003).  A tumour mass that is expanding in size requires oxygen and a supply of 
nutrients for its continuing survival and growth. Thus, recruiting new blood vessels is 
important and occurs via angiogenesis.   
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    Angiogenesis is normally controlled tightly by the balance of pro and anti-angiogenic 
factors. Both types of molecules are secreted by endothelial, stromal and blood cells, 
extracellular matrix and also cancer cells.  A considerable amount of growth factors are pro-
angiogenic in nature and include vascular endothelial growth factor (VEGF), acidic fibroblast 
growth factor, basic fibroblast growth factor (bFGF), placental growth factor, interleukins 
and angiopoietin-2.  To counter-balance their activities in the cellular environment, anti-
angiogenic factors such as angiostatin, endostatin, thrombospondin 1 and endothelial 
monocyte-activating polypeptide as well as some serine proteinases and metalloproteinases 
play their own role in suppressing angiogenic activity of the cells. A balanced expression 
between pro and anti-angiogenic factors is important for normal development and the well 
being of the cellular environment, but in tumourigenic conditions, an ‘angiogenic switch’ is 
turned on (Fidler and Ellis, 2004; Olson et al., 2006).  The tight regulation is disrupted and 
this leads to uncontrolled and disorganized angiogenesis.  
    It remains unclear how the signaling from the receptors on the cell surface to the nucleus in 
the cells controls the induction of angiogenesis in a cancerous environment.  There is 
considerable progress in understanding angiogenesis regulation but the intracellular 
machinery of the angiogenic signaling needs further explanation (Castellino and Durden, 
2007).  It was suggested that most of the pathways in the regulation of angiogenesis are 
similar in that they regulate endothelial cell proliferation, migration and permeability.  Thus, 
it is essential to implement the use of potential inhibitors to the fundamental principle of cell 
signaling (receptor interactions with the ligands) to combat angiogenesis in cancerous cells 
and hence inhibit brain tumour development (Deeken and Loscher, 2007).  
    Blood circulation in the central nervous system (CNS) is tightly regulated by the blood 
brain barrier (BBB).  The BBB is a vasculature organization in the CNS which is highly 
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specialized and well distinguished by a unique structure of blood capillaries.  Composed of 
walls of endothelial vessels with tight junctions in between, the BBB hence is both an 
anatomical and a physiological barrier as it limits blood vessel permeability, suppressing the 
flow of most substances from the blood stream to the neural system but sustaining the needs 
of brain cells with the required nutrients for continuous CNS function.  It is selective to 
molecules of a certain molecular mass, not allowing molecules of more than 50kDa to pass 
through, and solubility, in which water-soluble molecules are unfavourable (Jain et al., 2007).  
The BBB is of primary concern as a barrier to the successfully delivery of drugs to a tumour 
mass.  Moreover, the brain is confined in its space thus, breaking down the BBB and 
allowing leakage of fluid into the brain can lead to an undesirable increase in interstitial 
pressure.  In fact, BBB architecture in brain tumours is tortuous, disorganized, and with high 
permeability due to abnormality of the endothelial walls.  Thus, having more disruption in 
already disrupted structures of the BBB could result in oedema and cause increased morbidity 
in patients.  Hence, it is important that anti-angiogenic therapy is not only aimed at 
preventing tumour angiogenic event but also suppresses the pathological damage following 
changes in tissue permeability.  
Interventions aimed at preventing angiogenesis are high in importance when investigating 
the control of brain tumours.  Indeed, in a study (Jain, Tong and Munn, 2007), expanding 
research on anti-angiogenic therapy for brain tumours either in vivo or in vitro has shown that 
regulating angiogenic activity may be promising in managing this deadly cancer.  Such 
popular treatment is the use of Bevacizumab or Avastin, a humanized monoclonal antibody 
against VEGF, which is the prime target in angiogenesis. 
    A number of anti-angiogenic therapies such as sorafenib and sunitinib have been used for 
other solid cancers but not in gliomas, perhaps due to their non-specificity (Tourneau, Faivre 
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and Raymond, 2008).  VEGF is known for its pivotal role in angiogenesis.  The 
administration of Avastin as the main approach in anti-angiogenic therapy has shown Avastin 
to be an active regimen for recurrent grade III-IV glioma with acceptable toxicity 
(Vredenburgh et al., 2007).  Based on VEGF signaling as the target (monoclonal antibody 
against VEGF approach), other inhibitors have been developed; tyrosine kinase inhibitors 
(against VEGFR2 tyrosine kinase activity) (Batchelor et al., 2007) and soluble decoy 
receptors VEGFR1-developed (against VEGF signaling) (Folkman, 2007).  A potent αvβ3 
and αvβ5 integrin inhibitor, cilengitide, has also been used in a clinical trial (Nabors et al., 
2007).  It is a platelet-derived growth factor receptor (soluble decoy receptor) that inhibits 
alpha-V-beta-3 (αvβ3) and alpha-V-beta-5 (αvβ5) integrins.  Both integrins are expressed by 
both the tumour-associated vasculature and tumour cells (Gladson, 1996; Bello, Francolini 
and Marthyn, 2001). 
    Nevertheless, despite all the possibilities that research into angiogenesis brings, there is a 
concern that anti-angiogenic therapy could lead to a transition phase of the tumour.  It is a 
recurrence of the tumour growth after adaptation to the treatment.  Evasive resistance and 
intrinsic resistance are possible occurrences, with cells developing alternative pathways to 
develop new blood vessels (Berges and Hanahan, 2008).  However, this could be avoided by 
combining other therapies that are looking at another approach of killing the cells and thus 
may improve the efficacy of the treatment.  
1.11 Stem cells 
Stem cells are a primitive group of cells capable of reproducing themselves (self –renewal) 
and developing through cell division into specialized cells (potency) which make up the 
organs and tissues of the human body.  In a normal state of functionality, the hallmark is 
haematopoietic stem cells (HSCs) of the bone marrow that are able to produce new blood 
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cells and immune cells over a long term, demonstrating potency.  However, cancer stem cells 
(CSCs) are cancer cells that function likewise, but give rise to all cell types found in a 
particular cancer sample i.e. reinitiate the cancer (Eyler and Rich, 2008).  CSCs are therefore 
tumourigenic either via self-renewal or differentiation into perhaps multiple cancer cell types.   
In brain tumours, such cells are known as brain tumour stem cells (BTSCs) and have given 
new insights into chemo and radio resistance as the brain tumour stem cells persist as a 
distinct population hence surviving and initiating recurrence.  Several studies have reported 
on a fraction of BTSCs found in brain tumours of most types including GBs.  Clusters of 
differentiation 133 or CD133 was the first marker reported for hematopoietic stem/progenitor 
cells before becoming neural stem/progenitor stem cells.   
It was identified (Singh et al., 2004) that as few as 100 cells with CD133+ cells derived 
from GB has adequately initiating GB in immunodeficient mice following injection, but 
shown to be lack of tumourigenic capacity when injected with CD133- cells.  Nevertheless, 
there could be differences between mice and humans, such as the metabolism, lifespan and 
length of telomeres and better insights could be gained by using an appropriate model.  It is 
thought that BTSCs constitute only a small population of CD133+ cells and side population 
cells among the selected populations of cancer cells (Singh et al., 2004).  Side population 
cells (SP) are the cells that appear on the lower left of the dot plot graph in flow cytometry 
and are known to possibly to have cancer stem cell characteristics as they have been 
identified in cancers (hepatocellular, gastrointestinal, ovarian cancers and glioma) (Haraguchi 
et al., 2006; Chiba et al., 2006; Szotek et al., 2006; Hide et al., 2008; Wu and Alman, 2008;) 
and may be the cells that efflux chemotherapy drugs and account for resistance of cancers to 
chemotherapy.  
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    Besides the difficulties in purifying BTSCs from CD133+ fractions and SP cells, there are 
other complexities in the study.  Hypothetical models of CD133 expression in BTSCs 
developed by Hide et al (2008) suggest that CD133 expression in BTSCs derived from GBs 
from patients is diverse depending on the origin of the cells and different mutations expressed 
and thus altering the growth pattern of the cells (Bar, Chaudhry and Lin, 2007).  
Continuing study of BTSCs may increase our understanding of the development of brain 
tumours.  BTSCs offer a potential target for cancer therapy with Sonic Hedgehog (Shh) and 
Notch pathways as the target.  Due to their importance roles in brain development and 
sustaining the stem cell-like, Sonic Hedgehog and Notch pathways become a target by 
inhibiting the self-renewal functions and tumorigenicity in gliomas ( Fan et al., 2006; Birlik, 
Canda and Ozer, 2006; Clement et al., 2007).  
1.12 Apoptosis as a targeted therapeutic approach 
Alterations in cell death and cell proliferation are essential determinants of the physiologic 
and homeostatic functions of normal tissues. The balance between the two is key to 
understanding the pathogenesis and progression of several diseases such as cancer. Greatly 
increased in importance in clinical management and human disease, apoptosis studies in 
cancer have been well documented as a potent mechanism in combating carcinogenesis and 
also as a target for an effective therapy (Fleischer et al., 2006).  
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Figure 3: Pathways involved in apoptosis 
The induction of apoptosis occurs along either the intrinsic or the extrinsic pathway.  The 
intrinsic pathway (mitochondrial) is activated due to deprivation of growth factors and 
cytokines that result from DNA damage (Darzynkiewicz et al., 2004). Tumour suppressor 
p53 gene is responsible for the activation of genes transcribing pro-apoptotic Bcl-2 proteins. 
Dysregulation of its functions in cancer may interrupt the controlled ratio between pro- (Bax, 
Bad, Bik, Bcl-xs) and anti-apoptotic (Bcl-2, Bcl-xl) proteins (Darzynkiewicz et al., 2004).  
    The extrinsic pathway is activated by a tumour necrosis factor superfamily protein 
e.g.TNF-α post-binding to the death receptor on the cell surface (Darzynkiewicz et al., 2004).  
Following ligand binding, the receptor becomes trimerized which leads to recruitment of 
Caspase-8	activation																																															
Caspase	9	activation																																															
Caspase	3	activation																																															
Caspase	8																																														
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death domain containing Fas-Associated Death Domain (FADD- an example of adapter 
protein molecules) at the end of the receptor, intracellularly.  Initiator caspases such as 
caspase 8 is activated which in turn activates the other downstream effectors i.e. caspase 3, 6 
and 7, eventually eliciting cell death (Darzynkiewicz et al., 2004).  Many cytotoxic agents 
used in chemotherapy are thought to exert their therapeutic effects by inducing apoptosis in 
neoplastic cells, making them ideal anti-cancer agents.  
1.13 Current treatment options for Glioblastoma Multiforme 
GBs are the most challenging of cancers to treat and remain incurable.  The prognosis of 
malignant brain tumours in man is dismal despite conventional therapeutic approaches such 
as radio and/or chemotherapy regimes and various novel surgical approaches that have been 
introduced for their management (Grossman and Batara, 2004).  
1.13.1 Neurosurgery 
    Neurosurgery is regarded as relatively safe with respect to procedures and has improved 
with the precision in tumour removal made possible by neuro-navigation and robotic surgery 
(Rampling, James and Papanastassiou, 2004; Grossman and Batara, 2004).  However, 
surgical resection as well as its effects remains controversial as this modality does not cure 
the patient due to the impossibility of debulking 100% of the tumour.  The infiltrative nature 
of the tumour makes it difficult for the neurosurgeon to ascertain where the tumour ends and 
normal brain tissue starts. Single invading cells (“guerrilla” cells) tend to escape the 
surgeon’s knife, move a distance away into the normal brain and start proliferating 
(Pilkington, 1996).                  
    Undoubtedly, the outlook for patients with GB remains dismal and adult patients usually 
die of within less than 1 year after first diagnosis (McKinney, 2004).  As there has not been a 
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significant improvement in prognosis in 30 years, there is a very strong need for other 
therapeutic approaches in addition to conventional surgery and radio/chemotherapy. 
1.13.2 Radiotherapy 
Surgical procedure is usually followed by radiotherapy, which remains the most effective 
therapy for GB patients as it has been shown to prolong survival of the patients with 
malignant gliomas (Grossman and Batara, 2004; McKinney, 2004; Preusser et al., 2011). 
However, this modality is not recommended for elderly patients as radiotherapy puts their life 
at greater risk (Combs et al., 2008).  It can only be given when the tumour cells are rapidly 
dividing and it is harmful to the normal brain cells.  Radiotherapy also has some potential 
drawbacks, including resulting in learning difficulties in children or causing further tumours 
such as meningioma (Merchant, Pollack and Loeffler, 2010).   
1.13.3 Chemotherapy 
Chemotherapy is often given as an “adjuvant” to patients who are at a high risk of recurrence 
of the tumour.  Chemotherapy may improve a patient’s survival, but it has been disappointing 
due to problems of drug delivery across the BBB (Regina et al., 2001).  As the tumour has a 
disrupted BBB, cytotoxic drugs can be delivered to it but this therapy cannot reach the 
guerrilla cells which are protected by the intact BBB in the normal brain (Merzak and 
Pilkington, 1997).   
The use of Temozolomide (an oral alkylating agent) (Stupp et al., 2005) and Carmustine or 
gliadel wafers (Westphal et al., 2003) has been encouraging in recent years but there is still a 
strong need for novel therapeutic intervention.  
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1.13.3.1 Temozolomide 
Temozolomide (TMZ) is the 3-methyl derivative of mitozolomide, a tirazinic compound 
which is active in various neoplasias and has shown the most encouraging results in treating 
high grade gliomas in the past 30 years.  TMZ is a pro-drug that is rapidly converted through 
non-enzymatic processes to the active metabolite 5-(3-methyltriazen-1-yl)-imidazole-4-
carboxamide (MTIC).  Thus, without the need for hepatic metabolism, it transforms itself into 
MTIC (its active form) before being secreted by the kidneys and rapidly disappearing from 
the blood.  Targeting the O6, N7 position of guanine, TMZ disables DNA repair enzymes.  As 
a result, cells with unrepaired damaged DNA cannot pursue to the next phase of cell cycle i.e. 
cell cycle arrest occurs and apoptosis becomes a choice.   
Furthermore, TMZ tissue distribution is excellent as it has 100% bioavailability as it 
is able to cross the BBB to reach a sufficient dose.  TMZ is often given with radiotherapy or 
chemotherapy (either an injection or oral therapy) or to newly diagnosed patients (National 
Institute for Health and Clinical Excellence, 2007; Ohka, Natsume and Wakayabashi, 2011).  
Initial dosing consists of a 42-day concomitant phase of dosing while the patient receives 
radiation therapy.  6 dosing cycles are implemented following the completion of the 
concomitant phase with each cycle consisting of 28 days (5 days with therapy and 23 days 
without therapy).  A complete blood count is taken within 48 hours of day 22 of the cycle as 
to assess for dosage modification (if required) due to toxicity.  Post completion of the 6 
dosing cycles, a re-evaluation is done to determine requirements for following therapy (if 
needed) (Schering-Plough Corporation, 2008). 
However, a common adverse effect reported is an increased risk of the development 
of Pneumocystis jiroveci pneumonia (PCP) due to possible severe myelosuppression.  
Therefore, it is necessary for the patient to receive PCP prophylactic therapy alongside the 6 
dosing cycles (Schering-Plough Corporation, 2008).  Moreover, TMZ is toxic to organs that 
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have rapidly proliferating cells such as bone marrow, lymphatic and gastrointestinal systems 
(Avgeropoulus and Batchelor, 1999; Brandes and Pasetto, 2000).  Stupp et al. (2005) in his 
study with newly diagnosed GB patients showed a clinically meaningful and statistically 
significant increase in survival following TMZ administration alongside radiotherapy. 
Radiotherapy alone showed only 10% increase in survival rate but 27% was achieved with 
TMZ alongside (Stupp et al., 2005; Brown, Eckley and Wargo, 2010).  
Unfortunately, TMZ is not always effective in patients with GBM as the unsatisfactory 
outcome of chemotherapy with TMZ is mainly deﬁned by the intrinsic or acquired 
chemoresistance of GB cells which include not just p53, proliferation rate and DSB repair but 
also O6-methylguanine-DNA methyltransferase (MGMT) level of activity (Capper et al., 
2008; Lee et al., 2009;Glas et al., 2009). 
It was postulated that MGMT removes the mutagenic and cytotoxic adducts from the O6-
methylguanine in DNA which is the preferred point of attack of alkylating agents.  
Eventually, due to increased level of MGMT enzyme that present in the cells, it becomes 
irreversibly inactivated and consumed (Balana et al., 2008) and diminished after 
concentration of TMZ is increased. As a result, some cells die, while other, more resistant 
cells adapt and resume proliferation and evade apoptosis.  
1.13.3.2 Gliadel wafer (Carmustine) 
Westphal et al. (2006) have been researching the use of gliadel wafers in GBs for many years 
and these have now been used as a form of interstitial chemotherapy treatment.  Following 
radiation, this biodegradable polymer containing 3.85% Carmustine or bis-chloronitrosourea 
(BCNU) is placed in the resection cavity at the time of craniotomy.  Being implanted in the 
brain and lasting for 2-3 weeks, Carmustine is released into tumour sites, that cannot be 
removed surgically.  In a long term study a reduction in the risk of death reported compared 
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with placebo of nearly 30% was noted.  Indeed, patients who were treated with Carmustine 
have the advantage of 2 to 3 extra years of survival compared to patients given a placebo.  
Hence, it offers enormous hope of long term survival in malignant glioma patients but there 
could be potential adverse effects.   
    Another clinical study by Weber and Gobel, (2005) in GB management has introduced 
Carmustine wafers into the resection cavity when cerebral oedema occurrences following 
Gliadel implantation were experienced. Localized chemotherapy by wafers, together with 
other post-operative regimens reduced the systemic adverse effects but did not last for long as 
the patients developed neurological deficits gradually and these deteriorated over time.  In 
one case, death followed as increased oedema developed.  It is a fact of the infiltrative nature 
of the disease that some degree of cerebral oedema will develop in the malignant glioma 
where the resection has occurred, but it is usually around the adjacent areas of the craniotomy 
that corticosteroids are administered (Westphal et al., 2003; Weber and Goebel, 2005; ; Ohka, 
Natsume and Wakayabashi, 2011).  
1.13.3.3 Chlorimipramine 
Chlorimipramine (CIMP) or Anafranil is a tricyclic antidepressant that has been used widely 
for over 40 years (Peters, Davis and Austin,1990; Trimble, 1990). It works by inhibiting the 
re-uptake of the neurotransmitters, norepinephrine and serotonin, by nerve cells.  Following 
oral administration, CIMP is stored in high quantities in both the brain and lung and has a 
long half life of approximately 24 hours, increased to 40 hours once metabolized to its by 
product, desmethyl clomipramine. CIMP crosses the "blood-brain barrier” and therefore has 
an advantage in the treatment of brain tumours (Aitchison, et al., 2010).  
CIMP mode of action is different from other cytotoxic drugs that are used in GB treatment 
(which act by damaging the DNA within the nucleus of the cells) as it acts through 
29	
	
mitochondria, which are responsible for production of energy for the cell´s various activities. 
Therefore, it promotes programmed cell death (apoptosis) due to compromised respiratory 
function in cancer cells while leaving normal cells unaffected.  In essence, the drug enters the 
mitochondria and affects complex III of the respiratory chain, reducing oxygen consumption, 
thereby increasing reactive oxygen species (ROS) and liberating cytochrome c as a 
consequence. This, in turn, activates a series of enzymes which results in programmed cell 
death (Daley et al., 2005). 
1.13.3.4 Bevacizumab (Avastin) 
Bevacizumab or Avastin is a humanized monoclonal antibody that prevents the formation of 
new blood vessels by targeting and inhibiting the function of vascular endothelial growth 
factor (Ferrara et al., 2004). Considered as one of the most vascularized cancerous tumours, 
GB over-expression of VEGF leads to increased microvascular density and increased 
angiogenesis (Sathornsumetee and Rich, 2007).  By preventing VEGF association with its 
receptors, this disrupts new vessel formation and leads to inhibition of tumour growth 
(Friedman et al., 2009).  First used as an angiogenic inhibitor in metastatic cancers such as 
colorectal, lung and breast cancers, Avastin was approved for GB treatment in 2009.  The 
dose of Avastin used in GB is 10 mg/kg every 2 weeks, with the duration of therapy up to the 
discretion of the oncologist and patient (Genetech Inc., 2011). 
    The results of several clinical studies have been published and have shown positive effects 
for Avastin on GB progression.  Avastin, with a combination of other regimes in 
chemotherapy, may be a more effective treatment in recurrent GB but warrants further studies 
on its survival perspective (Norden et al., 2008; Kreisl et al., 2009; Nghiemphu et al., 2009; 
Readon et al., 2009; Zuniga et al., 2009).  Vredenburgh et al. (2007) has combined Avastin 
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with Irinotecan, a topoisomerase 1 inhibitor involving patients with recurrent GB.  This phase 
II trial has demonstrated that the combination is active against recurrent GB and yet the 
toxicity was acceptable.  This was one of the first trials to show positive response rates and 
increased duration of life.  At 6 months, the overall survival was found to be 77% and 20 of 
the 35 patients had at least a partial response as determined by MRI scans.  
    Friedman et al. (2009) compared treatment with Avastin alone and Avastin in combination 
with Irinotecan.  At 6 months, of the 167 patients with recurrent GB randomised to the two 
groups, Avastin alone had a 42.6% survival rate compared with 50.3% in the combination 
therapy group.  Moreover, as measured by MRI scan for tumour reduction assessment, 24 
patients on monotherapy while 31 patients on combination therapy manifested a response to 
therapy.  Despite the promise of Avastin for treating GB, there are drawbacks associated with 
side effects including gastrointestinal perforation, severe or fatal haemorrhage, and wound-
healing complications (Sathornsumetee and Rich, 2007).  In addition, hypertension has been 
observed in patients receiving this therapy as well as other common adverse events including 
thromboembolism formation, proteinuria/nephrotic syndrome, and reversible posterior 
leukoencephalopathy syndrome (Gressett and Shah, 2009). 
1.14 Novel treatment in Glioblastoma therapy: natural occurring 
micronutrients as an integrative treatment 
Naturally occurring agents such as micronutrients are being explored and researched as they 
have potential therapeutic effects on various tumours.  It is also important to have novel 
therapeutic approaches which have an impact on the tumours without being toxic.  For an 
agent to be of therapeutic value it should not only be cytotoxic, anti-invasive, anti-angiogenic 
or pro-apoptotic but most importantly it should be able to cross the BBB.  Rooprai et al. 
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(2001) hypothesized that naturally occurring micronutrients found in citrus flavonoids (from 
tangerine peel) may have potential as anti-cancer agents in the treatment of malignant 
gliomas based on their ability to interfere with invasion.   
Micronutrients are essential dietary components such as vitamins, minerals or other agents 
found in foods that are required in minute quantities for sustaining normal growth and 
development of living cells.  Micronutrients have been shown to exert potentially therapeutic 
effects in cell culture and animal models which include anti-cancer activity and other 
functional properties such as anti-microbial and anti-oxidative effects.  In addition, a 
combination of micronutrients or naturally occurring agents, known to have a variety of 
therapeutic properties such as anti- invasive and pro-apoptotic, has been suggested as one 
possible novel therapeutic approach to combat brain tumours.  (Rooprai , Christidou and 
Pilkington, 2003;Rooprai et al., 2007). 
1.14.1 Flavonoids 
Flavonoids or bioflavonoids, are an extensive group of naturally occurring polyphenolic 
compounds and responsible for the pigments found in fruits, vegetables, wine and tea. 
Consisting of two benzene rings on either side of a 3-carbon ring , multiple combinations of 
hydroxyl groups, sugars, oxygens, and methyl groups attached to these structures create the 
various classes of flavonoids: flavanols, flavanones, flavones, flavan-3-ols (catechins), 
anthocyanins, and isoflavones (Miller,1997). Daily intake in the Western diet is 
approximately 20mg to 1g per day (Pierpoint, 1990; Hertog et al., 1995).  
    Increased interest in studies on flavonoids has been due to their proposed protective role in 
cancer prevention which includes pro-oxidant activity, mitochondrial toxicity (potential 
apoptosis-inducing properties), and interactions with drug-metabolizing enzymes (Galati and 
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O’Brien, 2004).  Indeed, certain flavonoids have been found to exhibit anti-proliferative 
properties against some cancers and are known to cross the BBB (Datla et al., 2001; Zbarsky, 
et al., 2005). 
    Further research has now led to the inclusion of red clover extract, red grape seed extract, 
turmeric, chokeberry extract, lycopene and selenium. This combination of seven 
micronutrients has been carefully selected to target the tumours in different ways as a 
nutraceutical approach for a proposed clinical trial to treat malignant brain tumour patients 
(Rooprai , Christidou and Pilkington, 2003).  Turmeric and chokeberry were included as part 
of a large study of flavonoids and other micronutrients screened in vitro to evaluate their 
ability to induce apoptosis in GBs. 
1.15 Curcumin as a therapeutic agent 
1.15.1 Dietary sources of curcumin 
Curcumin (diferuloylmethane; 1,7-bis(4-hydroxy 3-methoxy phenyl)-1,6-heptadiene-3,5-
dione) is a polyphenol derived from Curcuma Longa, a medicinal plant.  Commonly called 
turmeric, it is an ancient spice with a distinct orange colour, which has been used for 
centuries in Asia, not just for indigenous medicine but also for colouring, food preservative 
and flavouring.  
1.15.2 Chemical structure and therapeutic properties 
Turmeric contains 3 main components; 77% curcumin (Fig. 4A), 17% demethoxycurcumin 
(Fig 4B) and 3% bisdemethoxycurcumin (Fig 4C).  Together, they are referred to as 
curcuminoids (Aggarwal, Kumar and Bharti, 2003; Sharma, Gescher and Steward; 2005).  
More recently, it has been reported that a new component has been identified: cyclocurcumin 
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(Fig 4D).  Curcumin has been identified as the most active component with several beneficial 
properties including anti-inflammatory, anti-oxidant, antibacterial, anti-amyloid and anti-
angiogenic properties (Kunwar et al., 2008; Jurenka, 2009).  
 
 
              
A) B) 
                            
C)                                                                    D) 
Figure 4: Chemical structures of curcumininoids; A) Curcumin, B) Demethoxycurcumin C) 
Bisdemethoxycurcumin and D) Cyclocurcumin 
 
    This phenolic compound has also been reported as having an anti-cancer 
chemopreventative role in tumour inhibition in breast, lung, colon and other types of somatic 
cancer (Simon et al., 1998; Pillai et al., 2004; Shi et al., 2006).  The powder is used to treat 
gastrointestinal inflammation, arthritic pain and as a tonic for the digestive system 
(Aggarwal, Kumar and Bharti, 2003).  However, mechanisms underlying the actions of 
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curcumin in pathological conditions remain unclear, but extensive literature on this 
polyphenol (that based on in vitro and in vivo preclinical and clinical results) has suggested 
its potential in the prevention and treatment of cancer (Aggarwal, Kumar and Bharti, 2003; 
Sharma, Gescher and Steward, 2005; Wilken et al., 2011).  
Curcumin has an excellent safety profile and a number of potent pleiotropic actions for 
neuroprotective efficacy.  Indeed, extensive research has reported that curcumin affects 
several targets (Fig. 5) including transcription factors, growth regulators, adhesion molecules, 
apoptotic genes, angiogenesis regulators and cellular signaling molecules (Anand et al., 
2008). Curcumin has been shown to downregulate the nuclear factor kappa B (NF-kB), which 
is an inducible transcription factor. NF-kB regulates genes expression as such involved in 
inflammation, cell proliferation and cell survival (Han, Seo and Surh, 2002;Aggarwal et al., 
2004;Bachmeier et al, 2008; Panicker and Kartha, 2010).Transcription factors have pivotal 
roles in cellular processes as they regulate gene transcription necessary for normal conditions 
as well as the genes needed for tumours to form.  For example, nuclear factor kappa B (NF-
kB) and activating protein-1 (AP-1) have been implicated in cell survival and tumour 
progression respectively (Sharma, Gescher and Steward, 2005).  It has been reported that the 
activation of these two major transcription factors is inhibited by curcumin in leukaemic 
cells.  Moreover, other researchers have documented that there could be involvement in the 
death receptor pathway through Fas-ligand interaction, caspase 3 activation (Duvoix et al., 
2005), caspase 8, BID cleavage, cytochrome c release and anti-apoptotic gene suppression 
(Bcl-2 and Bcl-xL) (Duvoix et al., 2005; Anto et al., 2002).   
Reactive oxygen species (ROS) such as superoxide radical (O2−), hydrogen peroxide 
(H2O2), singlet oxygen (1O2) and hydroxyl radical play important roles in initiating lipid 
peroxidation (Ahsan et al., 1999).  Lipid peroxidation has a significant impact, causing cell 
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cytotoxicty, as well as implications in inflammation, heart disease and carcinogenesis.  
Curcumin has been shown to scavenge the activated oxygen species which is an important 
mechanism in the prevention of cancer, thereby conferring its therapeutic advantages 
(Srejayan and Rao, 1994).  Curcumin’s potential as an anti-oxidant agent has been was 
demonstrated in a wide range of pathological conditions.  It was found that lipid peroxidation 
in rat brain homogenates and liver microsomes were inhibited by the three curcuminoids, 
compared with tocopherol (Srejayan and Rao, 1994).  The effects were proposed to be due to 
phenolic hydroxyl and the methoxyl groups on the phenyl ring and the 1,3-diketone system 
that are present.  Ahsan et al. (1999) have demonstrated that curcumin shows both pro-
oxidant and anti-oxidant effects as in the presence of Cu (II), curcumin causes strand 
cleavage in DNA through the formation of hydroxyl radical.   
Among the three components, curcumin was found to be the most effective in the reaction, 
followed by bis-demethoxycurcumin and demethoxycurcumin.  Furthermore, an antioxidant 
behaviour of curcumin in protecting proteins was proposed by Kapoor and Priyadarsini 
(2001) who found that the reduction (at the disulphide bond) or oxidation (at amino acid site) 
of proteins is ultimately involved in controlling the vital processes such as gene expression 
and signaling pathways.  In addition, long range electron transfer involved in the protein 
chain during the processes may extend to radiation which could damage the proteins sub-
cellular fractions.  As a result, oxidative damage that occurs may have initiated the 
progression of multi-stage carcinogenesis.  Thus, curcumin with anti-oxidant activity 
provides protection from free radical attack to cells and ultimately proteins. 
    The anti-cancer properties of curcumin have been extensively reviewed with respect to 
duodenal, stomach, colon, esophageal and oral cancer (via animal tumour bioassay) 
(Maheshwari et al., 2006).  In addition, a study on mice has shown that curcumin treatment 
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could stop the progression of breast tumour growth (Shao et al., 2002).  Clinical trials on 
curcumin administration to patients with progressive, advanced colorectal cancer had 
promising results with patients experiencing longer stability post-radiotherapy (Kunwar et al., 
2008).  Numerous molecular targets and different pathways of curcumin in combating large 
numbers of cancers have been reviewed by Anand et al. (2007).  
    Several mechanisms have been suggested in curcumin’s actions against breast cancer.  
Curcumin has been shown to inhibit vascular endothelial growth factor (VEGF) and basic 
fibroblast growth factor (b-FGF) which are overexpressed and correlate with increased 
angiogenesis and hence poor prognosis of breast cancer.  Its role in inducing p53 to regulate 
Bax expression and therefore to mediate apoptosis has also been widely debated (Schindler 
and Mentlein, 2006; Di et al., 2003). 
    In addition, matrix metalloproteinases (MMPs), which have been strongly implicated as 
mediators of tumour invasion, have been shown to be down-regulated by curcumin in breast 
cancer.  Concurrently, tissue inhibitor of MMP-1 (TIMP-1) is up-regulated. TIMPs play a 
critical role in the homeostasis of extracellular matrix (ECM) by regulating the activity of 
MMPs. Thus, the upregulation of TIMP activity enhances the anti-cancer properties of 
curcumin (Goel, Kunnumakkara and Aggarwal, 2008).   
    Gastrointestinal cancer studies suggest that a huge number of mechanisms may account for 
this effect.  A wide range of transcription factors and enzymes involved in multistage-cancer 
progression have been modulated by curcumin.  Curcumin was found to inhibit the cytokine-
induced activation of NF-kB in human pancreatic adenocarcinoma cells (Wang et al., 1999; 
Khanbolooki et al., 2006). 
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    Similar therapeutic effect was observed in colorectal cancers (Reddy et al., 2006), as well 
as in a number of bladder (Sun et al., 2004; Kamat, Sethi and Aggarwal, 2007; Aggarwal et 
al., 2007) prostate (Shi et al., 2006), cervical (Divya and Pillai, 2006) and ovarian cancers 
(Zheng, Tong and Wu, 2002; Zheng, Tong and Wu, 2006),as well as in leukeamias 
(Sokoloski, Shyam and Satorelli, 1997; Bielak-Mijewska et al., 2004; Mukherjee Nee 
Chakraborty et al., 2007; Pae et al., 2007), lymphomas (Wu et al., 2002; Thompson et al., 
2004;  Skommer et al., 2006) and melanomas (Siwak et al., 2005; Marin et al., 2007).  
    Remarkably, curcumin has significantly down-regulated the levels of hypoxia-inducible 
factor-1 (HIF-1) which is important in stimulating genes that promote tumour angiogenesis 
(Bae et al., 2006). This inhibition is thought to be via degradation of aryl hydrocarbon 
receptor nuclear translocator (ARNT), a sub-family of HIF-1 (Choi et al., 2006) which has 
been seen in other cell lines such as prostate, cervical and lung cancers.  
 
  
        
             
 
Figure 5: Multiple molecular targets of curcumin 
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1.15.3 Absorption, metabolism and transport 
Clinical pharmacokinetic studies on curcumin have shown that curcumin has a rapid and 
extensive metabolism (Kunwar et al., 2008; Garcea et al., 2004; Garcea et al., 2005; Ireson et 
al., 2001; Ireson et al., 2002; Goel, Kunumakkara and Aggarwal, 2008).  This may explain its 
poor bioavailability in plasma, urine and tissues in many pre-clinical studies (Strimpakos and 
Sharma, 2008; Sharma et al., 2001a; Sharma et al., 2001b).  A study on hepatocellular and 
colorectal cancer suggested curcumin’s poor availability, post-oral administration (450-
3600mg daily) and the concentration achieved may not be sufficient to exert pharmacological 
activity in humans (Garcea et al., 2004).  
1.15.4 Bioavailability with tissue distribution 
Curcumin is highly prone to conjugation (via glucuronidation and sulfation) and reduction 
especially in humans (Fig. 6) thus resulting in a deficit at the systemic level (Marczylo et al., 
2007).  Marczylo et al. (2007) has also suggested that the preferential uptake of curcumin by 
tumour cells compared to normal cells is possibly due to differences in membrane structure, 
protein content and size between normal and tumour cells. Being a lipophilic molecule, 
curcumin is being transported inside the cells where toxicity of curcumin is increased with 
the increasing uptake. The research suggests that curcumin uptake is different in different cell 
types based on polarity and hydrophobicity of composition within the cells. Marczylo et al. 
(2007) showed that poorly absorbed drugs have been increased in bioavailability in plasma 
with the use of phosphotidylcholine. Therefore, due to curcumin better uptake following its 
formulation with phosphotidylcholine, a better systemic level in humans may be achieved. 
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 Curcumin glucuronide Curcumin glucuronide sulphate 
Curcumin                       Curcumin sulphate 
 dihydrocurcumin             dihydrocurcumin glucuronide 
                                                                                                    hexahydrocurcuminol 
                           tetrahydrocurcumin                hexahydrocurcumin 
  
       tetrahydrocurcumin glucuronide                            hexahydrocurcumin glucuronide 
                     In rat/human hepatocyte culture or rat plasma in vivo 
                    In mice in vivo 
Figure 6: Metabolic pathways of curcumin in rodents and in vitro culture (rat and human 
hepatocytes).  Taken from: Marczylo et al., 2007. 
 
1.15.5 Cytotoxicity of Curcumin 
Studies in which normal subjects were given doses of between 8g/day and 10g/day showed 
no toxic effects (Aggarwal, Kumar and Bharti, 2003).  Furthermore, a review of a clinical 
trial by Goel, Kunnumakkara and Aggarwal (2008) has shown curcumin to be safe at a daily 
dose of 12g for 3 months.  However, a clinical study that administered doses of up to 8000 
mg daily for 4 months resulted in diarrhea and mild nausea but other toxicities were not 
reported (Hsu and Cheng, 2007).   
    Turmeric has most recently been reported to cross the rat BBB (Datla, Zbarsky and Dexter, 
2006) which makes it ideal for use in the management of malignant brain tumours and 
neurological diseases.  Extensive studies of anti-tumour activities of curcumin (described 
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earlier) have been reported in different types of cancer but those in malignant gliomas are still 
lacking.  
1.16 Lycopene, a naturally occurring pigment with health benefits 
1.16.1 Dietary sources of lycopene 
Lycopene belongs to the carotenoid family which represents one of the most widespread 
groups of naturally occurring pigments.  Tomatoes are the main source of lycopene besides 
apricots, guavas, papayas, rosehip, pink grapefruit and watermelon (Maiani et al., 2009). 
However, gac fruit has been identified to have the highest content of lycopene, 70 times 
higher than tomatoes. Due to its rarity in availability (Ishida et al., 2004) more than 85% of 
lycopene intake is from tomato-based juices and sauces for most people.   
 
1.16.2 Chemical structure and therapeutic properties 
Lycopene consists of 11 conjugated double bond in a 40 carbon acyclic with open chain 
structure (Fig. 7).  Insoluble in water, its conjugated double bonds characterize its deep red 
colour and antioxidant activity which has led to preliminary research in cancer expanding to 
the investigation of a correlation between tomato consumption and risk of cancer which 
include research into the prevention and treatment of breast and prostate cancers (Sato et al., 
2002; Bureyko et al., 2009; Wei and Giovannucci, 2012).  
 
Figure 7: Lycopene with 40 carbon acyclic in structure 
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Carotenoids are one of the classes of micronutrients that have been studied extensively for 
their potential protective effects against cancer.  One of the most active components in 
carotenoids is lycopene which has been suggested as having a role in preventing 
carcinogenesis and atherogenesis.  Moreover, lycopene is proposed to have greater anti-
oxidant properties and free radical scavenging activity compared to other carotenoids such as 
beta carotene or alpha tocopherol (Yeum and Russel, 2002).  For example, despite having no 
variants in the protein levels, lycopene was found to have effects on mRNA levels of BRCA1 
and BRCA2 genes and their splice variants in breast carcinogenesis (Chalabi et al., 2004).  
In addition, lycopene was found to inhibit the growth of human endometrial, mammary 
and lung cancer cells in vitro through reducing mutagenesis and improving anti-tumour 
immune response (Omoni and Aluko, 2005).  Epidemiological studies on prostate cancer 
have shown that a higher consumption of tomato products results in a lower risk of prostate 
cancer in men and it has been suggested that this may be due to lycopene’s health-protective 
effects that include strong anti-oxidant and anti-proliferative activity, growth factor inhibition 
and cell cycle arrest (Giovannucci, 2002; Teodoro et al., 2012).  
Lycopene exists in `trans` forms in plants and this form is poorly absorbed.  Bioavailability 
improves in human serum or plasma following heat-induced isomerization to the (`cis` forms) 
in vivo (Boileau and Erdman, 2002).  Thus, lycopene is suggested for its efficacy in 
preventing carcinogenesis due to its enhancement in tissue uptake, metabolism and 
distribution while maintaining its anti-oxidant properties in the body.  Furthermore, lycopene 
has been suggested as an inhibitor of insulin like growth factor-1 (IGF-1) signaling 
transduction hence delaying cell cycle progression (Karas et al., 2000; Teodoro et al., 2012).  
A study by Lo et al. (2007) has proposed that lycopene has anti-tumour activity, mediated 
through growth factor receptor inhibition in rat smooth muscle cells.   
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There is also compelling evidence (Yu, Ustach and Choi Kim, 2003) that platelet derived 
growth factor receptor BB (PDGFR-BB) overexpression occurs in diverse malignancies such 
as in breast cancer and brain tumours.  It was found that lycopene inhibited PDGF-BB in 
human cultured skin fibroblasts via binding activity which could be a possible target for 
cancer.  Therefore, inhibition or modulation of growth factor signaling may emerge as a 
possible mechanism for decreasing tumour progression hence designing better ways to treat 
the cancer. 
1.16.3 Absorption, metabolism and transport 
Growing interest in lycopene as a potential anti-cancer agent has followed from several 
studies on its disposition and distribution in vivo.  Following ingestion, lycopene is 
solubilized by bile salts in the small intestine prior to incorporation with other lipids.  
Incorporated into lipid micelles, it is then transported to the liver in chyclomicrons before 
being repackaged and transported through blood vessels in low and high density lipoproteins 
(Fig 8).  
    The processes by which the ingested lycopene is absorbed, transported in the body and 
deposited in tissues and organs are of fundamental importance in relation to any effect of 
lycopene on human health.  One study looked at a physiological pharmacokinetic model in 
healthy subjects following ingestion of a tomato beverage formulation in different doses 
(Diwadkar-Navsariwala et al., 2003).  Comprised of seven compartments (gastrointestinal 
tract, enterocytes, chylomicrons, plasma lipoproteins, fast-turnover liver, slow-turnover 
tissues, and a delay compartment before the enterocytes) that were looked at, optimal 
percentage absorption of lycopene occurred at 10mg of physiological dose while higher doses 
of lycopene showed lower percentage in absorptive activity although the absolute amount 
(mg) of lycopene absorbed was not statistically different between doses.  It was speculated 
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that there is possible saturation of lycopene at higher doses, indicating the importance of 
correctly planning clinical trials with multiple doses of lycopene in the treatment.  
 
 
 
Figure 8: Caretenoid uptake by micelles following ingestion and its release into the 
bloodstream prior to deposition in the tissues (Yeum and Russel, 2002). 
 GI: gastrointestinal, CAR: Carotenoids, apo-CAR: apo-carotenoids, VLDL: very low density 
lipoprotein, LDL: low density lipoprotein, HDL: high density lipoprotein, RAL: retinal 
 
 
1.16.4 Bioavailability of lycopene with tissue distribution 
Despite growing studies in the role of lycopene in reducing the risks of certain malignancies, 
data on the mechanisms of absorption and bioavailability of this carotenoid is poorly 
explored (Diwadkar-Navsariwala et al., 2003).  Most of the studies on bioavailability are 
limited to crude food-based dietary supplements with less information available on the pure 
compound.  Faisal, O’Driscoll and Griffin, (2010) in a study of bioavailability of lycopene in 
the rat and the role of intestinal lymphatic transport (as the major route for lycopene uptake) 
have found that the absolute bioavailability of lycopene after 8 hours was estimated to be as 
low as 1.85% as collected from the mesenteric lymph duct.   
    Another study investigating lycopene distribution in ferret and rat tissues (Ferreira et al. 
2000) has measured the highest lycopene levels in liver where cis-lycopene and all-trans-
lycopene are the predominant isomers in ferret and rat tissues, respectively.  Due to the 
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highly lipophilic properties of lycopene, important factors could influence the absorption 
process such as the solubility in the physiological media, the uptake by intestinal cells and its 
release into the general circulation.  
1.16.5 Cytotoxicity of lycopene 
An excess intake of lyopene is not known for its toxicity but may cause a deep orange 
discoloration of the skin, a harmless condition called lycopenemia (Reich et al., 1960).  It was 
reported in a 61 year old woman who had consumed 2 litres of tomato juice everyday for 
several years, but was reversible after 3 weeks of consuming tomato-free juice with the 
discolouration fading.   
There is a lack of data on the adverse effects of lycopene in either animal or healthy 
humans in vivo or in vitro, but Trumbo (2005) has reported that there were no adverse effects 
observed at intake levels up to 3g/(kg.d) of formulated lycopene in the diet.  In addition, it 
was also suggested that in there is neither tolerable intake of lycopene that standardized nor 
well documented by Institute of Medicine (Washington). Indeed in the UK, no definite 
recommendation for a dietary intake has been published to date for lycopene, presumably 
lycopene is present in so many food sources. 
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1.17 Aim and research objectives 
The aims of this study were to investigate whether curcumin and lycopene have any potential 
therapeutic effects on a number of biopsy-derived GBs in vitro, as outlined below: 
1. Determination of IC25, 50, and 75 values (concentration that inhibits 25, 50 and 75% of 
cell viability of the tumour cells in vitro) of the 2 micronutrients using DRAQ7 cell 
viability assay (flow cytometry).  Subsequent experiments were contingent upon 
obtaining this IC values.  
2. Evaluation on the expression of parameters responsible for invasion, angiogenesis and 
apoptosis (e.g.MMPs, CD44, growth factors) using immunocytochemistry and flow 
cytometry.   
3. Investigation of the ability of curcumin and lycopene to induce apoptosis in biopsy-
derived GBs using flow cytometry via Annexin-V staining. 
4. Determination of anti-invasive potential of micronutrietns studied using an invasion in 
vitro. 
5. Investigation of anti-angiogenic effects of micronutrients using an in vitro 
angiogenesis assay.  
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CHAPTER 2: Materials and Methods 
2.1 List of materials 
Equipment/ Labware 
Flasks Corning Life Sciences, Amsterdam, Netherlands 
0.22µm Filter     Milipore, Watford, United Kingdom 
6, 24 well plates Thermo Scientific Nunclon, Langenselbold, 
Germany  
Angiogenesis inserts    Corning Life Sciences, Amsterdam, Netherlands 
Column chromatography Fisher Scientific, Loughborough, United 
Kingdom  
Centrifuge ALC multispeed refrigerated centrifuge, 
PK13IR, DJB Labcare, Buckinghamshire, 
United Kingdom  
Biofuge Fresco (microcentrifuge) Heraeus Instrumetns, DJB Labcare, 
Buckinghamshire, United Kingdom 
GX Microscope    GX Optical, Suffolk, United Kingdom 
Ceti Microscope    Labmode, Borehamwood, United Kingdom 
JB Aqua 26 waterbath    Grant, Cmabridgeshire, United Kingdom 
Vortex-genie 2  Jencons Scientific Ltd, Bedfordshire, United 
Kingdom 
ACCULAB weighing scale VWR International Ltd, Leicestershire, United 
Kingdom 
Clifton sonicator Nickel-Electro Ltd, Weston-Super-Mare, United 
Kingdom 
Fluo Satr Optima microplate reader  BMG Labtech, Bucks, United Kingdom 
47	
	
BD FACS Calibur BD Biosciences, Oxford, United Kingdom 
Cryogenics Jencons Scientific Ltd, Bedfordshire, United 
Kingdom 
 
Reagents 
Purification of Tetrahydrofuran  
THF (tetrahydrofuran)   Sigma-Aldrich, Dorset, United Kingdom 
Aluminium oxide (alox)   Sigma-Aldrich, Dorset, United Kingdom 
Preparation of Curcumin and LycoRed concentrations 
DMSO (dimethyl sulphoxide) Fisher Scientific, Loughborough, United 
Kingdom  
THF (tetrahydrofuran) Sigma-Aldrich, Dorset, United Kingdom  
DMEM (Dulbecco’s Modified Eagle            Invitrogen, Paisley, United Kingdom 
Medium)  
 
FCS (Foetal calf serum)   Sigma-Aldrich, Dorset, United Kingdom 
Antibiotic  
(Penicillin-Streptomycin) (500U/M)  Invitrogen, Paisley, United Kingdom 
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Cell culture maintenance 
DMSO (dimethyl sulphoxide) Fisher Scientific, Loughborough, United 
Kingdom    
DMEM                                                         Invitrogen, Paisley, United Kingdom 
(Dulbecco’s Modified Eagle Medium)   
FCS (Foetal calf serum)   Sigma-Aldrich, Dorset, United Kingdom  
Antibiotic  
(Penicillin-Streptomycin) (500U/M)  Invitrogen, Paisley, United Kingdom 
 
HUVEC                                                        
(Human Umbilical Vein                                
 Endothelial Cells)  
Cell Growth Supplement TCS Cellworks (Caltag Medsystem),                            
Buckingham United Kingdom  
HUVEC Media TCS Cellworks (Caltag Medsystem), 
Buckingham, United Kingdom 
Gelatin      Sigma-Aldrich, Dorset, United Kingdom  
Population doubling time 
Trypsin       Invitrogen, Paisley, United Kingdom 
DMEM  
(Dulbecco’s Modified Eagle Medium) Invitrogen, Paisley, United Kingdom  
FCS (Foetal calf serum)   Sigma-Aldrich, Dorset, United Kingdom  
 
Antibiotic  
(Penicillin-Streptomycin) (500U/M)  Invitrogen, Paisley, United Kingdom 
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Calcein AM cell viability assay 
Calcein AM      Invitrogen, Paisley, United Kingdom  
DMEM  
(Dulbecco’s Modified Eagle Medium) Invitrogen, Paisley, United Kingdom  
FCS (Foetal calf serum)   Sigma-Aldrich, Dorset, United Kingdom  
Antibiotic  
(Penicillin-Streptomycin) (500U/M)  Invitrogen, Paisley, United Kingdom 
 
Cell viability assay using flow cytometry (DRAQ 7) 
DRAQ7     Biostatus Ltd, Leicestershire 
DMEM  
(Dulbecco’s Modified Eagle Medium) Invitrogen, Paisley, United Kingdom  
FCS (Foetal calf serum)   Sigma-Aldrich, Dorset, United Kingdom  
Antibiotic  
(Penicillin-Streptomycin) (500U/M)  Invitrogen, Paisley, United Kingdom 
 
Cell characterization via Immunocytochemistry (ICC) 
Trypsin       Invitrogen, Paisley, United Kingdom 
HBSS (Hanks Balance Salt Solution)  Invitrogen, Paisley, United Kingdom  
Anti-mouse IgG (developed in rabbit) 
biotin conjugated     Sigma-Aldrich, Dorset, United Kingdom   
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Alexa fluor 488  
streptavidin conjugated    Invitrogen, Paisley, United Kingdom  
 
Mouse monoclonal anti-GFAP 
(Glial Fibrillary Acidic Protein)   Abcam plc, Cambridge, United Kingdom 
 
PBS (phosphate buffer saline)  Invitrogen, Paisley, United Kingdom 
Monoclonal anti-NG2  
(neuron glial-2) antibody    Sigma-Aldrich, Dorset, United Kingdom  
 
Mouse anti-human GD3  
(ganglioside 3) monoclonal antibody   Milipore, Watford, United Kingdom 
Mouse anti-human CD44                              
(cluster differentiation 44)  
monoclonal antibody     Milipore, Watford, United Kingdom 
 
Mouse Anti-Beta-1-integrin  
monoclonal antibody     Abcam plc, Cambridge, United Kingdom 
 
CDS (Cell Dissociation Solution)  Invitrogen, Paisley, United Kingdom  
  
 DMEM  
(Dulbecco’s Modified Eagle Medium) Invitrogen, Paisley, United Kingdom  
FCS (Foetal calf serum)   Sigma-Aldrich, Dorset, United Kingdom  
Antibiotic  
(Penicillin-Streptomycin) (500U/M)  Invitrogen, Paisley, United Kingdom 
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Cell characterization via Flow cytometry 
Propidium iodide    Invitrogen, Paisley, United Kingdom 
Mouse anti-human CD44 
(cluster differentiation 44) 
monoclonal antibody     Milipore, Watford, United Kingdom 
 
Mouse Anti-Beta-1-integrin  
monoclonal antibody     Abcam plc, Cambridge, United Kingdom 
 
CDS (Cell Dissociation Solution)  Invitrogen, Paisley, United Kingdom  
 
Mouse anti-MMP14 
(matrix metalloproteinase 14)  
monoclonal antibody     Abcam plc, Cambridge, United Kingdom 
 
Mouse Anti-VEGF 
(Vascular Endothelial Growth Factor) 
monoclonal antibody     Abcam plc, Cambridge, United Kingdom 
  
Anti-mouse IgG (developed in rabbit) 
biotin conjugated     Sigma-Aldrich, Dorset, United Kingdom   
DMEM  
(Dulbecco’s Modified Eagle Medium) Invitrogen, Paisley, United Kingdom  
FCS (Foetal calf serum)   Sigma-Aldrich, Dorset, United Kingdom  
Antibiotic  
(Penicillin-Streptomycin) (500U/M)  Invitrogen, Paisley, United Kingdom 
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Apoptosis assay via flow cytometry analysis (Annexin V detection) 
Annexin V-Alexa fluor 647   Invitrogen, Paisley, United Kingdom 
Propidium iodide    Invitrogen, Paisley, United Kingdom 
Staurosporine     Sigma-Aldrich, Dorset, United Kingdom 
DMEM  
(Dulbecco’s Modified Eagle Medium) Invitrogen, Paisley, United Kingdom  
FCS (Foetal calf serum)   Sigma-Aldrich, Dorset, United Kingdom  
Antibiotic  
(Penicillin-Streptomycin) (500U/M)  Invitrogen, Paisley, United Kingdom 
 
In vitro invasion assay 
DilC (1,1’-dioctadecyl-3,3,3’,3’ 
-tetramethylindo 
carbocyanine perchlorate) BD Biosciences, Oxford, United Kingdom  
 
BD Fluoroblok BD Biosciences, Oxford, United Kingdom 
 
DMEM  
(Dulbecco’s Modified Eagle Medium) Invitrogen, Paisley, United Kingdom  
FCS (Foetal calf serum)   Sigma-Aldrich, Dorset, United Kingdom  
Antibiotic  
(Penicillin-Streptomycin) (500U/M)  Invitrogen, Paisley, United Kingdom 
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HUVEC 
(Human Umbilical Vein Endothelial Cells) 
Cell Growth Supplement TCS Cellworks (Caltag Medsystem), 
Buckingham, United Kingdom 
HUVEC Media TCS Cellworks (Caltag Medsystem), 
Buckingham, United Kingdom 
In vitro angiogenesis assay 
Trypan blue      Sigma-Aldrich, Dorset, United Kingdom  
DMEM  
(Dulbecco’s Modified Eagle Medium) Invitrogen, Paisley, United Kingdom  
FCS (Foetal calf serum)   Sigma-Aldrich, Dorset, United Kingdom  
Antibiotic  
(Penicillin-Streptomycin) (500U/M)  Invitrogen, Paisley, United Kingdom 
 
HUVEC  
(Human Umbilical Vein Endothelial Cells) 
Cell Growth Supplement TCS Cellworks (Caltag Medsystem), 
Buckingham, United Kingdom 
HUVEC Media TCS Cellworks (Caltag Medsystem), 
Buckingham, United Kingdom 
Matrigel (Extracellular matrix gel)  Sigma-Aldrich, Dorset, United Kingdom 
Suramin  TCS Cellworks (Caltag Medsystem), 
Buckingham, United Kingdom 
VEGF  TCS Cellworks (Caltag Medsystem), 
Buckingham, United Kingdom 
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Cell cultures 
CC2565 Primary brain tumour cell   Cambrex Biosciences Walkersville Inc. USA 
 cultures       
  
MUBP, MUBS, MUP, MUTC, 
MUMG 
Designated cell cultures from  
Glioblastoma biopsy derived Kings’ College Hospital, London, United 
Kingdom  
 
HT-1080 fibrosarcoma cell line  ATCC Middlesex, United Kingdom     
HUVEC human umbilical vein 
endothelial cells    University of Portsmouth, United Kingdom 
 
Micronutrients 
Two micronutrients were used in this study, Curcumin extracted from turmeric and LycoRed 
(lycopene) extracted from tomato.  
Curcumin   
Curcumin was donated by Sabinsa Corporation, New Jersey USA (Sabinsa Corporation- 
appendix 1). It was 77% pure from the ground rhizome of turmeric, and produced by solvent 
extraction method (acetone solution). It was dissolved in 100% dimethyl sulphoxide prior to 
use and stored in room temperature.     
LycoRed (lycopene) 
Lycopene powder was kindly provided by LycoRed Israel (appendix 2). It contains 10% 
lycopene (via spectrophotometric method) from tomato extract and stored at -20˚C in the 
dark. Other ingredients include maltodextrin, modified starch, gum acacia, sugar esters and 
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soy lecithin which amount were not provided. 500µM stock solutions were freshly prepared 
with purified tetrahydrofuran prior to use. Henceforth, lycopene used in this study will be 
referred to as LycoRed. 
2.2 Methods 
2.2.1 Purification of Tetrahydrofuran 
THF is >99.9% pure and has the tendency to form highly explosive peroxides on storage in 
air. Thus, as to minimize this, commercially available THF has been added with 250ppm 
BHT (butylated hydroxyl-toluene) as an inhibitor of peroxides formation. Peroxides destroy 
the carotenoid as such in LycoRed hence purification of tetrahydrofuran is a requisite.  
  A layer of glass wool was placed at the bottom of the column (height 30cm, diameter 
3cm) before filling the column with 20cm in height of aluminium oxide (Alox). Alox is a 
white, fine-grained powder that is generally used as a medium in column chromatography.  
As an activated basic alumina, it traps the peroxides that present in the THF.  Therefore, 50ml 
THF was poured in the column packed with Alox and the first 10ml of eluent was discarded.  
The remaining eluent was collected in a dark glass bottle as THF can degrade plastic.   
 
2.2.2 Preparation of Curcumin and LycoRed concentrations 
A range of curcumin concentrations were prepared in DMEM with 20% fetal calf serum and 
1% antibiotic (penicillin-streptomycin). 5mg curcumin was dissolved in 500µl DMSO and 
filtered by 0.22µm syringe driven filter to prepare the stock solution of 10mg/ml curcumin.  
To ensure that any cytotoxicity observed was not due to DMSO activity, the 100% DMSO 
present in the curcumin stock solution was reduced to less than 1%. Therefore, 150µl of the 
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curcumin stock solution was dissolved in 49.85ml complete medium (20% fetal calf serum, 
1% penicillin/streptomycin) to give 50ml in total volume. This is equivalent to 0.3% of 
DMSO present at 30µg/ml (highest concentration of curcumin used). 
   In order to see whether curcuminoids has any cytotoxicity effect on the normal brain cells 
(CC2565), a wide range of curcuminoids concentrations were prepared. From the 30µg/ml, a 
set of concentration was prepared in complete medium (20% fetal calf serum, 1% 
penicillin/streptomycin). These include 5 and 30ng/ml, 3, 5, 6, 9, 12, 15,18,20,21 and 
24µg/ml.   
    Solutions of lycopene were prepared in purified tetrahydrofuran. Lycopene is highly 
hydrophobic resulting in low aqueous solubility.  3mg LycoRed was dissolved in 11ml THF 
(500µM). LycoRed solution was then vortexed and filled with nitrogen stream before 
sonication take in place for 30 minutes. Then it was diluted in complete medium (20% fetal 
calf serum, 1% penicillin/streptomycin) to 25µM resulting in a final concentration of 5% 
THF.    
This was then filtered with a 0.22µm syringe driven filter (Milipore).  From the 
filtered 25µM, a range of LycoRed concentrations were prepared in complete media; 20 (4% 
THF), 10 (2% THF), 5 (1% THF), 2(0.4% THF) and 1µM (0.2% THF) which are equivalent 
to 12, 6, 3, 1.2 and 0.6µg/ml LycoRed.  
2.2.3 Cell culture maintenance 
Normal astrocytes, (CC2565 cell line), at passage 11, were used as the control.  This is a 
normal human brain cell population from an 18 year old male, purchased from Cambrex 
Biosciences.  Brain tumour cultures for the study were obtained from craniotomy (removing 
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small window of bone from the cranium to allow the tumour section biopsied) of the 
glioblastoma patients in Kings College Hospital London (LREC protocols 02-056). 
Following each craniotomy, the tissue biopsy was placed in a universal bottle with complete 
medium (DMEM) before taken to Middlesex University about 30 minutes journey time in a 
sealed container. Five glioblastoma biopsy derived samples were used; MUBS, MUBP, 
MUMG, MUP and MUTC. These samples approximately 2 years to be obtained (hence 
gathered as number of samples for this study) as glioblastoma is quite a rare cancer. Each 
biopsy was immediately cultured as soon as it arrived at laboratory in Middlesex University. 
Using a sterile scalpel with an appropriate container, the biopsy was chopped into very small 
pieces as possible in the presence of the complete medium, i.e. DMEM contain 20% fetal calf 
serum and 1% penicillin/streptomycin.  In order to achieve primary explant culture, each 
chopped biopsy was placed in a small flask in the complete medium as a monolayer and 
routinely passaged when it reached confluency. The physiological pH was maintained 
through equilibration with 5% CO2 atmosphere in 37°C humidified incubator. For each 
biopsy collected, one small flask generated approximately 100,000 cells. When the cells were 
nearly confluent, they were harvested by trypsinization. The cells were passaged and more 
flasks were grown in order to have sufficient cells for all experiments. When necessary, the 
cells were frozen down for storage in the liquid nitrogen tank until required.  
    For in vitro angiogenesis and invasion assays, Human Umbilical Vein Endothelial Cells 
(HUVEC) was used (donated by Dr Alan Cooper from Portsmouth University at passage 2).  
HUVECs were maintained in HUVEC Complete Medium, supplemented with 0.2% of each 
Penicillin/Streptomycin, Heparin, EGF and 2% of FCS and 0.1% Hydrocortisone (TCS Cell 
Works).  The cells were cultured in gelatin-coated flasks which were prepared one hour prior 
to culturing.  Gelatin (1%) was prepared in sterile PBS autoclaved before use.  In addition, a 
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fibrosarcoma cell line, designed as HT-1080, which is purchased from ATCC, was used as a 
positive control in the analysis due to its high invasive capacity (Rasheed, et al., 1974).  The 
medium was changed approximately twice a week and trypsinized when nearly confluent. 
2.2.4 Population doubling time 
In order to study the population doubling time (PDT) or cell kinetics of a cell line, primary 
brain tumour cells were seeded,  initially at 20 000 cells/well (in 2ml complete medium per 
well), in 6 well plates.  The cells were incubated overnight, harvested and resuspended in 1ml 
of complete media from which 20µl of this cells suspension was combined with 20µl of 
trypan blue stain.  20µl of this solution was placed onto the haematocytometer prior to 
counting.  This was carried out in triplicate, twice a day for up to 9-13 days.  Trypan blue is a 
vital stain that selectively stains the dead cells but not the live ones.  The cell count obtained  
by calculating the average of two counts (a and b) as in the equation as follow:  
 
  
   Population doubling time assess the time that cells take to double in number, determined by 
the growth curve plotted (Fig.9).  The lag phase represents slow growth as cells adapt to the 
in vitro environment before moving on to the log phase (exponential phase) of rapid growth. 
This is also known as exponential phase, the duration where the population doubling time of 
cells was measured. A plateau phase takes place subsequently when nutrients become 
depleted and the cells space limited; under such conditions cell growth is reduced before cell 
senescence occurs. A Doubling Time software (Roth, 2006) was used to determine the PDT 
of cells on the log phase with the formula as below. 
 
Number of cells/ml = (a + b) x 2 x 10,000 
       2 
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(t log2)/ (log Nt- log Ni) 
t= time period 
Nt= number of cells at time t 
Ni=initial number of cells 
 
 
  
 
 
 
 
 
 
                                                       Time (hours)  
Figure 9: A sigmoidal curve showing three different phases in cell growth.  The numbers of cells/ml 
obtained from the count are plotted against number of hours in culture.   
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2.2.5 Cell viability assays  
A number of cell viability assays were used in measuring the cytotoxicity of the solvents 
(DMSO and THF) and the IC value of micronutrients studied. One small flask generated 
approximately 100,000 cells per biopsy and 10,000 cells were required for each well in cell 
viability plates. Therefore, prior to each set of experiment, it is important to ensure that more 
flasks (grown with confluent cells) per biopsy were available to provide enough number of 
cells. 
IC25, IC50 and IC75 are described as the concentration of the substance (i.e. micronutrient) 
required for 75%, 50% and 25% inhibition of the cell viability respectively.  This study has 
used a cell viability graph with x axis as the concentrations of the micronutrient (or agent) 
studied and y axis as the percentage of cell that are viable (Fig 10). Therefore, the IC values 
were determined via the viability curve plotted. As it may be expected, IC75 will result to the 
least while IC25   to the most cytotoxic effect.  
 
Figure 10: A cell viability curve with % of viable cells (y axis) and concentration of micronutrient (x 
axis) shows IC values.  The IC values are derived at the point where % of viable cells crossed the 
curve and marked down towards the x axis to determine the concentration of micronutrient, i.e. IC 
value.  
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These values can be determined by a chemo-sensitivity assay, with either a 
colourimetric or a fluorometric method. However, throughout the experiment, it was noted 
that the distinct orange colour of curcumin affected the absorbance in the MTT assay and 
several washes as suggested by Peng et al (2005) had not resolved this problem.  Indeed, 
adaptation and/or modification of cell viability assay is acceptable depending on the 
substance or micronutrient tested, as such MTT assay (3[4, 5-dimethylthiazole-2-yl]-2,5-
diphenyltetrazolium bromide), has been modified and extensively used by other workers in 
the neuro-oncology field (Nikkah et al., 1992). Unlike MTT, which is a colourimetric, 
Calcein AM and DRAQ7 cell viability assays were used instead which are fluorescence dyes 
that are fluorometric in the detection.  These allow less interference in the analysis and no 
solubilization step is required, unlike MTT.  
2.2.5.1 Calcein AM cell viability assay  
Calcein AM is a cell-permeant dye that can be used to determine cell viability in most 
eukaryotic cells.  Once inside the cytoplasm of the cells, Calcein AM, a non-fluorescent 
molecule itself is hydrolyzed by endogenous esterase into the highly negatively charged 
green fluorescent Calcein (Brat-Boucher et al., 1995).  The fluorescent Calcein is retained in 
the cytoplasm in live cells.  The fluorescent signal is monitored using 492 nm excitation 
wavelength and 520 nm emission wavelength.  This signal generated from the assay is 
proportional to the number of living cells in the sample.   
The initial concentration of Calcein AM was 1mg/ml (1mM, molecular weight of 994.87) 
and diluted to 2µM/L in PBS for working concentration. 10,000 cells were grown in each 
well of the 96-well plate. A large number of cells were needed to run cell viability assay 
hence it is important to ensure that enough cells were available prior to setting up the 
experiment. Approximately 100,000 cells per biopsy will be collected from a small flask thus 
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preparing more flasks with grown, confluent cells beforehand is important. (see section 
2.2.3). The medium was removed from each well (including control wells) and washed with 
PBS twice.  100µl of Calcein AM solution was pipetted into each well and the plates were 
incubated for 1 hour (37°C 5%, CO2) prior to fluorescent spectrophotometer reading.  
2.2.5.2 Cell viability assay using flow cytometry (DRAQ 7)  
DRAQ 7 is a new Far-Red Fluorescent Live-Cell Impairment DNA dye (Biostatus Ltd) that 
only stains the nuclei in dead and permeabilized cells but not intact live cells.  Unlike 
Propidium Iodide, DRAQ 7 has no ultra violet excitation and  has far better spectral 
properties, (from the 488 nm, 568 nm and 633 nm lines, plus optimal 647 nm excitation, 
fluorescence emission from 665 nm into the low infra-red).  Thus, problems such as 
overlapping with Green Fluorescence Protein (GFP)/Fluorescein isothiocyanate (FITC) or 
Phycoerythrin (PE) needs no compensation (Biostatus Ltd., 2011).  DRAQ 7 fluorescent dye 
also requires no washing step which is helpful in preventing loss of cells due to washing.	
				Cells were harvested by trypsin and centrifuged at 800rpm for 5 minutes.  The fluorescence 
dye DRAQ 7 was prepared (3µM) in PBS from the stock concentration (0.3mM) prior to use.  
For each of the primary brain tumour cell cultures, the cells pre-treated with sterile distilled 
water is positive control while negative control is untreated cells (with no either curcumin or 
LycoRed).  The cells were not grown in the well of 96-well plates but small flasks due to 
higher number of cells required (100,000 cells) in FACS analysis.  Each cell culture was 
carried out in triplicate. Therefore, prior to each set of experiment, more flasks with grown, 
confluent cells (per biopsy) were needed hence prepared beforehand.  
To establish the position of DRAQ 7- and DRAQ 7+ gates, each control (negative and 
positive controls) were divided into 2 eppendorf tubes; with and without DRAQ 7 staining 
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(Fig. 11).  The other samples were resuspended in 100µl of the DRAQ 7 solution and 
incubated in the dark at room temperature for 15 minutes.  The cells were analyzed by flow 
cytometry within one hour of staining. 
 
 
 
  
 
Figure 11: Gating method in the DRAQ7 cell viability assay using controls as to establish the 
position of DRAQ7 positive and negative cells. This gating method is applied accordingly to each of 
the primary brain tumour cell cultures. 
 
These cell viability assays were then used to determine the IC values of each micronutrient 
via the viability curve plotted. Subsequent assays, such as Annexin-V-Alexa fluor 647 assay 
for detection of apoptosis by flow cytometry, are contingent upon the concentration (the IC 
Negative controls 
(untreated) 
Positive controls 
(treated with sterile 
distilled water) 
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values) determined primarily in the cell viability assay.  This was to confirm whether the IC 
values determined is inducing apoptosis or complete cell death.  Essentially for apoptosis 
assay, IC75 is selected to be used for their detection in inducing apoptosis, as it will results to 
the least cytotoxic effect on the cells hence to see the apoptotic induction rather than necrotic 
event in the occurrence. Another subsequent assays that also contingent upon the IC values 
obtained include in vitro invasion and angiogenesis assays. 
2.2.6 Cell characterization of primary brain tumour cells 
2.2.6.1 Immunocytochemistry (ICC) 
Primary brain tumour cells were grown (10,000 cells) on autoclaved glass coverslips in a 6-
well plate in growth medium DMEM through equilibration with 5% CO2 atmosphere in 37°C 
humidified incubator until it reached 80-90% in confluency prior to trypsinization. Further 
analysis was carried out under non-sterile conditions and included a negative control (in the 
absence of primary antibody), in duplicate. 
Primary antibody was prepared in Hanks Balance Salt Solution (HBSS -Sigma) or PBS 
according to manufacturer instructions (Table 2).  Secondary antibody-biotin conjugated 
(developed in rabbit, monoclonal, Sigma) of 1:100 dilution was also diluted in HBSS 
(Invitrogen) and the other two were Alexa fluor 488-Streptavidin conjugated (Invitrogen) and 
Propidium Iodide (Invitrogen), each in 1:100 dilution.  
Alexa fluor 488 that conjugated to a streptavidin is a fluorescence dye that is nearly 
identical to the spectral property and quantum yield of fluorescein isothicyanate (FITC). It 
has brighter and more photo-stable conjugates with excitation and emission of 495 and 
519nm respectively. 	 Alexa fluor-488 enables superior photostability in comparison with 
FITC since it allows more time for image observation and capture, permitting greater 
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sensitivity.	Streptavidin has a very high affinity for biotin, which commonly binds to variety 
of proteins and molecules such as the biotinylated secondary antibody used in the study. 
Therefore, the primary antibody that bound to the antigen on the cell surface can be detected 
via fluorescently labeled biotinylated secondary antibody.  	
Table 2: Working dilutions of the primary antibodies (*Abcam **Milipore ***Cancer 
Research UK 
Primary antibodies (developed in mouse, 
monoclonal) 
Working dilution 
GFAP (Glial Fibrillary Acidic Protein) * Used neat as pre-diluted (0.5µg/ml) 
CD44 (Cluster Differentiation of 44)** 1:250 (0.4µg/ml) 
Beta-1 integrin*** 1:100 (1-10µg/ml) 
NG2 (Neuron Glial 2) ** 1:100 (20µg/ml) 
GD3 (Gangliosides 3) ** 1:250 (4µg/ml) 
 
 Antigen 
          Primary antibody 
 
 Secondary antibody-biotin conjugated  cell surface 
 Alexa-fluor 488 
   Streptavidin 
Figure 12: Immunocytochemistry reaction using labelled secondary antibody (Alexa-Fluor 488-
Streptavidin conjugated). 
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After aspirating the medium from the petri dish, the cells were washed with Hanks for 1 
minute. For accessing cytoplasmic antigen such as GFAP, acid alcohol (1 part concentrated 
hydrochloric acid in 99 parts of 70% ethanol) was added initially and left for 2 minutes to 
make the cell membrane permeable, allowing the primary antibody to be accessible to the 
antigenic sites. 2 ml of anti-GFAP solution was added to the corresponding cells. Addition of 
acid-alcohol solution is not applied to cell surface antigens (CD44, Beta-1 integrin, NG2 and 
GD3) studied thus this procedure was omitted. For cell surface antigens, 2 ml of each primary 
antibody was added to each corresponding well but not to the negative control.  All primary 
antibodies added were left for one hour incubation at room temperature prior to washes with 
Hanks. 
Then they were incubated with 2ml of secondary antibody (biotin conjugated) for 30 
minutes at room temperature followed by washing with Hanks (three times).  2 ml of Alexa 
fluor 488-Streptavidin was added to it and left to incubate for 15 minutes in the dark.  In 
between secondary antibody and Alexa fluor 488-Streptavidin addition, washing with Hanks 
was carried out.  Subsequently, 1ml of Propidium Iodide was added to each well for 10 
seconds exactly followed by the addition of excess Hanks. 
For cells that were stained with cell surface antibody, acid-alcohol was added and left for 2 
minutes before washing 3 times in Hanks.  Propidium iodide then was added to counterstain 
the nucleus red. Cells stained with GFAP antibody were also stained with propidium iodide 
for the same principle. The cells were then washed with Hanks (three times for one minute 
each).  Next, the coverslip was removed from each well and placed on a labeled glass slide 
prior to mounting with Citifluor (a mounting media), designed to reduce the fading 
(bleaching) of the fluorescence of fluorochromes.  The slides were viewed under a confocal 
microscope (Leica TCS SP5) made together with control.  
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2.2.6.2 Flow cytometry 
Primary brain tumour cultures were initially grown in 25cm2 flask (Corning) until it reached 
70-80% confluent, i.e 70,000 to 80,000 cells (37°C, 5% CO2).  Each primary brain tumour 
cell cultures were stained with four different antibodies investigated and this analysis was 
carried out in three sets of experiment in duplicate.  
The cells were harvested by adding 1ml of Cell Dissociation Solution (CDS) for 10 
minutes.  CDS was used instead of trypsin as trypsin could damage the epitopes of the cell 
surface antigens.  The cells suspension was centrifuged for 5 minutes at 800rpm.  Following 
supernatant removal, the pellet was resuspended (in eppendorf tubes) in 100µl of primary 
antibody and incubated for 30minutes at room temperature.  
The cells were then washed with PBS twice before resuspending in 100µl of secondary 
antibody-FITC conjugated (1:100 in PBS) and incubating for 30 minutes in the dark at room 
temperature.  The cell suspension was transferred to FACS tubes. 50µl of Propidium Iodide at 
concentration of 50µg/ml was then added to the cell suspension prior to analysis. 
Simultaneously, the cell suspension that being aspirated for analysis was also undergoing 
statistical analysis carried out by Cell Quest Pro software.  
For each antibody investigated, in order to differentiate the positive (M2) and negative 
(M1) sides of the histogram in the analysis, a negative control was also run alongside the 
other samples investigated in which primary antibody was omitted but secondary antibody-
FITC conjugated was added (Fig 13).   
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Figure 13: A histogram shows a negative control in the flow cytometry analysis in which the primary 
antibody was omitted leaving only secondary antibody (with biotin conjugated) being incubated. M2 
will represent the positive stained cells while M1 is negative in staining.  
 
In order to establish the positive control for each primary antibody studied, the cells 
that are known to be positive in its expression was sought to be analysed hence finding the 
optimal concentration to be used next, particularly for the primary brain tumour cells being 
investigated. For example, CD44 and Beta-1-integrin was known to be expressed by a breast 
cancer cell line, MCF-7 (Park et al 2006, Hiscox et al 2012) while  MMP-14 and VEGF in 
U373 cells (Nuttal RK et al 2003, Feldkamp et al 1999), an established glioblastoma cell line.  
The final concentration of primary antibody which prepared in PBS has been 
optimized initially. Each primary antibody was titrated using doubling dilutions (twofold) of 
the primary antibody and a standard number of cells (x106 in 100µl of buffer for each 
titration). Cells were stained with the isotype control or the primary antibody titrated 
separately, in which the concentration and conditions of both staining are the same. Isotype 
control used was the mouse IgG which acts as a reference population to estimate the non-
specific binding (due to Fc receptor binding or other protein-protein interactions) of the 
primary antibodies to cell surface antigens. The optimal dilution chosen was based on the 
best separation between the isotype and the titrated antibody measured (the difference in the 
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fluorescence intensity) at a dilution point. A summary of concentrations used is tabulated in 
table 3.  
Table 3: Working dilutions of the primary antibodies (Abcam). 
Primary antibodies (monoclonal) Working dilution 
MMP-14 (Matrix metalloproteinase 14)  50µg/ml 
CD44 (Cluster Differentiation of 44) 2.5µg/ml 
Beta-1 integrin 10µg/ml 
VEGF (Vascular Endothelial Growth Factor)  12.5µg/ml 
 
2.2.7 In vitro invasion assay 
Invasion assay in vitro by Albini et al (1987) has been widely used in the investigation of 
invasive capacity of most cancer cells which is based on the movement of cancer cells 
through a porous filter coated with Matrigel. BD Biocoat Fluoroblok invasion has make 
invasion assay in vitro easier and quantitative in the analysis.  
The process of cellular invasion is comprised of distinct events which include 
attachment of cells into the basement membrane, secretion of enzymes which degrade the 
basement membrane and the migration of cells into the target tissue in response to specific 
chemotactic stimuli. Indeed, a similar sytem of invasion assay in vitro was applied in both 
invasion assay in vitro but with Fluoroblok system it is pre-coated with the Matrigel. This 
uniform layer of BD Matrigel Matrix serves as a reconstituted basement membrane in vitro 
providing a true barrier to non-invasive cells. BD Fluoroblok has a membrane which is 
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effectively blocks the passage of light from 490-700 nm. Indeed, fluorescently-labeled cells 
that have not invaded are not detected by a bottom-reading fluorescence plate reader. 
Before use, each well in the invasion plate was rehydrated with 75µl serum free media 
for 2 hours (37°C, 5% CO2).  The cells were then incubated with DilC (a fluorescence dye 
that fluoresces inside the cells only) at 10µg/ml for 1 hour. HT1080 cells were used as the 
positive control and the invasive capacity of the untreated and IC75 treated cells were 
compared. After 1 hour incubation with DilC dye, the cells were trypsinized and counted. 
After rehydration with the serum free medium, 25µl of serum free media were aspirated out. 
Then the cells were seeded on the Matrigel (12,500 cells in 25µl are needed for each insert) 
followed by addition of micronutrients studied. Finally, 200µl of chemoattractant (growth 
media at 5% fetal calf serum) was added to the base plate through the feeding hole next to the 
insert. The plate was incubated at 37°C, 5% CO2 and read every 24hour with the plate reader 
at excitation of 450 and emission of 460 nm.  
 
2.2.8 Apoptosis assay via flow cytometry analysis (Annexin V detection)  
An important feature in apoptotic cells is the translocation of phosphotidylserine (PS) from 
the inner to the outer leaflet of the plasma membrane, exposing PS to the external cellular 
environment.  Annexin-V is a Ca2+ dependent phospholipid binding-protein that has a high 
affinity with PS (Vermes et al., 1995).   
Conjugation of Annexin-V with Alexa fluor 647, a fluorochrome, was used since it is a 
sensitive probe for flow cytometric analysis of cells that are undergoing apoptosis.  Flow 
cytometers use separate fluorescence (FL) channels to detect light emitted. For example, 
Annexin-V Alexa fluor 647 conjugated (BD Biosciences) has maximal emission of 665nm 
which uses channel FL4 (FL4-H in the diagram) in the flow cytometer setup. Its staining 
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identifies early apoptosis PS externalization occurs at an early stage of apoptosis.  Propidium 
iodide, with maximal emission of 617nm stains the nucleus of dead cells. This uses channel 
FL3 (FL3-H in the diagram) that represents late apoptosis. Thus, cells that are late in 
apoptosis will be positive in both Annexin-V and PI, while an early apoptotic event will be 
shown as positive for Annexin-V but negative for PI.  For viable cells, Annexin-V and PI are 
both negative (Fig 14). 
 
Figure 14: A quadrant in the Annexin V apoptosis. Each region in the quadrant i.e. lower right, lower 
left, upper right and upper left represents the population of cells. Axis with FL3-H indicates PI and 
axis with FL4-H indicates Annexin V.  
 
Cells were incubated for 24, 48, 72 and 96 h with or without curcumin prior to analysis. 
The cells were harvested by adding 1ml of Cell Dissociation Solution (CDS) for 10 minutes. 
The cells suspension was centrifuged for 5 minutes at 800rpm. Following supernatant 
removal, the pellet was resuspended (in eppendorf tubes) in PBS for washing before 
resuspending in 5µl of Annexin-V-Alexa fluor-647 conjugated was added (prepared initially 
in 1x Annexin V binding buffer) and incubated at room temperature in the dark for 30 
minutes.  50µl of Propidium Iodide at concentration of 50µg/ml was then added to the cell 
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Early	apoptotic	
cells	
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suspension prior to analysis. A positive control for apoptosis used was staurosporine treated 
cells (1µM) in order to set up the quadrant of dead and live cells respectively.   
2.2.9 In vitro angiogenesis assay (co-culture method) 
Angiogenesis is a physiological process that occurs during wound healing and normal 
development which involves the growth of new blood vessels from pre-existing vessels.  It is 
essential for normal	 growth and homeostasis yet can be altered in disease states with 
excessive or inadequate blood vessel occurrence (Kim and Lee, 2009).	 	 There are an 
abundance of angiogenesis assays available to screen various compounds in the analysis 
(exploiting the tubule formation of endothelial cells) but co-culture assay with the use of 
Matrigel (in transwell chamber) was selected to be carried out. 
    Following degradation of the capillary wall by extracellular proteinases, Human Umbilical 
Vein Endothelial Cells (HUVEC) respond to angiogenic factors secreted by the cancer cells 
prior to tubule formation.  Starting with a branching point in the vessel wall, HUVEC cells 
will migrate into the extracellular matrix (ECM) towards the angiogenic stimulus, resulting in 
re-organization of endothelial cells to form tubules with a central lumen and hence a network 
(anastomosis). 
Primary brain tumour cultures were harvested and seeded in 24-well plates in 500µl of 
DMEM with 20% foetal calf serum and 1% antibiotic (penicillin-streptomycin) at density of 
100,000 cells per well.  The physiological pH is maintained through equilibration with 5% 
CO2 atmosphere in 37°C humidified incubator.  Cells were incubated as to allow the cells to 
settle on the surface of the wells.  Then, 8µm pore size inserts (Costar Corning, Netherlands) 
were coated with 100µl of undiluted (8-12mg/ml) Matrigel (Sigma) Matrigel is the 
extracellular matrix gel that prepared from Engelbreth-Holm Swarm (EHS) sarcoma 
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produced in mice and mainly contains laminin as a major component (Kleinman et al., 1993).  
Inserts were seeded with HUVEC at the cell density of 50,000 cells per insert in 300ul of 
HUVEC Complete Media which consisted of 2% fetal bovine serum, 0.1% of hydrocortisone 
and 0.2% each of penicillin and streptomycin, Epidermal Growth Factor (EGF) and heparin. 
Matrigel coated inserts (which HUVEC were grown) were placed above the wells.  Both 
negative (Suramin at 20µM) and positive (VEGF at 2ng/ml) controls were included. Suramin 
is an inhibitor of tubule formation while VEGF is act as a stimulant for it. Each concentration 
investigated was run in triplicate and experiments were repeated when necessary.  This co-
culture plate was incubated at 37°C for 6 to a maximum 16 hours as recommended by Becton 
Dickinson (BD Biocoat Angiogenesis Systems, 2006). 
Medium was aspirated and each insert was then washed twice in PBS. HUVEC cells in the 
insert were fixed with 100% of methanol for 10 seconds and stained with crystal violet 
(1:1000 dilution in PBS) for 1 hour at 37°C.  Six random fields of each insert were 
photographed under Ceti (10x10) microscope. Tubule networks were traced from these 
images using paint software. These were then analysed using Image J.  
Image J software (Carpentier, Universite Paris Est ) consists of segmentation of the cell 
areas followed by a skeletonization. Skeletonization includes the detection of pixels; 
extremities (one neighbor pixel), nodes (three neighbor pixels) and junctions (one or more 
nodes). Next, the pseudo vascular tree analysis was sorted into different pieces resulting to 
branches (pieces connected to one extremity, one node or junction) and segments (pieces 
connecting to two nodes or junctions). Once all the parameters read and analysed, all data 
obtained will be displayed and tabulated in an Excel (Microsoft). Of all the parameters 
measured, only four were taken into analysis which are mainly reported and representative in 
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angiogenesis analysis. Tubules that formed following curcumin treatment were quantified 
from the photograph captured and results were presented as mean and standard error of mean.  
 
							
				 		
 
Figure 15: The tubule network traced with Paint software (A and B) before analysed  using Image J 
software (C). With the image J software, each colour represents a parameter measured in the 
angiogenesis. The four parameters are total length of the tubules, node and junction (red in blue 
circle) and branches (green).  
A 
B 
C 
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2.2.10 Statistical analysis 
Statistical analysis was performed using Microsoft Excel 2007 and Minitab 16 to analyse the 
readings obtained from each assays being carried out; i.e. cell viability, flow cytometry, in 
vitro invasion and angiogenesis assays.  One way ANOVA (Analysis of variation) was 
employed to determine whether differences exist among the means of the experimental data 
sets. If differences existed, 2 sample t-test analyses were carried out. p value obtained 
determined significance at value of <0.05. Each concentration studied, either duplicate or 
triplicate (when required) was averaged.  For cell viability, the mean value was then 
compared to the positive control (representing100% cells that are viable as untreated) in order 
to get the percentage of residual viable cells (in cell viability assays). For flow cytometry 
analysis, Cell Quest Pro was used in order to get the data analysed and presented.   
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Chapter 3: Results 
 
 
3.1 Morphology of primary brain tumour cell cultures 
 
Glioblastoma multiforme is widely known for its characteristic of extensive 
heterogeneity not only at molecular but also at cellular levels, hence the word “multiforme”. 
Not only in brain tumours, this feature ascends in many types of other tumours which 
contribute to the general consequence of the malignancy such as tumour aggressiveness and 
creating hurdles for effective therapies to be achieved. Indeed, within the heterogenous cell 
population of glioblastoma, there are different sub populations of cells that respond 
differently towards the therapies (Bradford et al, 1997) hence surviving and growing in the 
tumour bed.  
Morphological appearances of both the normal brain cell line and glioblastoma cell 
cultures were viewed and compared under phase contrast microscopy (200 x magnification).  
CC2565, the normal brain cell line was used as a control in this study (passage 10 and above) 
while the four primary cell cultures were glioblastoma-biopsy derived.  
Each of the primary cell cultures showed some degree of heterogeneity. This is a 
feature of brain tumour cell cultures. Figures 16A-16E show the different population of cells 
within each cell line studied.   
Normal brain cells (Fig 16A) showed less heterogeneity in the morphology with 
elongated spindle cells with few of small star shaped cells. MUBS cell primary cell culture 
was various in the shapes and cells size when it was not only comprised of small, large, star 
shaped cells but also some spindle shaped cells as indicated by the colour coded arrows in fig 
16B. As with MUBP (Fig 16C) and MUP (Fig 16E) cell cultures, spindle, small and large star 
shaped cells were photographed by the phase contrast microscope. As indicated by the 
coloured arrows, MUTC cell culture was comprised with intermittently arranged of cells (Fig 
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16D) with a mixed morphology of spindle, small and large stars as well as broad, straight and 
blunt end shaped cells. Thus, based on the different cell morphology observed in a population 
of cells, it is suggested that in these primary cell cultures, they are more heterogenous in the 
morphology compared to the normal brain cells, CC2565.  
  
  
 
Figure 16: Phase contrast micrographs of the normal brain cell line; A) CC2565-passage 10 and 
primary brain tumour cell cultures (GB biopsy-derived); (B) MUBS-passage 6 (C) MUBP-passage 9 
(D) MUTC-passage 8 and (E) MUP-passage 8.  The different morphology of cells was shown by the 
colour coded arrows which include spindle (red), small star (green), large star (blue) and broad, 
straight and blunt end (purple) in shapes. All cell cultures were viewed and compared under phase 
contrast microscopy (20X magnification). 
A 
E 
D 
B 
C 
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Below are the summary of the biopsy reports which were taken on the day the surgery 
was completed at Kings College Hospital at an appropriate procedure (as mentioned in the 
materials and methods chapter).  Following surgeons’ confirmation on Glioblastoma (grade 
IV), each biopsy was processed in Middlesex University in the tissue culture laboratory to 
generate a cell culture prior to be used in this study. See appendix for an example of the 
report (all details are confidential). 
 
Designated 
Biopsy 
Histology/Pathology details Clinical details 
MUBP • Multiple fragments of an extensive necrotic 
tumour.  
• Hypercellularity with glial fibrillary 
background, increased mitotic activity and 
nuclear pleomorphism 
• Endothelial hyperplasia with glomeruloid 
changes 
• Headaches, confusion, 
4 weeks of left sided 
weakness 
MUP • No deletion of 1p and 19q  
• Showed areas of fibrillary astrocytes and 
gemistocytic astrocytes 
• Necrosis and vascular hyperplasia seen 
• Not mentioned  
MUBS • Pleomorphic cells seen 
• Occasional giant cells and mitotic figures 
• Cells with eosinophilic processes embedded 
within fibrillary background 
• Florid vascular endothelial cell proliferation, 
necrotic areas with surrounding 
pseudopalisading of tumour cells 
• Previously fit and well 
until experienced 
headache with 
incoordination of left 
side. 
• Improve on 
steroids. MRI showed 
enhancement with 
gadolinium with 
central necrosis 
MUTC • Pleomorphic, elongated, round nuclei, 
proliferation marker (Ki67) was expressed 
(35% of tumour cells)  
• Not mentioned 
 
Table 4: A summary of the pathology and histopathology details of all biopsies studied. These details 
were provided by Kings College Hospital at an appropriate procedure. For the purpose of record, each 
biopsy was designated to an acronym according to the patient’s first and last names.  
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3.2 Population doubling time of primary brain tumour cell cultures 
 The doubling time of each cell culture was measured from the log phase of the growth 
curve using Doubling Time Calculator software (Roth, 2006). The PDT results obtained via 
Doubling Time Calculator software uses the same formula as in the principle of determining 
PDT in cells as described in section 2.24 in chapter 2. This was carried out during the log 
phase of the growth curve when the growth rate is constant, (see chapter 2, section 2.2.4). 
Each PDT of a primary brain tumour cells were compared to the normal brain cells.  
Primary brain tumour cell cultures were relatively slow growing compared to the 
normal brain (40 hours) and established cell lines, as reported in two unpublished studies by 
other members (U373; PDT of 48 hours, IPSB-18; PDT of 16 hours). The PDT results ranged 
from 80 to 208 hours, in different cell cultures (Fig 17) and statistically analysed using One 
Way-ANOVA (with Fishers comparison)  method as tabulated in table 5. 
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Figure 17: Population doubling time of each primary brain tumour cell cultures. The x and y axis 
represent the doubling time (h) and cell cultures, respectively. Standard error of the mean is 
represented by the error bars. Data represents the mean ± standard error of the mean for n=2 
experiments with each experiment being carried out in duplicate. Statistical analysis was carried out 
using a 2 sample t-test analysis to obtain the p value (each group of treated cells were compared with 
the normal brain cells). * p<0.05 
 
 Cell cultures Mean Standard deviation Difference from control (95% CI) 
P (vs control cell 
line) 
CC2565 (control) 39.67 6.66 - - 
MUBS 80.00 38.5 40.3 (-18.9-99.6) <0.05 
MUBP 144.3 13.23 104.7 (45.4-163.9) <0.05 
MUP 154.3 45.0 114.7 (55.4-173.9) <0.05 
MUTC 208.3 39.7 168.7 (109.4-227.9) <0.05 
 
Table 5: Statistical analysis (One way-ANOVA-Fisher comparison) to show differences in doubling 
time between brain tumour cell cultures (MUBP, MUBS, MUP and MUTC). The doubling time 
ranged between 80 to 208h between primary brain tumour cell cultures studied 
(MUBS<MUBP<MUP<MUTC). Data showed that there are significant differences between the cell 
cultures studied with p<0.05 
 
 
 
Population doubling time of cells (hours) 
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3.3 Dimethyl sulphoxide and Tetrahydrofuran cytotoxicity  
Dimethyl sulphoxide (DMSO) and tetrahydrofuran (THF) are the organic solvents used to 
dissolve curcumin and lycopene respectively. In order to confirm that any cytotoxicity seen 
during experimentation is due to the effect of micronutrients rather than the solvents used, 
cell viability assays were carried out initially using DMSO and THF in the Calcein AM assay 
for cell viability.  Different cells were used to test the toxicity of these 2 solvents, i.e. MUBS 
with DMSO and MUTC with THF. Due to limitation of the cells to grow in the same rate of 
doubling time, any cells that were readily confluenced at the time were used as not all brain 
tumour cells samples were established at the same time. 
Cell viability of a representative cell culture (MUBS) remained at 80 to 100% 
following treatment with DMSO for the range of concentrations used (Fig 18) at four 
different incubation periods (between 24 and 96 h), suggesting that DMSO is not cytotoxic to 
the cells at these concentrations.  However, a decrease in cell viability was seen with DMSO 
at a concentration of 0.5% and higher. At the highest concentration used (3.84 %) cell 
viability was significantly decreased at each time point tested when compared to viability in 
the absence of DMSO.  
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Figure 18: Cell viability of MUBS following treatment with DMSO at a range of concentrations at 
four different time points of incubation. DMSO is only cytotoxic to the primary brain tumour cell 
culture at a concentration of 0.5% and above. Residual cell viability is shown as a percentage of the 
untreated (control).  Data represents the mean ± standard error of the mean for n=2 experiments with 
each experiment being carried out in duplicate. (See chapter 2, section 2.2.5.1). 
 
For determination of THF cytotoxicity to the cells, cell viability was again measured 
using the Calcein AM assay on the MUTC cell culture (Fig.19).  A range of THF 
concentrations was used; (0.2 to 25.6%).  It was found that above 0.2 % THF,  cell viability 
decreased to about 80% of that seen in the absence of THF. This decrease was statisticaly 
significant at each time point measured (p<0.05), suggesting that THF is toxic to the cells at a 
concentration of 0.2% and higher. A further decrease in cell viability was seen at 
concentrations of 6.4% and above (figure 19) The final concentration of THF used in the 
assays was 4% due to the fact that it was the initial point to prepare the working 
concentrations yet to see if the same toxicity effect is demonstrated with the presence of 
LycoRed in the solution.  
v/v	(%)	
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Figure 19: Cell viability of the MUTC cells following treatment with THF at a range of 
concentrations at four different time point of incubation. THF is cytotoxic to the cells above 
concentration of 0.2%. Residual cell viability is shown as a percentage of the untreated (control). Data 
represents the mean ± standard error of the mean for n=2 experiments with each experiment being 
carried out in duplicate. (See chapter 2, section 2.2.5.1). 
 
 Thus, DMSO was used to dissolve curcumin (contained in the curcumin solution 
0.3% DMSO) and THF for dissolving lycoRed (4% concentration of THF) in all further 
assays.  
3.4 IC values of the Curcumin and LycoRed  
The cytotoxicity of Curcumin or LycoRed was determined using a DRAQ 7 cell viability 
assay. Four different incubation periods were carried out (24, 48, 72 and 96 h) with the IC 
values (IC25, IC50 and IC75) determined at each time point.  
In the normal brain cells (Fig 19A), curcumin effect on the cell viability at 5ng/ml is 
similar to the effect seen with 5µg/ml (cell viability remained at 90%). Higher concentrations 
of curcumin decreased the cell viability to 60 and 30% compared to the untreated cells 
(absence of curcumin).  In figure 19A, the graph was plotted in a log scale due to the wide 
range of curcumin concentrations that studied (5ng/ml to 30 µg/ml). Therefore, in order to 
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illustrate the effect of curcumin (wide range of concentrations) in normal brain cells, a log 
scale (x axis) has been chosen to demonstrate the cell viability graph (Fig 20A). Each log 
point represents a concentration of curcumin as showed in the graph. For example, as 
demonstrated in figure 20A, 0.7 at x axis  represents 5ng/ml curcumin, 1.5 for 30ng/ml, 3.7 
for 5000ng/ml 5 µg/ml), 4.2 for 15000ng/ml (15 µg/ml ) and 4.5 for 30000ng/ml (30 µg/ml). 
Incubation with curcumin has significantly decreased the cell viability of MUBP cells. 
Curcumin decreased the cell viability of MUBP cells by 50% at 16.8 µg/ml (Fig 20B). 19 
µg/ml of curcumin has significantly decreased it further, leaving only 25% cells that are 
viable.  Likewise, MUBS and MUP cell viability was also significantly decreased. The cell 
viability in MUBS primary cell cultures (Fig 20C) was decreased to 75% when treated with 
14.2 µg/ml curcumin while 15.2 µg/ml  in MUP cells (Fig 20D). However, with MUTC cells, 
the cells remain viable (95-100%) throughout the concentrations of curcumin studied which 
may reflected its resistance towards curcumin treatment.  
The dose response curve plotted determined the IC values of each primary cell 
cultures studied. For example, the blue, green and purple arrow (Fig 20A-20D) indicated the 
IC75, IC50 and IC25, respectively. MUBP cells have the IC values of 15, 16.8 and 19 µg/ml, 
each corresponds to the IC75, IC50 and IC25, respectively (Fig 20B). MUBS cells have 14.2, 
16.8 and 19.5 µg/ml while MUP cells with 15.2, 16.3 and 17.5 µg/ml for the respective IC75, 
IC50 and IC25 values. These IC values were approximately similar among primary brain 
tumour cell cultures studied except with MUTC cells which were tabulated in table 4 as 
follows. 
For each primary brain tumour cell cultures, no cytotoxicity was detected for 
LycoRed at any length of incubation. In addition, normal brain cells (CC2565) remained 
viable at all concentrations and incubation time (Fig. 20F) which suggested that LycoRed is 
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not toxic to normal brain cells. Hence no IC value could be detected for LycoRed in normal 
brain and all primary brain tumour cells (see Figure 20F-20J for indicative results).  
Increasing the length of incubation had negligible impact on cell viability and 
therefore a single length of incubation is used to illustrate the findings. For each cell culture, 
all IC values were determined from the viability curve plotted and the results are shown in 
table 6.  Thus, figure 20 (A-J) shows the cell viability of normal brain and primary brain 
tumour cell cultures, following 24 hours incubation with Curcumin or LycoRed.
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Normal brain A 
D MUP 
E MUTC 
C MUBS 
B MUBP 
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Figure 20 A-J: Percentage of live cells of each cell culture after 24hours treatment with Curcumin (A-E;yellow curves) or LycoRed (F-J;red curves). IC 
values are showed by the blue, green and purple lines representing IC75, IC50 and IC25 respectively. Standard error of the mean is represented by the error bars. 
Data was taken from at least 3 sets of experiments in duplicate. Statistical analysis was carried out using a 2 sample t-test analysis to obtain the p value (each 
group of treated cells were compared with the untreated cells). * p<0.05. See chapter 2, section 2.2.5.2 
F Normal brain G MUBP 
MUBS H I MUP 
MUTC J 
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Table 6: IC values of each cell culture  after 24 hour incubation with Curcumin. IC values were similar for all primary brain tumour cell cultures with 
Curcumin. See chapter 2, section 2.2.5.2. 
 
Cell 
cultures 
/IC values 
in µg/ml 
Normal brain MUBP MUBS MUP MUTC 
Curcumin treated Curcumin treated Curcumin treated Curcumin treated Curcumin treated 
IC75  (blue 
arrow) 
10 
 
15 14.2 15.2 ND 
IC50  
(green 
arrow) 
20 16.8 16.8 16.3 ND 
IC25  
(purple 
arrow) 
32 19 19.5 17.5 ND 
 
ND=no detectable effect 
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Table 6 demonstrated that the IC values of curcumin were in the same range among 
primary brain tumour cell cultures studied. The IC values ranged from 14 to 19 µg/ml (at 24 h 
of incubation) and addition of curcumin concentrations decreased the cell viability 
significantly. Due to the findings that there was no significant difference between IC75 and 
IC50 values, either one was chosen to be used in the following assays. The IC25 was rejected, 
as at this concentration incubation with curcumin led to significant cell death which might 
have resulted in cell loss before detection as early as 24 hour incubation. Hence, IC75 value 
obtained were used in subsequent analysis in the insight of it is lower in concentration to 
avoid less cell death which is useful particularly in compromising antigen detection 
experimentation.  
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3.5 Antigens expression in primary brain tumour cells 
It is good to know the character of the tumour being sampled as to see their invasive, 
angiogenic and apoptotic potentials through the antigens expressed. The antigens expressed 
in each cell culture were studied by two methods; immunocytochemistry (qualitative) and 
flow cytometry (semi-quantitative). Expressions in primary brain tumour cell cultures were 
compared with the negative control, i.e. normal brain cell culture, CC2565.  No specific 
positive control was used in this experiment as it is purely to compare the presence of these 
antigens in the tumour samples as opposed to the normal brain cells. In addition, the choices 
of antigens used were established previously by former brain tumour (associated to this study) 
researches thus expanding the finding in brain-tumour biopsy derived with the same setting 
of methodology. The experiments were repeated 3 times with each experiment being carried 
out in duplicate. See chapter 2, section 2.2.6.1 for immunocytochemistry and section 2.2.6.2 
for flow cytometry methods. 
 
3.5.1 Qualitative analysis of antigen expression using 
immunocytochemistry  
The antigen expression of each cell culture was measured using 
immunocytochemistry (ICC). All cells were stained with each of the five antibodies followed 
by secondary antibody conjugated with Alexa fluor-488 for visualization showed by bright 
fluorescent green. Propidium iodide was applied to stain the nucleus of the cells, as showed 
by the bright red that fluoresced (see chapter 2 section 2.2.6.1). The 5 micrographs (A-F) in 
each (Figs 21 to 25) represent a primary brain tumour cell culture that was stained by 5 
different antibodies as follows; A) GFAP B) GD3  C) NG2 D) CD44  E) Beta-1 integrin. A 
negative control (F) was also included where the primary antibody was omitted. Therefore, in 
the negative control, where the antibody was omitted, no Alexa fluor-488 but Propidium 
91 
 
iodide staining only was seen. The staining was quantified by scoring with respect to the 
staining intensity. All staining were compared to normal brain cells as showed in Table 7. 
All cell cultures expressed GFAP, an establish marker of astrocytes, including normal 
brain cells, confirming that all primary brain tumour cell cultures being investigated are of 
astrocytic origin. Figure 21 shows normal brain cell culture (CC2565) stained with the five 
antibodies and a negative control (F). A high intensity of GFAP (A) staining, a marker of 
astrocytes was noted as well as significant CD44 (D) staining, while GD3 (B), NG2 (C) and 
Beta-1-integrin (E) were negligible in expression.  
 In comparison with normal brain cells, MUBS cell cultures (Fig 22) showed a slightly 
higher expression of CD44 (D). MUBS cells showed increased expression of NG2, CD44 and 
Beta-1-integrin compared to normal brain cells due to the higher in intensity of green 
fluorescence that observed in this population of cells hence suggesting that MUBS may have 
a high invasive capacity.  
 MUBP (Fig 23) and MUTC cell cultures (Fig 24) showed similar pattern of antigen 
expression compared with normal brain cells. The expression of CD44 (D) and NG2 (C) were 
slightly higher in intensity in MUBS cells than in normal brain cells which suggests the 
invasive and angiogenic potential of MUBS cell cultures.  
MUP cells shown in figure 23 exhibited greater CD44 expression (D) than normal 
brain cells, but less GD3 (B) and Beta-1-integrin expression (E). In addition, NG2 expression 
was high which may indicate MUP cells are angiogenic and proliferative in the capacity. 
 The invasive, proliferative and angiogenic capacity of the primary brain tumour cell 
cultures are varied, demonstrated by the level of antigens that were expressed as compared 
with the normal brain cells. Each primary brain tumour cell culture may have either invasion 
or angiogenic potential or perhaps both due to the variation in the expression of CD44, Beta-
1-integrin, GD3 and NG2.  
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Figure 21: Antigen expression of CC2565 cell culture following staining with different antibodies via 
immunocytochemistry. A) GFAP B) GD3 C) NG2 D) CD44 E) Beta-1 integrin. F) Negative control. 
 
   
    
Figure 22: Antigen expression of MUBS cell culture following staining with different antibodies via 
immunocytochemistry. A) GFAP B) GD3 C) NG2 D) CD44 E) Beta-1 integrin. F) Negative control. 
A B C 
D E F 
  C 
D F 
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Figure 23: Antigen expression of MUBP cell culture following staining with different antibodies via 
immunocytochemistry. A) GFAP B) GD3 C) NG2 D) CD44 E) Beta-1 integrin. F) Negative control. 
 
     
n   
Figure 24: Antigen expression of MUTC cell culture following staining with different antibodies via 
immunocytochemistry. A) GFAP B) GD3 C) NG2 D) CD44 E) Beta-1 integrin. F) Negative control. 
A B C 
D E F 
A B C 
D E F 
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Figure 25: Antigen expression of MUP cell culture following staining with different antibodies via 
immunocytochemistry. A) GFAP B) GD3 C) NG2 D) CD44 E) Beta-1 integrin. F) Negative control. 
 
Table 7: Summary of immunocytochemistry results (qualitative) for antigen expression in normal 
brain cells (CC2565) compared to primary brain tumour cultures (MUBS, MUBP, MUTC and MUP) 
  
Antigens/Cell 
line 
CC2565 MUBS MUBP MUTC MUP 
Beta-1-
integrin 
- ++ - - - 
CD44 + ++ + + ++ 
GD3 - - - - - 
NG2 - + - - + 
GFAP +++ ++ +++ +++ ++ 
Negative 
control 
- - - - - 
+++=strong positivity    ++=positive    +=weak positivity   - =negative 
 
 
 
 
 
A B C 
D E F 
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3.5.2 Quantitative analysis of antigen expression using flow cytometry 
A semi quantitative analysis was carried out to determine the level of antigen expression in 
all primary brain tumour cell cultures investigated. Four antibodies were investigated; Beta-1-
integrin, CD44, MMP-14 and VEGF. These antigens overexpression often associate in 
promoting invasion and angiogenesis in glioma as with most other cancers. For an example, 
MMP-14 was overexpressed in both primary cells and established cell line of glioblastoma by 
several studies (Fillmore et al., 2001; Hagemann et al., 2010; Hagemann et al., 2012). GD3 
and NG2 were not able to be investigated due to time that constraint as well as not enough 
cells that were readily available at the time of investigation. Each primary brain tumour cell 
culture was stained with the respective antibodies (MUBP at passage 9-12; MUP at passage 
8-14; MUBS at passage 6-9; MUTC at passage 8-10). To visualize the antibody stained, 
secondary antibody fluorescein isothiocyanate (FITC) conjugated was applied and the 
relative FITC intensity was measured by the bright green colour that fluoresced (see chapter 2 
section 2.2.6.2). The results are summarised in figure 25a-c and table 8-11. 
Markers of invasion in glioblastoma include Beta-1-integrin, MMP-14 and CD44. 
After 24h incubation, Beta-1-integrin was increased significantly in MUBP cells compared to 
control cells (normal brain cells) but lower levels were detected in other cell cultures studied 
(Fig 26a). However, no significant difference was noted in the level of expression between 
MUTC and normal brain cells. Using the ANOVA with Fisher post hoc test, mean value of 
Beta-1-integrin was significantly different among the 4 primary brain tumour cell cultures as 
well as when compared with the control cells but not between MUBS and MUP cell cultures 
with p value >0.05 (table 8). 
After 24h incubation, when compared to normal brain cells (control), all three primary 
brain tumour cell cultures expressed significant levels of CD44  with p value <0.05 (Fig 26b) 
except for MUBS cells (via ANOVA with Fishers post hoc test in table 9) . The highest level 
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was detected in MUTC cells followed by MUP and MUBP cells. Further statistical analysis 
via Fishers comparison showed that the mean value of CD44 was significantly different 
among the primary brain tumour cell cultures studied but exclusively not between MUTC and 
MUP cell cultures with p value >0.05 
MMP-14 (a membrane type MMP; MT1-MMP) is known to be highly expressed in 
glioblastoma. As one of the matrix metalloproteinases that degrades the extracellular matrix 
in infiltrating tumours it was surprising that a low level of MMP-14 was detected in three out 
of four cell cultures studied. Only MUTC cells expressed a high level of MMP-14 at 
approximately twice that of control cells (Fig 26c). As established via Fishers statistical 
analysis, the mean value of MMP-14 was significantly different among the primary brain 
tumour cell cultures studied except between MUBP and MUP cell cultures (table 10). 
In addition to high level of MMP-14, MUTC cells also have much higher levels of 
VEGF than the other tumour cells studied. This was almost three times higher than the 
control cells but the level of expression was significantly lower in MUBS cell culture 
compared to normal brain cells (Fig 26d).  However, the level of VEGF in MUBP and MUP 
cells was similar with the control cells. However, there was no statistically significance in 
VEGF mean values between MUBP and MUBS as well as between MUBP and MUP cell 
cultures due to their p value >0.05 (table 11). 
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Figure 26a: The level of Beta-1-integrin expression in control and primary brain tumour cells following 24h incubation. All cells were stained with each of 
the four antibodies followed by a secondary antibody with FITC conjugated in order to enable the visualization. Standard error of means was represented by 
the error bars. Data was taken from at least 3 sets of experiments in duplicate. Statistical analysis was carried out with 2 sample t-test analysis to obtain the p 
value (* p<0.05) which is the value of each brain tumour cell culture compared with the control cells.  
 
 Cell 
cultures Mean Difference from cell culture (95% CI) 
  CC2565 MUBP MUBS MUP MUTC 
CC2565 
(control) 131.55 - 75.5* (44.4-106.5) 58.3* (-89.3- [-27.2]) 
56.6* (-87.6- [-25.5]) 32.1* (3.4-60.9) 
MUBP 207.0 75.5*(44.4-106.5) - 133.7*(-166.9-[-100.5]) 
132.1*(-165.3-[-98.8]) 43.3*(-74.4-[-12.3]) 
MUBS 73.29 58.3*(-89.3- [-27.2]) 133.7*(-166.9-[-100.5]) - 1.7(-31.5-34.9) 90.4*(59.3-121.5) 
MUP 74.96 56.6*(-87.6- [-25.5]) 132.1*(-165.3-[-98.8]) 1.7(-31.5-34.9) - 88.7*(57.6-119.8) 
MUTC 163.7 32.1*(3.4-60.9) 43.3*(-74.4-[-12.3]) 90.4*(59.3-121.5) 88.7*(57.6-119.8) - 
 
Table 8: Statistical analysis (One way-ANOVA-Fisher comparison) of each primary brain tumour cell culture against each other as well as against the control 
(after 24h incubation).  The p value was denoted by* (p<0.05) indicated that the mean value for all cell cultures were statistically significant against each 
other cell culture (including when compared with the control) except for MUBS against MUP cell culture (each difference in mean value in bold has p 
value>0.05). 
98 
 
 
 
Figure 26b: The level of CD44 expression in control and primary brain tumour cells following 24h incubation. All cells were stained with each of the four 
antibodies followed by a secondary antibody with FITC conjugated in order to enable the visualization. Standard error of means was represented by the error 
bars. Data was taken from at least 3 sets of experiments in duplicate. Statistical analysis was carried out with 2 sample t-test analysis to obtain the p value (* 
p<0.05) which is the value of each brain tumour cell culture compared with the control cells.  
 
 Cell 
cultures Mean Difference from cell culture (95% CI) 
  CC2565 MUBP MUBS MUP MUTC 
CC2565 
(control) 111.90* - 118.2*(83.2-153.3) 26.6(-8.4-61.7) 
161.5*(126.4-196.6) 171.9*(136.8-206.9) 
MUBP 230.133* 118.2*(83.2-153.3) - 91.6*(-129.1-[-54.1]) 43.3*(5.8-80.8) 53.6*(16.1-91.1) 
MUBS 138.53* 26.6(-8.4-61.7) 91.6*(-129.1-[-54.1]) - 134.9*(97.4-172.4) 145.2*(107.7-182.7) 
MUP 273.4* 161.5*(126.4-196.6) 43.3*(5.8-80.8) 134.9*(97.4-172.4) - 10.4(-27.1-47.9) 
MUTC 283.8* 171.9*(136.8-206.9) 53.6*(16.1-91.1) 145.2*(107.7-182.7) 10.4(-27.1-47.9) - 
 
Table 9: Statistical analysis (One way-ANOVA-Fisher comparison) of each primary brain tumour cell culture against each other as well as against the control 
(after 24h incubation).  The p value was denoted by* (p<0.05) indicated that the mean value for all cell cultures were statistically significant against each 
other cell culture (including when compared with the control) except for MUBS against control and MUTC against MUP cell culture (each difference in mean 
value in bold has p value>0.05) 
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Figure 26c: The level of MMP-14 expression in control and primary brain tumour cells following 24h incubation. All cells were stained with each of the four 
antibodies followed by a secondary antibody with FITC conjugated in order to enable the visualization. Standard error of means was represented by the error 
bars. Data was taken from at least 3 sets of experiments in duplicate. Statistical analysis was carried out with 2 sample t-test analysis to obtain the p value (* 
p<0.05) which is the value of each brain tumour cell culture compared with the control cells.  
 
 Cell 
cultures Mean Difference from cell culture (95% CI) 
  CC2565 MUBP MUBS MUP MUTC 
CC2565 
(control) 9.008 - 
3.793*(-5.417-[-
2.168]) 6.072*(-7.697-[-4.448) 
3.230*(-4.855-[-1.605]) 13.102*(11.478-14.727) 
MUBP 5.215 3.793*(-5.417-[-2.168]) - 2.28*(-3.905-[-0.655]) 0.562(-1.062-2.187) 16.895*(15.270-18.520) 
MUBS 2.935 6.072*(-7.697-[-4.448) 2.28*(-3.905-[-0.655]) - 2.842*(1.218-4.467) 19.175*(17.550-20.800) 
MUP 5.7775 3.230*(-4.855-[-1.605]) 0.562(-1.062-2.187) 2.842*(1.218-4.467) - 16.333*(14.708-17.957) 
MUTC 22.110 13.102*(11.478-14.727) 16.895*(15.270-18.520) 19.175*(17.550-20.800) 
16.333*(14.708-17.957) - 
 
Table 10: Statistical analysis (One way-ANOVA-Fisher comparison) of each primary brain tumour cell culture against each other as well as against the 
control (after 24h incubation).  The p value was denoted by* (p<0.05) indicated that the mean value for all cell cultures were statistically significant against 
each other cell culture (including when compared with the control) except for MUBP against MUP (each difference in mean value in bold has p value>0.05). 
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Figure 26d: The level of VEGF expression in control and primary brain tumour cells following 24h incubation. All cells were stained with each of the four 
antibodies followed by a secondary antibody with FITC conjugated in order to enable the visualization. Standard error of means was represented by the error 
bars. Data was taken from at least 3 sets of experiments in duplicate. Statistical analysis was carried out with 2 sample t-test analysis to obtain the p value (* 
p<0.05) which is the value of each brain tumour cell culture compared with the control cells.  
 
 Cell 
cultures Mean Difference from cell culture (95% CI) 
  CC2565 MUBP MUBS MUP MUTC 
CC2565 
(control) 8.080* - 
2.005*(-3.591-[-
0.419]) 3.535*(-5.121-[-1.949]) 
1.975*(-.3561-[-0.389]) 14.867*(13.282-16.453) 
MUBP 6.075* 2.005*(-3.591-[-0.419]) - 1.53(-3.116-0.056) 0.03(-1.556-1.616) 16.872*(15.287-18.458) 
MUBS 4.545* 3.535*(-5.121-[-1.949]) 1.53(-3.116-0.056) - 1.56(-0.026-3.146 18.402*(16.817-19.988) 
MUP 6.105* 1.975*(-.3561-[-0.389]) 0.03(-1.556-1.616) 1.56(-0.026-3.146 - 16.842*(15.257-18.428) 
MUTC 22.947* 14.867*(13.282-16.453) 16.872*(15.287-18.458) 18.402*(16.817-19.988) 
16.842*(15.257-18.428) - 
 
Table 11: Statistical analysis (One way-ANOVA-Fisher comparison) of each primary brain tumour cell culture against each other as well as against the 
control (after 24h incubation).  The p value was denoted by* (p<0.05) indicated that the mean value for all cell cultures were statistically significant against 
each other cell culture (including when compared with the control) except for MUBP against MUBS and MUBP against MUP cells (each difference in mean 
value in bold has p value>0.05).  
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3.6 Curcumin anti-invasive property in primary brain tumour cells  
Invasive potential of each primary brain tumour cell culture was measured using an in vitro 2 
dimensional invasion assay (see chapter 2 section 2.2.7). The cells were stained with DilC,a 
fluorescence dye prior to seeding onto the wells of 96 well format plate. The intensity of the 
staining was measured by the fluorometric plate reader. A fibrosarcoma cell line, HT-1080, 
purchased from ATCC, was selected as a positive control for the invasion assay as it is 
known to be invasive. Normal brain cells were also included as a negative control (CC2565). 
The invasive potential of the primary brain tumour cell cultures (MUBP, MUBS and 
MUP) were found to be significantly higher than in the normal brain cells (Fig 27). However, 
after 24 hour of curcumin treatment, there was a significant reduction of 13-16% in the 
invasive potential of these cells. 
However, this was not observed in the MUTC cells in which the percentage of 
invasion was maintained at 30% after treatment with curcumin. It is of interest to note that of 
the four cancer cell cultures, this showed the lowest invasive potential in the absence of 
curcumin. This suggests that the MUTC cell culture may not show invasive potential and 
indeed, that the invasive potential may be lower than that of the normal brain cells.  
With longer incubation periods of 48, 72 and 96 hours, all of the primary brain 
tumour cell cultures showed the same pattern of invasive potential with no changes seen in 
the reduction of invasion (data not shown). Thus, although the invasion data suggests that the 
level of invasive capacity present in these cell cultures varied, curcumin decreased the 
invasion to the same extent regardless of the cell cultures and length of incubation. 
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Figure 27: 2 Dimensional invasion assay in vitro showed the percentage of invasion of each cell 
culture after 24h incubation. Data represents the mean ±standard error of mean for n=2 experiments 
with each experiment being carried out in duplicate. Data was taken from at least 2 sets of 
experiments in duplicate. Statistical analysis was carried out with 2 sample t-test analysis to obtain the 
p value (* p<0.05). Ŧ p value <0.05 (significant different between untreated normal brain cells and 
untreated brain tumour cells. *p value<0.05 (significant different between untreated and curcumin 
treated for each cell culture. Percentage of invasion is made by using HT1080 cells (positive control) 
that is known to be invasive, i.e. 100% invasion.  
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3.7 Curcumin as a pro-apoptotic agent 
The apoptotic potential of curcumin was measured using Annexin V assay via flow 
cytometry. Apoptosis induces a variety of changes in the plasma cell membrane which 
includes permeability changes and membrane lipid alterations. Membrane lipid alterations 
occur when the phosphotidylserine residues are externalized; Annexin V has high affinity to 
these residues hence detected via flow cytometry.  
Each primary brain tumour cells were treated with curcumin prior to staining with Annexin 
V which has Alexa fluor 647 (a bright green fluorescence dye) conjugated. Propidium iodide 
(bright red fluorescence dye) was also added to the staining to distinguish between viable and 
dead cells. The cells were gated into viable, early apoptotic and dead population of cells (see 
chapter 2 section 2.2.8). A positive control for apoptosis used was staurosporine treated cells 
(1µM) in order to set up the quadrant of dead and live cells respectively (the quadrants not 
shown here).   
The following quadrants (Figs 28, 30, 32, 34, 36) represent population of cells gated 
after curcumin treatment at different time of incubation (24, 48, 72 and 96h). From the 
quadrants, four bar graphs showed each cell population; viable, early apoptotic, late apoptotic 
and necrotic cells, for each brain tumour cell cultures studied.  
In the normal brain cells population, although early apoptotic cells population 
increased as the incubation time increased, this is negligible as only 3 to 8 % cells were gated.  
More than 40% of cells remained viable after 24 hour of incubation (figure 29) yet curcumin 
treatment at the IC75 value improved the viability of normal brain cells, as demonstrated by 
the live cell population that was improved after 48 hour of incubation. This improvement was 
maintained after treatment throughout the incubation time studied, up to 96 hour. Normal 
brain cells were not significant in late apoptotic cells population only when the p value is 
more than 0.05 (fig 29, table 12c). 
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Among all primary brain tumour cell cultures investigated, MUTC cells showed 
significant amount of early apoptotic cells gated at 24h incubation (approximately 22%) 
before declined to 17% at 48h (Fig 37). This was not shown by other cell cultures studied as 
less than 12% of cells were gated following curcumin treatment as different hour of 
incubation (Figs. 31, 33, 35). However, for all brain tumour cell cultures studied, necrotic 
cells population gated were profound except for MUTC cells that were not significant (Fig 37, 
table 16d).  
In addition, for most of the primary brain tumour cell cultures investigated, the cell 
viability remained between 40 to 60% and necrotic event was seen more than apoptotic 
occurrence. It could be suggested that the IC75 value of curcumin may have not cytotoxic 
enough in initiating the apoptotic occurrence in these primary brain tumour cell cultures. 
However, the remaining 40 to 60% were non-viable cells which are mainly composed of 
necrotic cells which may suggests that curcumin even at low concentration is already 
cytotoxic to the primary brain tumour cells. 
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Figure 28 : Four representative diagrams from Annexin V apoptosis assay of normal brain cells at 
different hour of incubation (following curcumin treatment); 24h (upper left box), 48h (upper right 
box), 72h (lower left box) and 96h (lower right box). In a diagram, each quadrant represents viable 
cells (lower left), early apoptosis cells (lower right), late apoptotic cells (upper right) and necrotic 
cells (upper left). Percentage of cell gated in the quadrant is made by CellQuest software. 
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Figure 29: Normal brain cells population from each quadrant (viable, early apoptotic, late apoptotic, 
necrotic) of every incubation time (following curcumin treatment) are represented in a bar graph. 
Error bars show standard error of mean. Data represents the mean ±standard error of mean for n=3 
experiments with each experiment being carried out in duplicate. Percentage of cell gated was 
followed by statistical analysis (one way ANOVA-Fisher comparison) as to obtain the p value (*p 
value<0.05) and tabulated as below. 
a)Viable 
quadrants 
Mean Difference from time of incubation 
  24h 48h 72h 96h 
24h 47.78 - 1.92 (-6.14-
9.98) 
10.27 (2.43-
18.12) 
8.02 (0.18-
15.87) 
48h 49.70 1.92 (-6.14-
9.98) 
- 8.35 (0.29-
16.42) 
6.11 (-1.95-
14.17) 
72h 58.05 10.27 (2.43-
18.12) 
8.35 (0.29-
16.42) 
- -2.25 (-10.09-
5.60) 
96h 55.80 8.02 (0.18-
15.87) 
6.11 (-1.95-
14.17) 
-2.25 (-10.09-
5.60) 
- 
 
b)Early 
apoptotic 
quadrants 
Mean Difference from time of incubation 
  24h 48h 72h 96h 
24h 3.528 - -1,190 (-3.3735-
1.354) 
-2.383 (-4.833-
0.068) 
4.427 (1.977-
6.877) 
48h 2.338 -1,190 (-3.3735-
1.354) 
- -1.192 (-3.602-
1.218) 
5.617 (3.208-
8.027) 
72h 1.146 -2.383 (-4.833-
0.068) 
-1.192 (-3.602-
1.218 
- 6.809 (4.499-
9.120) 
96h 7.955 4.427 (1.977-
6.877) 
5.617 (3.208-
8.027) 
6.809 (4.499-
9.120) 
- 
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c)Late apoptotic 
quadrants 
Mean Difference from time of incubation 
  24h 48h 72h 96h 
24h 4.202 - 2.638 (0.28-
5.149) 
1.023 (-1.421-
3.467) 
2.349 (-0.095-
4.793) 
48h 6.841 2.638 (0.28-
5.149) 
- -1.615 (-4.126-
0.895) 
-0.289 (-2.800-
2.221) 
72h 5.225 1.023 (-1.421-
3.467) 
-1.615 (-4.126-
0.895) 
- 1.326 (-1.118-
3.770) 
96h 6.551 2.349 (-0.095-
4.793) 
-0.289 (-2.800-
2.221) 
1.326 (-1.118-
3.770) 
- 
 
d)Necrotic 
quadrants 
Mean Difference from time of incubation 
  24h 48h 72h 96h 
24h 46.24 - -5.15 (-14.15-
3.85) 
-10.66 [(-19.42-
(-1.90)] 
-16.55 [(-25.31-
(-7.79)] 
48h 41.09 -5.15 (-14.15-
3.85) 
- -5.51 [(-14.51-
3.49)] 
-11.40 [(-20.40-
(-2.40)] 
72h 35.58 -10.66 [(-19.42-
(-1.90)] 
-5.51 [(-14.51-
3.49)] 
- -5.89 (-14.65-
2.87) 
96h 29.69 -16.55 [(-25.31-
(-7.79)] 
-11.40 [(-20.40-
(-2.40)] 
-5.89 (-14.65-
2.87) 
- 
 
Table 12(a-d) : Statistical analysis (One way-ANOVA-Fisher comparison) of % cells gated for all 
incubation time; 24h-48h-72h-96h (against each other) for every quadrant, i.e. a) viable, b)early 
apoptotic, c) late apoptotic and d) necrotic quadrant.  The p value was denoted by* (p<0.05) indicated 
that the mean value for all incubation time were statistically significant against each. Each difference 
in mean value in bold showed that p value>0.05). Significant difference was noted between different 
incubation time studied in all quadrants except for late apoptotic cells quadrant. 
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Figure 30 : Four representative diagrams from Annexin V apoptosis assay of MUBS cells at different 
hour of incubation  (following curcumin treatment); 24h (upper left box), 48h (upper right box), 72h 
(lower left box) and 96h (lower right box). In a diagram, each quadrant represents viable cells (lower 
left), early apoptosis cells (lower right), late apoptotic cells (upper right) and necrotic cells (upper 
left). Percentage of cell gated in the quadrant is made by CellQuest software 
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Figure 31: MUBS cells population from each quadrant (viable, early apoptotic, late apoptotic, 
necrotic) of every incubation time (following curcumin treatment) are represented in a bar graph. 
Error bars show standard error of mean. Data represents the mean ±standard error of mean for n=3 
experiments with each experiment being carried out in duplicate. Percentage of cell gated was 
followed by statistical analysis (one way ANOVA-Fisher comparison) as to obtain the p value (*p 
value<0.05) and tabulated as below. 
a)Viable 
quadrants 
Mean Difference from time of incubation 
  24h 48h 72h 96h 
24h 70.648 - -4.996 (-10.824-
0.832) 
3.649 (-2.179-
9.477) 
0.200 (-5.628-
6.028) 
48h 65.653 -4.996 (-10.824-
0.832) 
- 8.645 (2.261-
15.029) 
5.196 (-1.188-
11.580) 
72h 74.298 3.649 (-2.179-
9.477) 
8.645 (2.261-
15.029) 
- -3.449 (-9.833-
2.935) 
96h 70.848 0.200 (-5.628-
6.028) 
5.196 (-1.188-
11.580) 
-3.449 (-9.833-
2.935) 
- 
 
b)Early 
apoptotic 
quadrants 
Mean Difference from time of incubation 
  24h 48h 72h 96h 
24h 0.966 - 0.940 (0.060-
1.820) 
-0.432 (-1.312-
0.448) 
-0.896 [(-1.776-
(-0.017)] 
48h 1.906 0.940 (0.060-
1.820) 
- -1.372 [(2.336-
(-0.409)] 
-1.837 [(-2.800-
(-0.873)] 
72h 0.533 -0.432 (-1.312-
0.448) 
-1.372 ([(2.336-
(-0.409)] 
- -0.464 (-1.428-
0.500) 
96h 0.069 -0.896 [(-1.776-
(-0.017)] 
-1.837 [(-2.800-
(-0.873)] 
-0.464 (-1.428-
0.500) 
- 
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c)Late apoptotic 
quadrants 
Mean Difference from time of incubation 
  24h 48h 72h 96h 
24h 3.086 - -0.784 (-3.082-
1.515) 
-0.970 (-3.268-
1.329) 
-2.796 [(-5.095-
(-0.498)] 
48h 2.302 -0.784 (-3.082-
1.515) 
- -0.186 (-2.704-
2.332) 
-2.013 (-4.530-
0.505) 
72h 2.116 -0.970 (-3.268-
1.329) 
-0.186 (-2.704-
2.332) 
- -1.827 (-4.344-
0.691) 
96h 0.289 -2.796 [(-5.095-
(-0.498)] 
-2.013 (-4.530-
0.505) 
-1.827 (-4.344-
0.691) 
- 
 
d)Necrotic 
quadrants 
Mean Difference from time of incubation 
  24h 48h 72h 96h 
24h 25.300 - 4.840 (0.404-
9.276) 
-2.245 (-6.681-
2.191) 
3.492 (-0.944-
7.927) 
48h 30.140 4.840 (0.404-
9.276) 
- -7.085 [(-11.94-
(-2.226)] 
-1.348 (-6.207-
3.511) 
72h 23.055 -2.245 (-6.681-
2.191) 
-7.085 [(-11.94-
(-2.226)] 
- 5.737 (0.878-
10.596) 
96h 28.792 3.492 (-0.944-
7.927) 
-1.348 (-6.207-
3.511) 
5.737 (0.878-
10.596) 
- 
 
Table 13(a-d) : Statistical analysis (One way-ANOVA-Fisher comparison) of % cells gated for all 
incubation time; 24h-48h-72h-96h (against each other) for every quadrant, i.e. a) viable, b)early 
apoptotic, c) late apoptotic and d) necrotic quadrant.  The p value was denoted by* (p<0.05) indicated 
that the mean value for all incubation time were statistically significant against each. Each difference 
in mean value in bold showed that p value>0.05). Significant difference was noted between different 
incubation time studied in all quadrants except for viable and late apoptotic cells quadrants. 
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Figure 32 : Four representative diagrams from Annexin V apoptosis assay of MUBP cells at different 
hour of incubation  (following curcumin treatment); 24h (upper left box), 48h (upper right box), 72h 
(lower left box) and 96h (lower right box). In a diagram, each quadrant represents viable cells (lower 
left), early apoptosis cells (lower right), late apoptotic cells (upper right) and necrotic cells (upper 
left). Percentage of cell gated in the quadrant is made by CellQuest software 
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Figure 33: MUBP cells population from each quadrant (viable, early apoptotic, late apoptotic, 
necrotic) of every incubation time (following curcumin treatment) are represented in a bar graph. 
Error bars show standard error of mean. Data represents the mean ±standard error of mean for n=3 
experiments with each experiment being carried out in duplicate. Percentage of cell gated was 
followed by statistical analysis (one way ANOVA-Fisher comparison) as to obtain the p value (*p 
value<0.05) and tabulated as below. 
a)Viable 
quadrants 
Mean Difference from time of incubation 
  24h 48h 72h 96h 
24h 64.488 - 8.447 (2.926-
13.968) 
16.984 (11.463-
22.506) 
16.297 (10.776-
21.818) 
48h 72.935 8.447 (2.926-
13.968) 
- 8.537 (3.016-
14.058) 
7.849 (2.328-
13.371) 
72h 81.472 16.984 (11.463-
22.506) 
8.537 (3.016-
14.058) 
- -0.688 (-6.209-
4.833) 
96h 80.784 16.297 (10.776-
21.818) 
7.849 (2.328-
13.371) 
-0.688 (-6.209-
4.833) 
- 
 
b)Early 
apoptotic 
quadrants 
Mean Difference from time of incubation 
  24h 48h 72h 96h 
24h 5.840 - -1.276 (-5.433-
2.882) 
-5.222 [(-9.380-
(-1.065)] 
-5.131 [(-9.289-
(-0.974)] 
48h 4.564 -1.276 (-5.433-
2.882) 
- -3.947 [(-8.104-
0.211)] 
-3.856- (-8.013-
0.302) 
72h 0.618 -5.222 [(-9.380-
(-1.065)] 
-3.947 [(-8.104-
0.211)] 
- 0.091 (-4.066-
4.249) 
96h 0.709 -5.131 [(-9.289-
(-0.974)] 
-3.856- (-8.013-
0.302) 
0.091 (-4.066-
4.249) 
- 
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c)Late apoptotic 
quadrants 
Mean Difference from time of incubation 
  24h 48h 72h 96h 
24h 7.429 - -1.553 (-4.122-
1.015) 
-5.085 [(-7.653-
(-2.517)] 
-5.164 [(-7.732-
(-2.595)] 
48h 5.876 -1.553 (-4.122-
1.015) 
- -3.532 [(-6.100-
(-0.963)] 
-3.611- [(-
6.179-(-1.042) 
72h 2.344 -5.085 [(-7.653-
(-2.517)] 
-3.532 [(-6.100-
(-0.963)] 
- -0.079 (-2.647-
2.490) 
96h 2.266 -5.164 [(-7.732-
(-2.595)] 
-3.611- [(-
6.179-(-1.042) 
-0.079 (-2.647-
2.490) 
- 
 
d)Necrotic 
quadrants 
Mean Difference from time of incubation 
  24h 48h 72h 96h 
24h 22.243 - -5.624 [(-
10.193-(-
1.056)] 
-6.677 [(-
11.245-(-
2.109)] 
-6.003 [(-
10.571-(-
1.435)] 
48h 16.619 -5.624 [(-
10.193-(-
1.056)] 
- -1.053 (-5.621-
3.515) 
-0.378 (-4.946-
4.190) 
72h 15.566 -6.677 [(-
11.245-(-
2.109)] 
-1.053 (-5.621-
3.515) 
- 0.674 (-3.894-
5.243) 
96h 16.241 -6.003 [(-
10.571-(-
1.435)] 
-0.378 (-4.946-
4.190) 
0.674 (-3.894-
5.243) 
- 
 
Table 14(a-d) : Statistical analysis (One way-ANOVA-Fisher comparison) of % cells gated for all 
incubation time; 24h-48h-72h-96h (against each other) for every quadrant, i.e. a) viable, b)early 
apoptotic, c) late apoptotic and d) necrotic quadrant.  The p value was denoted by* (p<0.05) indicated 
that the mean value for all incubation time were statistically significant against each. Each difference 
in mean value in bold showed that p value>0.05). Significant difference was noted between different 
incubation time studied in all quadrants. 
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Figure 34: Four representative diagrams from Annexin V apoptosis assay of MUP cells at different 
hour of incubation  (following curcumin treatment); 24h (upper left box), 48h (upper right box), 72h 
(lower left box) and 96h (lower right box). In a diagram, each quadrant represents viable cells (lower 
left), early apoptosis cells (lower right), late apoptotic cells (upper right) and necrotic cells (upper 
left). Percentage of cell gated in the quadrant is made by CellQuest software 
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Figure 35: MUP cells population from each quadrant (viable, early apoptotic, late apoptotic, necrotic) 
of every incubation time (following curcumin treatment) are represented in a bar graph. Error bars 
show standard error of mean. Data represents the mean ±standard error of mean for n=3 experiments 
with each experiment being carried out in duplicate. Percentage of cell gated was followed by 
statistical analysis (one way ANOVA-Fisher comparison) as to obtain the p value (*p value<0.05) and 
tabulated as below. 
a)Viable 
quadrants 
Mean Difference from time of incubation 
  24h 48h 72h 96h 
24h 61.72 - 1.01 (-10.48-
12.50) 
1.72 (-9.77-
13.21 
-14.26 [(-27.91-
(-0.61)] 
48h 62.73 1.01 (-10.48-
12.50) 
- 0.71 (-11.32-
12.74) 
-15.28 [(-29.39-
(1.17)] 
72h 63.44 1.72 (-9.77-
13.21 
0.71 (-11.32-
12.74) 
- -15.99 [(-30.10-
(-1.88)] 
96h 47.45 -14.26 [(-27.91-
(-0.61)] 
-15.28 [(-29.39-
(1.17)] 
-15.99 [(-30.10-
(-1.88)] 
- 
 
b)Early 
apoptotic 
quadrants 
Mean Difference from time of incubation 
  24h 48h 72h 96h 
24h 11.64 - -8.33 [(-16.62-(-
0.04)] 
-10.14 [(-18.44-
(-1.85)] 
-10.98 [(-20.83-
(-1.13)] 
48h 3.31 -8.33 [(-16.62-(-
0.04)] 
- -1.82 (-10.50-
6.87) 
-2.65 (-12.83-
7.53) 
72h 1.49 -10.14 [(-18.44-
(-1.85)] 
-1.82 (-10.50-
6.87) 
- -0.84 (-11.02-
9.35) 
96h 0.66 -10.98 [(-20.83-
(-1.13)] 
-2.65 (-12.83-
7.53) 
-0.84 (-11.02-
9.35) 
- 
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c)Late apoptotic 
quadrants 
Mean Difference from time of incubation 
  24h 48h 72h 96h 
24h 7.006 - 0.328 (-2.295-
2.951) 
-0.507 (-3.130-
2.116) 
-3.042 (-6.158-
0.074) 
48h 7.334 0.328 (-2.295-
2.951) 
- -0.835 (-3.582-
1.912) 
-3.370  [(-
6.591-(-0.149)] 
72h 6.499 -0.507 (-3.130-
2.116) 
-0.835 (-3.582-
1.912) 
- -2.535 (-5.756-
0.686) 
96h 3.964 -3.042 (-6.158-
0.074) 
-3.370  [(-
6.591-(-0.149)] 
-2.535 (-5.756-
0.686) 
- 
 
d)Necrotic 
quadrants 
Mean Difference from time of incubation 
  24h 48h 72h 96h 
24h 19.65 - 6.97 (-2.00-
15.95) 
8.92 (-0.06-
17.90) 
28.28 (17.61-
38.94) 
48h 26.62 6.97 (-2.00-
15.95) 
- 1.95 (-7.46-
11.35) 
21.30 (10.28-
32.33) 
72h 28.57 8.92 (-0.06-
17.90) 
1.95 (-7.46-
11.35) 
- 19.36 (8.33-
30.38) 
96h 47.93 28.28 (17.61-
38.94) 
21.30 (10.28-
32.33) 
19.36 (8.33-
30.38) 
- 
 
Table 15(a-d) : Statistical analysis (One way-ANOVA-Fisher comparison) of % cells gated for all 
incubation time; 24h-48h-72h-96h (against each other) for every quadrant, i.e. a) viable, b)early 
apoptotic, c) late apoptotic and d) necrotic quadrant.  The p value was denoted by* (p<0.05) indicated 
that the mean value for all incubation time were statistically significant against each. Each difference 
in mean value in bold showed that p value>0.05). Significant difference was noted between different 
incubation time studied in all quadrants except for viable and late apoptotic cells quadrants. 
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Figure 36: Four representative diagrams from Annexin V apoptosis assay of MUTC cells at different 
hour of incubation  (following curcumin treatment); 24h (upper left box), 48h (upper right box), 72h 
(lower left box) and 96h (lower right box). In a diagram, each quadrant represents viable cells (lower 
left), early apoptosis cells (lower right), late apoptotic cells (upper right) and necrotic cells (upper 
left). Percentage of cell gated in the quadrant is made by CellQuest software 
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Figure 37: MUTC cells population from each quadrant (viable, early apoptotic, late apoptotic, 
necrotic) of every incubation time (following curcumin treatment) are represented in a bar graph. 
Error bars show standard error of mean. Data represents the mean ±standard error of mean for n=3 
experiments with each experiment being carried out in duplicate. Percentage of cell gated was 
followed by statistical analysis (one way ANOVA-Fisher comparison) as to obtain the p value (*p 
value<0.05) and tabulated as below. 
a)Viable 
quadrants 
Mean Difference from time of incubation 
  24h 48h 72h 96h 
24h 62.510 - -1.323 (-9.482-
6.835) 
12.561 (3.660-
21.462) 
15.375 (6.474-
24.276) 
48h 61.187 -1.323 (-9.482-
6.835) 
- 13.884 (6.763-
21.005) 
16.699 (9.577-
23.820) 
72h 75.071 12.561 (3.660-
21.462) 
13.884 (6.763-
21.005) 
- 2.814 (-5.147-
10.776) 
96h 77.875 15.375 (6.474-
24.276) 
16.699 (9.577-
23.820) 
2.814 (-5.147-
10.776) 
- 
 
b)Early 
apoptotic 
quadrants 
Mean Difference from time of incubation 
  24h 48h 72h 96h 
24h 22.62 - -4.62 (-13.26-
4.03) 
-18.22 [(-27.65-
(-8.80)] 
-21.74 [(-31.17-
(-12.31)] 
48h 18.00 -4.62 (-13.26-
4.03) 
- -13.61 [(-21.15-
(-6.07)] 
-17.12 [(-24.67-
(-9.58)] 
72h 4.39 -18.22 [(-27.65-
(-8.80)] 
-13.61 [(-21.15-
(-6.07)] 
- -3.52 (-11.95-
4.92) 
96h 0.88 -21.74 [(-31.17-
(-12.31)] 
-17.12 [(-24.67-
(-9.58)] 
3.52 (-11.95-
4.92) 
- 
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c)Late apoptotic 
quadrants 
Mean Difference from time of incubation 
  24h 48h 72h 96h 
24h 3.691 - -0.057 (-1.442-
1.328) 
-0.721 (-2.232-
0.790) 
-2.667 [(-4.178-
(-1.156)] 
48h 3.635 -0.057 (-1.442-
1.328) 
- -0.665 (-1.873-
0.544) 
-2.610 [(-3.819-
(-1.401)] 
72h 2.970 -0.721 (-2.232-
0.790) 
-0.665 (-1.873-
0.544) 
- -1.946 [(-3.297-
(-0.594)] 
96h 1.024 -2.667 [(-4.178-
(-1.156)] 
-2.610 [(-3.819-
(-1.401)] 
-1.946 [(-3.297-
(-0.594)] 
- 
 
d)Necrotic 
quadrants 
Mean Difference from time of incubation 
  24h 48h 72h 96h 
24h 12.45 - 12.74 (-7.01-
32.48) 
5.11 (-16.42-
26.65) 
7.76 (-13.78-
29.30) 
48h 25.19 12.74 (-7.01-
32.48) 
- -7.62 (-24.85-
9.61) 
-4.98 (-22.21-
12.21) 
72h 17.56 5.11 (-16.42-
26.65) 
-7.62 (-24.85-
9.61) 
- 2.64 (-16.62-
21.91) 
96h 20.21 7.76 (-13.78-
29.30) 
-4.98 (-22.21-
12.21) 
2.64 (-16.62-
21.91) 
- 
 
Table 16(a-d) : Statistical analysis (One way-ANOVA-Fisher comparison) of % cells gated for all 
incubation time; 24h-48h-72h-96h (against each other) for every quadrant, i.e. a) viable, b)early 
apoptotic, c) late apoptotic and d) necrotic quadrant.  The p value was denoted by* (p<0.05) indicated 
that the mean value for all incubation time were statistically significant against each. Each difference 
in mean value in bold showed that p value>0.05). Significant difference was noted between different 
incubation time studied in all quadrants except for necrotic cells quadrant 
 
 
3.8 Curcumin as a potential anti-angiogenic agent 
The anti-angiogenic property of curcumin was measured using an in vitro angiogenesis assay 
with the use of co-culture. This included an extracellular matrix gel (or also commercially 
known as matrigel) which mainly contains laminin and type IV collagen (see chapter 2 
section 2.2.9).  The insert was coated with matrigel prior to HUVEC seeding. HUVEC that 
grown on the matrigel surface were examined as to see if they form networking of tubules 
when co-culturing with primary brain tumour cells that grown in the well, which located 
underneath the insert. 
In the co-culture setting, each normal brain and primary brain tumour cell culture was 
treated with different concentrations of curcumin over 16 hours prior to analysis. Each insert 
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containing HUVEC was processed as described in the chapter 2, section 2.2.9 before 
photographed.  For each insert, randomly, 6 areas were captured under the magnification of 
100 x. This include the inserts of both controls, Suramin (negative) and VEGF (positive) but 
not displayed in the graphs plotted (Fig 28). Each photograph was traced with Paint software 
(Microsoft) before quantification with Image J software (see chapter 2, section 2.2.9).  
Normal brain cells showed almost equal number of nodes, junctions and branches at 
each of the curcumin doses used.  Nodes are the points where branches intersect; they are an 
important feature in quantifying angiogenic tubule formation. In comparison with the 
HUVECS treated with normal brain cells, the number of nodes was increased with MUBS, 
MUTC and MUP untreated primary brain tumour cells. However, the number of nodes in 
MUBP cells prior to curcumin treatment was not significantly different from normal brain 
cells (CC2565). The number of nodes in MUBS, MUTC and MUP then decreased when 
treated with curcumin and greater in reduction was seen as the concentration of curcumin 
increased. At concentrations of 20µg/ml and above the number of nodes was significantly 
lower than in untreated normal brain cells. 
Total length of the tubules was measured based on the whole areas analysed by the 
software used. This is another important feature in the quantification of potential 
angiogenesis activity. Similarly to the finding for nodes, MUTC (figure 28e), MUP (figure 
28d) and MUBS (figure 28c) cell cultures showed increased values in the total length of the 
tubule as compared to the normal brain cells (figure 28a). The length of tubules decreased 
with the treatment of curcumin at all concentrations studied.  
Junctions (the points where groups of nodes were formed) is another parameter 
measured in angiogenesis potential. The number of junctions was increased on co-culture 
with all three primary cell cultures as compared to the normal brain. However, this difference 
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did not reach statistical significance.  However, curcumin treatment has significantly 
decreased the number of junctions present in each of the tumour cell lines. 
The number of branches in all untreated primary brain tumour cells investigated was 
lower (from 11 to 17 branches) than what has been quantified in the normal brain cells (18 
branches). Incubation with curcumin decreased the number of branches in each primary brain 
tumour cell culture at concentration as low as 10µg/ml. The anti-angiogenic effect of 
curcumin was also demonstrated by the number of junctions, nodes and total tubule length, 
that reduced after incubation with curcumin at each concentration studied.  
Results are suggestive that MUBP cell culture might not have the angiogenic potential 
as compared to the other primary cell cultures studied due to the findings that seen. All the 
angiogenic parameters investigated in MUBP cell culture showed lower values than was 
perceived in the normal brain cells.  
All remaining primary cell cultures may suggested to be pro-angiogenic based on the 
number of nodes and total tubule length that were high in the untreated ones. However, the 
angiogenic potential was reduced markedly when treated with curcumin hence demonstrated 
curcumin suggesting an anti-angiogenic property for curcumin in these primary brain tumour 
cells. 
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Normal brain cells (CC2565) 
 a) 
 
   
 
 
b) 
   
 
Figure 38: a) In vitro angiogenesis assay (co-culture) showed the tubule network analysed using 
Image J software. A= untreated, B=10µg/ml, C= 20µg/ml, D= 40µg/ml. b) Bar graphs showed normal 
brain cells (CC2565) treated with 0µg/ml (untreated)-blue, 10µg/ml- red, 20µg/ml-green and 
40µg/ml curcumin-purple. Number of nodes, junctions, branches and total length of the tubules (µm) 
were quantified by Image J software analysis as demonstrated by the bar graphs. Data represents the 
mean ±standard error of mean for n=3 experiments with each experiment being carried out in 
triplicate. Statistical analysis (one way ANOVA and 2 sample t-test analysis) was carried out to obtain 
the p value (*p<0.05). Normal brain cells were not affected by curcumin treatment at all 
concentrations studied due to the value that is not statistically different (p>0.05) compared to the 
untreated cells.  
A B 
C D 
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Figure 39: a) In vitro angiogenesis assay (co-culture) showed the tubule network analysed using 
Image J software. A= untreated, B=10µg/ml, C= 20µg/ml, D= 40µg/ml. b) Bar graphs showed normal 
brain cells (CC2565) treated with 0µg/ml (untreated)-blue, 10µg/ml- red, 20µg/ml-green and 
40µg/ml curcumin-purple.  Number of nodes, junctions, branches and total length of the tubules (µm) 
were quantified by Image J software analysis as demonstrated by the bar graphs. Data represents the 
mean ±standard error of mean for n=3 experiments with each experiment being carried out in 
triplicate. Statistical analysis (one way ANOVA and 2 sample t-test analysis) was carried out to obtain 
the p value (*p<0.05). In MUBP cells, curcumin treatment has affected all angiogenic parameters but 
only at highest concentration with p value <0.05. 
 
A B 
C D 
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Figure 40: a) In vitro angiogenesis assay (co-culture) showed the tubule network analysed using 
Image J software. A= untreated, B=10µg/ml, C= 20µg/ml, D= 40µg/ml. b) Bar graphs showed normal 
brain cells (CC2565) treated with 0µg/ml (untreated)-blue, 10µg/ml- red, 20µg/ml-green and 
40µg/ml curcumin-purple. Number of nodes, junctions, branches and total length of the tubules (µm) 
were quantified by Image J software analysis as demonstrated by the bar graphs. Data represents the 
mean ±standard error of mean for n=3 experiments with each experiment being carried out in 
triplicate. Statistical analysis (one way ANOVA and 2 sample t-test analysis) was carried out to obtain 
the p value (*p value<0.05). With MUBS cells, reduction was noted significantly at each angiogenesis 
parameters and concentrations studied when compared between untreated and curcumin treated cells. 
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Figure 41: a) In vitro angiogenesis assay (co-culture) showed the tubule network analysed using 
Image J software. A= untreated, B=10µg/ml, C= 20µg/ml, D= 40µg/ml. b) Bar graphs showed normal 
brain cells (CC2565) treated with 0µg/ml (untreated)-blue, 10µg/ml- red, 20µg/ml-green and 
40µg/ml curcumin-purple. Number of nodes, junctions, branches and total length of the tubules (µm) 
were quantified by Image J software analysis as demonstrated by the bar graphs. Data represents the 
mean ±standard error of mean for n=3 experiments with each experiment being carried out in 
triplicate. Statistical analysis (one way ANOVA and 2 sample t-test analysis) was carried out to obtain 
the p value (*p value<0.05) Three out of four parameters of angiogenesis were affected significantly 
by curcumin at all concentrations.  
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Figure 42: a) In vitro angiogenesis assay (co-culture) showed the tubule network analysed using 
Image J software. A= untreated, B=10µg/ml, C= 20µg/ml, D= 40µg/ml. b) Bar graphs showed normal 
brain cells (CC2565) treated with 0µg/ml (untreated)-blue, 10µg/ml- red, 20µg/ml-green and 
40µg/ml curcumin-purple.  Number of nodes, junctions, branches and total length of the tubules (µm) 
were quantified by Image J software analysis as demonstrated by the bar graphs. Data represents the 
mean ±standard error of mean for n=2 experiments with each experiment being carried out in 
triplicate. Statistical analysis (one way ANOVA and 2 sample t-test analysis) was carried out to obtain 
the p value (*p value<0.05). With MUTC cells, the numbers of branches were not statistically 
significant in difference following curcumin treatment as compared to the untreated cells. 
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Controls (Suramin /VEGF) 
 
 
Figure 43: Positive (A)- Suramin treated) and negative (B)- VEGF treated) cells were used as 
controls. *p value<0.05 (significant different noted between untreated and curcumin treated cells at 
each angiogenesis parameters and cell culture studied). 
 
 
 
 
 
 
 
A B 
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Chapter 4: Discussion 
Despite decades of major investigations for better understanding of the mechanisms underlie 
the development of cancers in recent years, the  treatment and diagnosis of glioblastoma 
multiformes continues to harbour significant challenges hence remain incurable. Due to the 
exceptionally infiltrative nature of glioblastoma multiforme together with the scarcity in 
effective therapies, any new modality to replace or support current treatments would be 
helpful in improving the prognosis, to the least. In this study, we evaluated the potential 
therapeutic effects of 2 micronutrients; curcumin and lycoRed, on primary brain tumour cells 
(biopsy derived). We believed that this is the first study that did not use established glioma 
cell lines (unlike in other studies) in elucidating the potential therapeutic roles of both 
curcumin and lycoRed on malignant glioblastoma multiforme. 
Curcumin is cytotoxic to the primary brain tumour cells but not LycoRed 
Our results show that curcumin is cytotoxic the primary brain tumour cell cultures 
studied. Consistently with what we have demonstrated in this study, other previous studies on 
curcumin have also showed its cytotoxic effects but in different types of cell line in vitro. 
These include curcumin at a concentration of 4 µg/ml which produced 50% cytotoxicity in 
Dalton’s lymphoma ascites cells, inhibition in the growth of Chinese hamster ovary cells and 
human leukemic lymphocytes in culture (Kuttan et al., 1985) and 50% growth arrest in K-562 
human chronic myelogenousleukemia cells (Anuchapreeda et al., 2006) at a concentration of 
20 µg/ml. Moreover, the anti-proliferative action of curcumin is mediated by suppression of 
the hepatocyte growth factor (HGF) and its receptor c-met.184 in the human hepatoma G2 
cell line (Seol, 2000). In some other cell lines, curcumin potent therapeutic action in targeting 
cancer was reported to be mediated by its capability in generating reactive oxygen species 
(ROS) at a very low concentration (15 µM) which then caused damage to mitochondria, as 
demonstrated by decrease in the mitochondrial membrane potential and externalization of 
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phosphatydylserine, and the whole process eventually ended up in the initiation of apoptosis 
(Atsumi, 2006). It is suggested that this multifaceted anti-cancer effects by curcumin are 
predominantly mediated through various transcription factors, growth factors, oncogenic 
molecules, protein kinases and cytokines (Shanmugam et al., 2015).  
It is crucial for an agent or micronutrient to be cytotoxic to the tumour cells and at the 
same time is safe to the normal cells during the treatment. For most of the concentration 
studied, curcumin is not cytotoxic to the normal brain cells. Indeed, the pharmacological 
safety of curcumin is well documented and demonstrated due to its natural occurrence, well 
established and long history of dietary use (Aggarwal, Kumar, Bharti, 2003). However, our 
finding of normal brain cells fragility towards higher concentration of curcumin may suggest 
that the toxicity level of curcumin reached may not be safe per se to be used in vitro.  With 
respect to in vivo studies, although it has stated that beyond 8000 mg daily, curcumin is 
physiologically unattainable due to its average peak serum level that reach only up to 1.77± 
1.87µM yet its serum level gradually declined within 12 hours after an oral intake, thus 
suggesting its poor bioavailability (Cheng et al., 2001). More extensive clinical and metabolic 
studies have reported that 8 to 12g/day is safe to be consumed (Aggarwal et al., 2003;Anand 
et al., 2007) though its level was reported to either undetected or extremely low 0.006 ± 
0.005µg/mL at 1 h serum levels (Shoba et al., 1998). In a pancreatic cancer study, curcumin 
was well-tolerated as an adjuvant when studies conducted on combination therapy using 8 g 
oral curcumin daily with gemcitabine-based chemotherapy was safe and feasible (Rahmani et 
al., 2014). 
The IC values obtained for these three primary brain tumour cells (MUBS, MUBP 
and MUP) were in the similar range between 14.2-15.2 µg/ml for the IC75, 16.3-16.8 µg/ml 
for the IC50   and 17 -19.5 µg/ml for the IC25 values. Thus, the IC values of curcumin for these 
primary brain tumour cell cultures lie between 14.2 and 19.5 µg/ml which is limited in range 
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but it does show that curcumin has a significant effect on causing cytotoxicity to these 
malignant brain tumour cells by 25 to 75% inhibition of the cell viability. With respect to the 
normal brain cells, they remained viable when treated with the same concentrations of 
curcumin up to 5µg/ml before declining in the percentage of cell viability when treated with 
higher concentrations of curcumin. It is likely that the normal brain cells tend to become 
vulnerable to curcumin concentration at higher doses due to the nature of these cells which  
are fragile in ex vivo, especially during resuscitation from frozen and high maintenance 
during passaging in vitro.  
24-hours incubation time was chosen to demonstrate the effect of each potential 
therapeutic agent studied; curcumin, LycoRed. As with previous studies, 48-hours period of 
incubation was set up as the standard. However, at earlier stage of this study, at 48-hours 
incubation, most of these treated biopsy-derived cells experienced necrotic event as gated via 
flow cytometry (DRAQ7 assay). Thus 24 hours was preferred. This is also to prevent the loss 
of cells during incubation (easily prone to contamination). Indeed, the period of incubation 
has been set out on different assays hence has to be standardised for all experiments that were 
carried out. 
Curcumin has been studied in many cancer clinical trials such as oral, breast, bladder, 
colorectal, cervical, liver and skin cancer. Initiation of clinical studies in human were 
concurrent with clinical trials implemented in vivo as in animal studies, exhibiting 
chemopreventative effects against carcinogen (arsenic) in most cancers in mammals.. Clinical 
trials against cancers in human have mostly involved pharmacodynamic and pharmacokinetic 
effects of oral dose curcumin (Cheng et al., 2001). It is demonstrated that multi-targeted 
actions of curcumin are more effective than the most current anti-cancer therapies which are 
mostly mono-targeted. An example of mono targeted therapy is sorafenibin used to treat renal 
cell carcinoma (RCC) via the inhibition of platelet derived growth factor (PDGF) which 
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resulted to decreased in tumour angiogenesis in RCC (Ibrahim et al., 2012). Hence, this 
pleotropic molecule may serve as a single drug that potentially acts on different type of 
cancers and studies, both in vivo and in vitro, have demonstrated curcumin’s therapeutic 
value. There have been several mechanisms proposed for the action of curcumin in targeting 
multiple pathways in inflammatory diseases and carcinogenesis. Such mechanisms involve 
invasion and angiogenesis which are the hallmarks of human malignant gliomas (Jain et al., 
2007). The mechanisms by which curcumin exerts its anti-cancer effects are extensive and 
varied. This includes many levels of regulation in the downstream processes of cellular 
growth. Curcumin effects on various transcription factors, oncogenes and signalling proteins. 
These include NF-kB, AP-1, p53 gene, c-myc, Bcl-2, COX-2, NOS, Cyclin D1, TNF-α, 
interleukins and MMP-9. Curcumin also acts at various sequential stages of carcinogenesis 
such as mutagenesis, cell cycle regulation, apoptosis, and metastasis (Wilken et al., 2011).  
In contrast, LycoRed failed to demonstrate any cytotoxic effects to these primary 
brain tumour cells. The data presented here demonstrated that exposure of LycoRed to 
primary brain tumour cell cultures  grown in vitro did not cause the cytotoxic effect even 
though these were higher concentrations of lycopene than the normal physiological range for  
humans. The normal brain cells remained viable at a very wide range of concentrations 
studied (5ng/ml-24µg/ml) thus indicated that LycoRed also is not cytotoxic to the normal 
brain cells. Indeed, the viability of each cell line was increased compared to that seen where 
diluent (THF) was added in the absence of LycoRed. Thus, it appears from our studies that 
LycoRed has a protective effect on cells and may inhibit cytotoxic effects. As shown in 
Figure 18 in section 3.3 (result chapter), although the concentration of THF present was in 
the range of 0.2 to 3.2%, approximately 70% of the primary brain tumour cells remained 
viable following THF treatment. However, when these primary brain tumour cells were 
treated with LycoRed concentrations (dissolved in THF), 80 to 90% of the cells remained 
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viable which is believed that LycoRed may have a protective role on the cells from THF 
cytotoxicity. 
Although the safety profile of lycopene as supplements has not been thoroughly 
studied, there are many reviews and scientific literatures available on tomatoes and tomato-
based products. For instance, a report has investigated a range of botanical herbs which has 
included tomato extract in the randomized controlled trial and has endowed a safety dietary 
supplement of these herbs including the tomato extract. In addition, they have showed that 
tomato extract which was part of the combination is also effective in modulating the 
oxidation indices values as well as lowering the increased low density lipoprotein cholesterol 
values (Gupta et al., 2012). 
Lycopene is the predominant carotenoid in tomato products after phytoene, 
phytofluene, and β-carotene (Wyss et al., 2001). In addition, lycopene rapidly oxidizes and 
degrades in cell culture systems, making it difficult to interpret results of in vitro studies. 
Variability in cell lines, culture conditions, solvents used to deliver lycopene as well as the 
source of lycopene, may contribute to different findings seen among in vitro researches 
conducted. Furthermore, a lycopene study (Ford et al., 2011) has demonstrated that oxidative 
metabolites of lycopene released in vitro and/or metabolic products of lycopene secreted by 
DU145 cells (prostate cancer cells) reduce the proliferation of prostate cancer cells, more 
than lycopene alone.  
Although there are epidemiological studies that shown a relationship between diets 
rich in tomato and/or lycopene and a reduction in cancer rates (Gann et al., 1999;Giovannucci 
et al., 2002; Jian et al., 2005), unfortunately, it  has not been upheld if lycopene alone is the 
sole compound suggested to reduce cancer rates (Bosetti et al., 2004). Perhaps, it is not the 
lycopene alone but rather the group of carotenoids and nutrients that may responsible for the 
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lower cancer rates seen in the epidemiological. Thus, LycoRed may not be exclusively 
responsible for the effects seen in vivo or in cell culture systems. As an anti-carcinogenic 
compound, LycoRed may not relate to the consumption of the whole tomato or other fruit in 
order to contribute to potential therapeutic effects for brain tumour.  
The source of lycopene used in this study (commercially available as LycoRed) 
contained only 10% of lycopene (via spectrophotometric method) with the other ingredients  
including maltodextrin, modified gum starch, sugar esters, soya lecithin and gum acacia (see 
appendix). Thus, it is a mixture of other components yet only 10% lycopene is present. 
Indeed, difficulties with stability and solubility of lycopene in cell culture systems make it 
difficult to elucidate the mechanisms of action. Therefore, the results for LycoRed remain 
inconclusive and only curcumin findings will be discussed in further.  
 
Curcumin’s cytotoxicity induced via non-apoptotic pathway in the primary brain tumour 
cells 
Although curcumin clearly showed a decrease in cell viability in our studies, we did not 
observe a significant induction of apoptosis by curcumin in the primary brain tumour cells 
studied. Thus, it is likely to be a non-apoptotic pathway triggered by curcumin in these 
malignant primary brain tumour cells. Although a contradictory report has stated previously 
that curcumin induced apoptosis in brain tumour cells via telomerase shortening (Khaw et al, 
2013), it is not comparable to this study which have used primary brain tumour cell cultures 
(GBM, biopsy-derived) instead. The telomerase shortening study by curcumin used 
established cell lines; ONS-76- a medulloblastoma, KNS60- not astrocytic in origin (GFAP 
negative) unlike the four primary brain tumour cell cultures used in this study, which are 
astrocytomas. According to Li et al (2008), established cell lines may not represent primary 
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cell cultures at best thus established glioma cell lines are poorly representative of primary 
human gliomas. Moreover, unlike primary cells, cell lines have been in vitro and in vivo 
environment for more than two decades thus may have extensively changed in cellular or 
genomic level.  
Progress has been made in understanding the route of apoptosis induced by curcumin, 
yet the primary site of its action remains elusive. It is well documented that survival 
signalling and apoptosis resistance are major regulators of cancer survival in glioblastoma. 
Both of these have to be targeted at the same time for the therapeutics to be effective 
(Krakstad and Chekenya, 2010). Curcumin’s ability to induced programme cell death 
includes three pathways; I (apoptosis), II (autophagy) and III (necrosis). In a previous report, 
it was documented that curcumin induced G2/M cell cycle arrest and non-apoptotic 
autophagic death in malignant glioma cells (Aoki et al, 2007). Although the mechanism of 
autophagy on cell death by curcumin remains unclear, this protein degradation system of the 
cell's own lysosomes (autophagy) mediated the growth inhibition of malignant gliomas both 
in vivo and in vitro.  Moreover, a number of reports have documented that malignant glioma 
cells are very resistant to apoptosis but that they undergo autophagy in response to anticancer 
therapies such as radiation, temozolomide, and ceramide (Daido et al., 2004, 2005; Kanzawa 
et al., 2004; Ito et al., 2005; Jo et al., 2014; Noack et al., 2014). Thus, it could be the same 
scenario with these primary brain tumour cells but with different treatments involved. While 
the current debates on autophagy and cancer is far from providing a conclusion, regulation of 
autophagy may contribute to an improved response to therapy hence warrant further 
investigations.  	
Initial assays established an IC75 value for curcumin i.e, a concentration at which75% 
of cells that were viable and 25% that were dead. However, in a subsequent assay to measure 
apoptosis, it was observed that curcumin treatment at its IC75 value did not alter the viable 
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population of the primary tumour cells throughout the incubation time studied, i.e. between 
40-60% viable cells remained. As expected in cell viability assay, IC75 value resulted to the 
least cells cytotoxicity (25% cells inhibition) thus chosen to be used in Annexin V assay i.e. 
minimising cell death hence increasing probabilities to apoptosis occurrence.  
However, with Annexin V assay, curcumin appeared to be non-apoptotic at its IC75 
value, but the same IC value is cytotoxic to the primary brain tumour cells as seen in the 
previous assay. One could speculate that the concentration of curcumin used in this study 
may be too low to elicit apoptosis or that it may be high enough to result in necrosis.  
The IC75 value (with the least cell death among other IC values studied) caused less 
cytotoxicity (more viable cells remained). Less cytotoxic level of curcumin concentration 
may have directed the unhealthy cells (not viable) to either undergo early or late apoptotic or 
necrotic event according to the condition of the cells at cellular level. Cells that were gated 
via flow cytometry analysis were mostly necrotic and very slightly in apoptotic areas (early 
and late quadrants).  The necrotic event seen may be the outcome of the serial passage of the 
biopsy-derived cells. These fragile cells may have changed in durability while experienced 
difference microenvironment when propagated in vitro. Therefore, via flow cytometry 
analysis, most of the cells were gathered in the necrotic quadrant rather than apoptotic ones. 
It is also plausible that among the unhealthy cells, there was other proportion of cells that 
become externalized hence exposed the phosphotidylserine (PS) to be recognized by 
Annexin-V molecule. This may be little yet not significant to conclude that curcumin induced 
apoptosis occurrence but requires further investigation. 
Indeed, there is no cut off point that is certain to hold on that will definitely trigger 
apoptosis to occur. The IC values used to investigate apoptosis may thus reflect curcumin 
cytotoxicity via non-apoptotic pathways. As seen in the initial assays, cell viability decreased 
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as the concentration of curcumin increased, suggesting that very high concentrations of 
curcumin could have been toxic to the cells which reflects an inhibition of cell growth but did 
not result to apoptosis to occur in the cells. It is also possible that the inhibitory action of 
curcumin to these primary brain tumour cells is due to arrest of the cell cycle. This is 
supported by a curcumin study which showed that the percentage of U251 cells (malignant 
glioma cell line) in G0/G1 and G2/M were decreased and increased respectively, after treated 
with curcumin (4 or 10µM) (Liu et al, 2007). Another study has also demonstrated that 15µM 
curcumin induced cell cycle arrest at G2/M phase in U251 cells (Wang et al., 2015). 
Although in the previous study, curcumin at the same range of concentration was noted to 
induce apoptosis in an established malignant glioblastoma cell line (Abdullah Thani et al., 
2012), this was not the case in the primary brain tumour cells in this study.  There may be 
underlying features that are responsible for the evasion of apoptosis in the microenvironment. 
It has been reported in both neurons and prostate cancer studies that evasion of apoptosis 
occurred due to the cancerous cells that produce Insulin growth factor (IGF) survival factors, 
proteins with high sequence similarly to insulin. Furthermore, IGF proteins used by cells to 
communicate with their physiological environment which resulted in increased cell 
proliferation and decreased apoptosis (Chung et al., 2007; Tu et al., 2010).  
In contrast, compelling scientific and dietary evidence has demonstrated the potential of 
curcumin to induce apoptosis in various cancer cells. Indeed, curcumin has been widely 
reported for its pro-apoptotic potential in various tumour cells, both in vitro and in vivo. This 
includes induction of several mechanisms responsible for curcumin pro-apoptotic activity 
such as caspase-cascade and mitochondria-dependent pathways, production of superoxide 
anions and involvement of p53 as well as inhibition of many other cell signalling pathways. 
Curcumin’s roles in anti-cancer activity also include the inactivation of Activator Protein-1, 
Phosphatidylinositide 3-kinases, enzymes (Cyclooxygenase-2, MMPs), cell cycle arrest 
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(cyclin D1), proliferation (Epidermal Growth Factor Receptor and Akt), survival pathways 
(β-catenin and adhesion molecules), and Tumour Necrosis Factor. PI-3 kinase activity 
produced growth factor and regulators upon its activation. Akt-pathway or protein kinases 
B/RAC inactivate pro-apoptotic factors like Bad as well as anti-apoptotic genes (Dorai, 
2004).   
However, the apoptotic occurrence may be limited by other factors and cellular event in 
the miroenvironment. For example, curcumin’s pleiotropic roles in anti-cancer activity have 
been reported (Dorai, 2004) mainly on inactivation of transcription factor, NF-κB.  In various 
cancers NF-kB is deregulated with increased expression of anti-apoptotic proteins. Thus, an 
interplay of a multitude of factors are thought to be unsolved but not elucidated yet. A critical 
review on emerging literatures regarding survival and apoptosis signalling in GBM has 
highlighted experimental, preclinical and recent clinical trials attempting to target these 
pathways. It has been suggested that combining the therapies of targeting apoptosis and 
survival signalling defects might result in greater cytotoxic effect and inevitable apoptosis. 
The review has taken vast collection of studies which has used glioblastoma cell line such as 
U87MG, D54MG. It has been suggested that targeting apoptosis resistance would likely 
resulted to efficacy in increasing survival.  Therefore, combining these two targets (apoptosis 
resistance and survival signalling) might be associated with greater therapeutic benefits 
(Krakstad and Chekenya, 2010).   
Curcumin suppressed angiogenic activity of primary brain tumour cells in vitro 
The results of this study have shown that curcumin has demonstrated the anti-angiogenic 
effect towards these malignant glioma cells (MUBS, MUP and MUTC) in vitro. Indeed, 
angiogenesis is one of the most important parameters involved in tumour developments 
which accompany glioblastoma progression through the development of a new vascular 
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network for the glioma cells to survive in the tumour microenvironment.  Angiogenesis can 
be divided into 3 stages: endothelial cell (EC) proliferation, EC migration and vessel 
morphogenesis which results in polygons or honeycomb patterns in the formation of a 
complex mesh. An animal study (Perry et al., 2010) has shown that curcumin inhibited 
tumour growth and angiogenesis in glioblastoma as indicated by the decreased endothelial 
cell marker from newly formed vessels and by the reduction of the haemoglobin 
concentration. Another animal study has also shown that curcumin supressed angiogenesis in 
the ovarian carcinoma by inhibiting the transcription factor nuclear kappa B (NF-kB) 
(Yvonne et al., 2007). Particularly in GBM which is highly vascularized within the hypoxic 
region, angiogenesis is mediated by vascular endothelial growth factor (VEGF), a factor that 
has been demonstrated to be present in the cyst fluid from glioma at high concentration 
(Takano et al., 2010).  
However, it has been debated in the literatures that VEGF is not the only factor 
responsible for angiogenesis to occur in tumour cells. Numerous previous studies have 
demonstrated curcumin’s potential therapeutic effect in regulating a variety of pro-angiogenic 
factors, enzymes and transcription factors which include bFGF, angiopoetin-1 and 2, COX-2, 
matrix metalloproteinase-9 (MMP-9), activator protein-1 (AP-1) and NF-kB (Gururaj et al., 
2002; Mohan et al., 2000; Yoysungnoen et al., 2006). Other factors such as integrins, 
adhesion molecules and proteases also have an integrated role in permitting and mediating 
angiogenic potential in many malignant tumours (Ray et al., 2003). Moreover, another animal 
study has also presented that curcumin exerts in vitro anti-angiogenic and in vivo anti-tumour 
properties through combined PDE2 and PDE4 (Cyclic nucleotide phosphodiesterases 2 and 
4) inhibitions. Their up regulations in human umbilical vein endothelial cells are implicated 
in VEGF-induced angiogenesis. Thus, inhibition of PDE2 and PDE4 activities increased 
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cAMP level which in turn inhibited VEGF-induced endothelial cell proliferation and 
migration (Abusnina et al., 2015). 
Our results showed that in the in the primary brain tumour cell cultures studied, the 
number of nodes decreased when treated with increased concentration of curcumin. Of all 
primary brain tumour cell cultures, MUBS cell cultures was the only cells that decreased 
significantly in all angiogenic parameters (nodes, junctions, branches, total tubule length) at 
all concentrations studied.  Besides the number of nodes, other angiogenic measures such as 
the total length of tubules had high values but curcumin treatment reduced the formation of 
tubules. While this may suggests curcumin anti-angiogenic potential in the treatment of 
glioblastoma, it is also had indicated curcumin’s safety profile. In the normal brain cells, each 
parameter (number of nodes, junctions and branches) was maintained with increasing 
concentrations of curcumin (0 to 40µg/ml) hence depicted curcumin efficacy as a highly 
pleiotropic molecule as well. Moreover, its long history of medicinal use, especially for the 
treatment of inflammation and many of other traditional therapeutic uses have been 
extensively demonstrated in cellular systems as well as in animal models of disease 
(Aggarwal, 2009).  
There are a lot of divergent opinions published in earlier years which have suggested the 
best method (both in vitro and in vivo) in analysing angiogenesis (Aeurbach and Polakowski, 
1991; Fan and Polverini, 1997; Bishop et al., 1999). Several steps exist in angiogenesis, i.e. 
proliferation, migration and invasion, sprouting and vessel formation, and vessel modelling 
and reorganisation. Therefore, these key events neither are reflected in an in vitro assay alone 
nor in vivo study.  For that reason, in this study, Matrigel assay was chosen for angiogenesis 
in vitro assay. Moreover, according to a review on bioassays involving brain tumour- induced 
angiogenesis, with an in vitro setting, certain key events are measureable in a short period of 
time while leaving other parameters not detected (Hock et al., 2013). Indeed, this study 
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investigated the efficacy of a potential anti-angiogenic agent, i.e. curcumin, which is easy to 
perform via in vitro assay as to prevent certain aspects of the in vivo condition, such as 
artificial cells responses towards treatment, i.e. considering the complexity of glioma cells 
microenvironment.   
The in vitro angiogenesis assay described in this study offered the simplicity and speed in 
measuring the angiogenic event which could not be achieved through in vivo assays. The 
tubules network formed by endothelial cells may not a resemblance to the capillaries formed 
in vivo. This is due to the fact that this in vitro assay was shorter in time for completion hence 
the endothelial cells activity (perhaps proliferation, migration as well as differentiation) may 
not be greater  as compared to the long run of in vivo angiogenesis assays. Moreover, while in 
vivo assay requires higher demand in time, material as well as maintenance, surgical skills are 
also needed and result can be inaccurately interpreted.  
For both in vivo and in vitro settings, parameters such as branching, sprouting, tubule 
length or number of connecting tubules (junctions) are common and widely used for the 
estimation of angiogenic capacity of the tumour cells to form tubules. However, not all of the 
parameters may be necessarily applied as it can also depend on the type of cells and analysis. 
It was observed that in kidney cells, tubule formation on matrigel was no longer occurred 
unless the medium was further supplemented with epidermal growth factor (Taub et al., 
1990). In addition, the morphology of tubules may vary between different types of assays as 
demonstrated in another study (Donovan et al., 2001). Thus, the consideration of which 
parameters to be used in angiogenesis assay is depending on the types of analysis (in vitro or 
in vivo) and cells.  
For most of in vitro angiogenesis assays involving cancer cells, number of junctions, 
branches and nodes and total length of tubules were chosen to be used. However, the first two 
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measures (number of junctions and branches) were not demonstrated as they were negligible 
and insignificant in values as compared to the normal brain cells hence were not considered 
relevant to be studied further in demonstrating the angiogenic capacity in this study.  
In summary, normal brain cell in a co-culture angiogenesis assay model showed no dose 
response to curcumin. Moreover values for the main tubule network parameters were lower 
than those achieved where co-culture with the neoplastic cells MUBS and MUTC were 
involved.  Cell cultures MUP and MUBP gave intermediate overall readings.  As the HUVEC 
cells and the brain cells were separated by a membrane, the effect is mediated by soluble 
factors rather than cell contact. 
Corresponding to the overall picture, dose responsiveness to curcumin was also strongest 
with MUBS and MUTC, increasing doses of agent further inhibiting angiogenic 
parameters.  MUBP showed increased tubule formation at the lowest curcumin dose tested 
(10µg/ml) but an inhibitory dose response thereafter.  The dose responsiveness of MUP cells 
was less smooth, but inhibition was seen.   
Patterns of inhibition were similar with all of the tubule network parameters 
measured.  There is a strong indication from these experiments that curcumin might have 
anti-angiogenic properties that are relatively specific for at least some tumour cell types.  The 
caveat is, of course, that HUVECs are not representative of all endovascular cell types and 
that the angiogenesis assay itself is a simple monoculture, albeit on Matrigel, an artificial 3-
dimensional substrate including basement membrane components. 
The effect of Curcumin on the invasive potential of glioblastoma cells  
In addition to curcumin’s potential therapeutic effects on angiogenesis, our results have also 
demonstrated that curcumin has the potential to affect the invasive potential of these 
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malignant gliomas. Three of the primary brain tumour cell cultures investigated (MUBS, 
MUBP and MUP), were high in the invasive capacity but curcumin treatment at IC75 
concentration reduced the percentage of invasion as early as 24 hours of incubation (fig 27, 
section 3.6 in chapter 3). MUTC cells however did not show invasive potential and curcumin 
treatment demonstrated no significant change in the reduction of invasive capacity of the 
cells.  An alternative scratch assay was not chosen here as motility of the cells was not the 
parameter to be investigated. Moreover, a pilot study with scratch assay was carried out by 
others which always give consistent results (e.g. distinct area) for migration however resulted 
to qualitative and subjective in interpretation.  
Glioblastoma rarely metastasizes to the periphery but there is a high propensity for 
these tumours to invade locally (Holland, 2000). This invasion occurs along the white matter 
tracts, with GBMs often crossing the midline via the corpus callosum. The tumour cells also 
migrate by direct invasion into the adjacent brain parenchyma, involving progressive 
replacement of normal brain tissue (Mikkelson and Bjerkvig, 1998). Moreover, previously 
this series of processes has involved the redistribution of protease receptors to sites of 
dynamic change in neural cell processes, and in invading cell processes in cancer cells 
(Deryugina et al., 1997; Binder and Berger, 2002). Invasion is the most significant biological 
feature of glioblastoma multiformes that precludes successful therapy. The tumour cells 
infiltrate the normal brain in a complex way, thereby rendering all current forms of therapy 
ineffective. Invasion in glioblastoma includes three different but interrelated pathways; 
proteolytic alteration of the extracellular matrix, secretion of new extracellular structural 
proteins, and adhesion to elements of the matrix for which membrane-bound receptors exist 
(Pilkington, 1994). Thus, the cross-talk between cell-surface receptors and the redundancy of 
downstream effectors make analysis of invasive signals even more complex. 
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The anti-invasive potential of curcumin identified in this research is supported by 
other studies suggesting pathways or downstream events have been affected by curcumin. 
Indeed, these effects are facilitated through curcumin’s regulation on various transcription 
factors, growth factors, inflammatory cytokines, protein kinases, and other enzymes. For 
examples, results of a downstream effect study (Senft et al., 2010) involving glioblastoma 
cell proliferation, migration and invasion was suggested to be hampered by curcumin through 
JAK/STAT3 pathway. It was also demonstrated in an animal model that curcumin attenuated 
glioma growth by inhibiting the JAK1, 2/STAT3 signalling pathway (Weissenberger et al., 
2010) which holds promise for clinical application in glioma therapy. 
There are many reports have documented curcumin anti-invasive potential in various 
signalling pathways in cancers. Curcumin was shown to inhibit JAK/STAT signalling via 
phosphorylation of STAT hence resulting in a significant reduction in nuclear 
phosphorylated-STAT-1 (Wang et al., 2009) which resulted in inhibited cell proliferation and 
apoptosis in hepatoma cell line. Curcumin has also significantly inhibited JAK2/STAT3 
signalling in laryngeal squamous cell carcinoma which resulted to inhibition of invasion and 
vasculogenic mimicry in vitro (Hu et al., 2015).  The anti-inflammatory property of curcumin 
was delivered through the inhibition of JAK1 and JAK2 phosphorylation via the increased 
phosphorylation of SHP-2 and its association with JAK1/2 (Kim et al., 2002). 
Phosphorylation of SHP-2 makes it a negative regulator of the JAK-STAT pathway (Kim et 
al., 2003). It has also been demonstrated that curcumin inhibits STAT3 phosphorylation in 
ovarian cancer cells (Seo et al., 2010).  Moreover, a previous study of human lung 
adenocarcinoma cells has reported that 1–20 µmol curcumin inhibited cancer cell invasion 
and metastasis through activation of the tumor suppressor DnaJ-like heat shock protein 40 
(HLJ1) hence leading to activation of the JNK/JunD pathway (Chen et al., 2008). In addition, 
curcumin has been shown in microglia in which the JAK/STAT pathways were inhibited.  
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Therefore, it could be suggested that our previous finding on curcumin cytotoxicity effect on 
the cells integrity has interrupted the transmitting signals from the cell membrane to the 
nucleus following response to extracellular growth factors and cytokines. The activation of 
this series of pathways has been found in many tumours including in brain tumours (Tu et al., 
2011) and lung cancer (Ye et al., 2012).  
Variations in the antigen expression induced interplay of multitude events in glioblastoma 
cells 
In this study, the results have also indicated that there were variances in the level of 
expressions of antigens studied which observed among the four primary brain tumour cells 
via immunocytochemistry and flow cytometry techniques. Differences in morphology, 
genetic and immunology arise from the same neoplasm, rendering the tumour mass highly 
resistant to both radiotherapy and chemotherapy. Published research has indicated that every 
cancer cells expresses specific proteins either inter or intra-cellularly with distinct functions 
and characteristics (Aplin et al., 1998; Ponta, Sherman and Herrlich, 2003; Luque-García et 
al., 2010). Thus, all findings obtained were linked together from this point onwards as to 
understand the whole picture of the study conducted. 
For all glioblastoma cell cultures and normal brain cells, our results from the 
immunocytochemistry analysis with Alexa fluor 488 and PI staining showed strongly positive 
for GFAP (glial fibrillary acidic protein), a cellular antigen. GFAP has been selected as a 
positive control as it is widely known to be expressed in gliomas and can be regarded as a 
sensitive and reliable marker of astrocytes. Although there are still debates on GFAP 
existence either in oligondendrocytes or astrocytes, GFAP has been widely acknowledged 
and demonstrated as a positive control in this study due to its reliable and representative 
staining. A review on astrocyte biology and pathology has regarded GFAP as a sensitive and 
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reliable marker for astrocytic tumour (overexpressed) and normal astrocytes (consistently 
expressed) (Sofroniew and Vinters, 2010). Hence, this 47 kDa protein is widely used to 
confirm the astrocytic nature of glioblastoma which originate from astrocytic lineage. This is, 
usually done by immunostaining analysis with antibody against GFAP which is the classic 
intermediate filament contained within the cytoplasm of both astrocytic tumour and normal 
astrocytes. GFAP is heavily and specifically expressed in astrocytes, non-myelinating 
Schwann cells in peripheral nerves, peripheral ganglia (in satellite cells) and neural stem 
cells. However, many types of brain tumour (most probably astrocytic cell- derived) 
profoundly express GFAP (Knott et al., 1990; Hadjipanayis and Van Meir, 2009). Therefore, 
all primary brain tumour cells (biopsy derived) in this study are confirmed to be astrocytic in 
origin as demonstrated via immunocytochemistry analysis.  
In our study, no NG2 results were available from the flow cytometry data due to time 
constraints. Moreover, not enough cells were harvested for additional staining at the time 
when flow cytometry assay was conducted. In addition, with the time that is limited, cell loss 
(as cells become fragile with passaging) was experienced and growing back the cells made 
such experiments unnecessary. However, it is suggested that there is an association between 
NG2 that expressed with angiogenesis that demonstrated in vitro. Prior to curcumin treatment 
in the angiogenesis assay in vitro, both MUBS and MUP cells (fig 28, section 3.8) were 
angiogenic in comparison with normal brain cells as shown by the high number of nodes and 
total length of tubules. Indeed, both cell cultures were also positive though weak in NG2 
staining as seen in the immunocytochemistry analysis. Thus, it is suggested that NG2 is 
linked with the promotion of angiogenesis. It was reported that NG2’s role in angiogenesis is 
due to its interaction with plasminogen and angiostatin in which modulation of the functional 
properties of both angiostatin and plasminogen resulted to cell migration and proliferation in 
the tumour cells (Chekenya et al., 2002a; Goretzki, 2000).  
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The same primary cell cultures (MUBS and MUP), were also found to have the 
shortest population doubling times (80 h and 154 h respectively). This finding is supported by 
a published study which reported that NG2 is present in GBM with high rates of cell 
proliferation in vitro (Chekenya et al., 2002a). NG2’s role in tumourigenecity was 
investigated in an in vivo animal study involving implanting tumour spheroids (U251N cell 
line) intracerebrally into immunodeficient nude rats to see whether cell proliferation 
supported by NG2 activity in vitro would have the same effect in vivo. In the NG2-
transfected U251N, it was observed that NG2 has increased the GBM tumourigenicity in vivo 
by 87.5%, compared to 40% in wild type (without NG2 being transfected) (Chekenya et al., 
2002a).  This implies that NG2’s expression may correlate with an aggressive course when 
expressed on tumour cells. Therefore, high NG2 expression observed in both MUBS and 
MUP cell cultures may indicate that MUBS and MUP cells are angiogenic besides found to 
be proliferative in the capacity. This has been demonstrated in a study of tumour growth of 
central nervous system that NG2 promotes tumour angiogenesis in vivo by binding and 
sequestering endogenous angiostatin hence leading to increased tumour neovascularization 
(Chekenya et al., 2002).  
A further study on NG2 expression in GBM has shown vascular leakiness, oedema 
and high microvascular density in comparison with the control. Intracranial distribution and 
volume of the tumour were reported as higher cellular densities with more mitotic figures that 
present as demonstrated via contrast-enhanced MRI (magnetic resonance imaging) analysis. 
Thus it is likely that NG2 has the capability to recruit neo-vasculature as well as regulating 
cell morphology thus suggested that NG2 might have been associated with cross-talk between 
tumour cells and cellular environment (Brekke et al., 2006; Caspani et al., 2014 ).  
Initially, Chekenya et al. (1999) has been reported that NG2 expression is inversely 
related to the invasive capacity of the tumour cells. It was demonstrated in the migration and 
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invasion assays that NG2 positive glioma cells migrated more efficiently on collagen IV 
while NG2 negative cells were more invasive than the NG2 positive cells. NG2 is responsible 
in modulating both cell-extracellular matrix and cell-cell adhesion molecule hence it may 
have supporting migration in glioma but perhaps not invasion. NG2 positivity has also been 
reported in the normal human adult brain and peripheral tissues in which NG2 roles are not 
only in migration but also adhesion and differentiation of cells. However, (Chekenya and 
Pilkington, 2002) in an experiment of xenografting Ki-67-labelled cells into nude rat brains 
showed that NG2 is important in proliferation rather than migration or invasion activity in 
human glioma cells.  
Taken together on NG2’s various roles in tumourigenicity, our results showed weak 
positivity in NG2 expression in MUBS and MUP cell cultures and negative in other cell 
cultures. NG2, as with most studies (Burg et al., 1997, 1998; Wiranowska et al., 2006) is a 
cell surface marker was first identified in immature glial cells and has been shown to have 
strong associations with ECM ligands such as collagen IV and cellular ligands such as CD44. 
In another study, it was suggested that not only CD44, NG2 is also an invasive marker in 
gliomas which both demonstrated to aid the tracing and targeting the invading cells 
(Wiranowska et al., 2006). Thus, it is likely that NG2 has an indirect role in mediating 
invasion by interacting with certain adhesion molecules like CD44 to various ECM 
components. Unfortunately, via immunocytochemistry assay, NG2 was not detected in 
MUBP and MUTC cells and weakly positive in MUBS and MUP cells. It could be suggested 
that MUBS and MUP cell cultures (besides MUBP) that showed invasive potential via the 
invasion assay in vitro may not necessarily due to the role of NG2 but perhaps there are other 
antigens present that may have contributed to proliferation, survival, migration, invasion and 
angiogenesis in these glioblastoma cells. Therefore, the results obtained in this study may 
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suggest that the invasive capacity in these cells may be regulated by expression of multiple 
factors by different cells that overlap in the malignant microenvironment. 
Indeed, the cross talk of signalling network transmitted between these antigens may 
responsible for the contradictory seen in this study. Such example is CD44, one of the major 
categories of adhesion molecules besides integrins immunoglobulin superfamily and selectins 
(Aplin et al., 1998). They are expressed on the extracellular surface of the cell via a complex 
interaction between the tumour cell and the glial limitans externa, the brain parenchyma and 
the vascular basement membrane. With respect to CD44, our results from the qualitative 
immunocytochemistry may have only showed two cell cultures (MUBP and MUBS) that 
were intense in CD44 staining compared to the normal brain cells. However, the quantitative 
flow cytometry analysis demonstrated that the level of CD44 expressed were significantly 
high in all glioblastoma cells investigated. CD44 immunostaining may not correlated with 
flow cytometry analysis but both confirmed the expression of the antigen though not in all 
cells and it so happened that with flow cytometry technique is a better assay to determine the 
level of antigen expression of such as CD44. 
Thus, the invasive potential determined in these glioblastoma cell cultures (MUBP, 
MUBS and MUP) are suggested to be indirectly co-ordinated by the CD44 positive cells that 
present. This is consistent with studies (Radotra, 1997; Ji et al., 2009) suggested that glioma 
invasion in vitro is mediated by hyaluronan interaction with CD44. Overexpression of CD44 
in glioma is related to invasion in which the receptor binds with hyaluronic acid (HA) in the 
extracellular matrix, leading to cells detachment induction and stimulates migration and 
invasion of glioma cells in vitro (Merzak et al., 1994; Koochekpour, et al., 1995; Radotra et 
al., 1997; Bouterfa et al., 1997; Knupfer et al., 1999; Ranuncolo et al., 2002; Ji et al., 2009). 
Therefore, the increase in the expression of CD44 observed in these glioblastoma cells may 
add to the potential migration and invasion capacity of the cells. It is possible that there 
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would have been molecular events that have modulated the migration in these primary brain 
tumour cells at any stage of growth, hence contributed to the highly infiltrative nature 
characteristic of a glioblastoma multiforme. Indeed, migration and invasion are co-ordinated 
and integrated events  identified by Liotta (1986) in the sense that extracellular matrix 
proteolysis and migration is mutually dependent. Although migration and invasion are often 
used interchangeably in the perspective of malignant gliomas, migration refers to the 
locomotive capacity of the tumour cells while invasion includes degradation of extracellular 
matrix barriers by proteases.  
It is tempting to suggest that the angiogenesis activity detected in these two 
glioblastoma cell cultures (MUP and MUTC) may be due to the role(s) of CD44 that 
measured in flow cytometry assay. Indeed, CD44 is also responsible for mediating 
angiogenesis indirectly in addition to its role in promoting invasion in glioma cells.  It is 
possible that CD44 positive cells detected in all four primary brain tumour cells studied may 
have produced high amount of hyaluronic acid (HA). As one of the main components in the 
extracellular matrix of the brain, high production of hyaluronic acid provides hydrated spaces 
that support glioma cell migration and angiogenesis. Both processes are under the tight 
regulation of a balance between stimulating and inhibiting factors. This is supported by a 
number of studies on CD44 positive glioma cells that interacts with hyaluronic acid produced 
angiogenesis in vivo and further promoted tumour establishment (Wiranowska et al., 2010; 
Onishi et al., 2011; Park et al., 2012). It is feasible that there is an association and alteration 
of glioma environment which requires a complex cross-talking between endothelial and 
tumour cells, extracellular matrix components, and cellular elements of the host 
microenvironment.  
From the flow cytometry analysis, MUBP cells have high level of beta-1-integrin and 
CD44 level. As demonstrated in a glioma study, it appears that integrins are fundamental in 
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the process of tumour cell invasion, in which perturbation of integrin function can inhibit 
invasion in vitro. Integrins are crucial for cell invasion and migration, not only for physically 
tethering cells to the matrix, but also for sending and receiving molecular signals that regulate 
these processes (Rooprai et al., 1999). This may mean that there is a possible interaction 
between the two protein families on promoting invasion activity in the glioblastoma cells. In 
comparison, MUBS and MUP cells showed high level of CD44 expression (as with MUBP 
and MUTC), but the level of beta-1-integrin was much lower. However, these cells showed a 
high invasive capacity as measured via in vitro invasion assay. Hence, the level of beta-1-
integrin was greatly varied among cell cultures studied. It could be suggested that the 
invasive capacity possessed by these two cell cultures (MUBS and MUP) was promoted by 
beta-1-integrin which was highly expressed in the immunocytochemistry analysis.  
In addition, previous studies have indicated that beta-1-heterodimers are over-
expressed in glioma primary cultures. Blocking its function with specific antisera decreased 
the ability of glioma cells to adhere to, and invade through many different extracellular 
matrix proteins in vitro (VanMeter et al., 2001). Furthermore, increased expression of certain 
integrins and of CD44, has been associated with glioma malignancy hence play a role in 
migration of gliomas in vitro (Giese and Westphal, 1996; Rooprai et al., 1999; Stivarou and 
Patsavoudi, 2015).  
Among the eight Beta sub-units integrin members, Beta-1 is the most important one 
to glioma biology in which its expression has been correlated with the invasive behaviour of 
glioma (Paulus et al., 1996). An altered integrin expression was suggested to contribute an 
influence on the development of the malignant phenotype via many fundamental processes 
which include proliferation, resistance to apoptosis, genomic instability, MMP expression 
and invasion (Jones, 1999). Previously, it has been reported that neutralizing antibodies 
directed towards beta-1-integrin result in suppression of glioma migration in vitro (Tysnes 
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et. al., 1996). In vivo overexpression of beta-1-integrin in rat glioma cells (C6) implanted 
intracranially into the brain of nude mice leads to diffuse invasion in the brain (Paulus et.al, 
1996). Integrins, cell surface receptors mediate the physical and functional interactions 
between a cell and its surrounding extracellular matrix (ECM). Hence, its role has been 
ascribed to anchoring cells to the ECM. Indeed, the role of specific integrins in 
tumourigenesis has been demonstrated in numerous cancer types which include breast and 
lung cancer (Taherian et al., 2011; Morello et al., 2011). Integrins, such as beta-1-integrin, 
due to their location on the cell surface and interactions with the extracellular matrix 
proteins, are known to be ideal candidates to mediate both migration and invasion. 
As in these primary brain tumour cell cultures, none of them expressed GD3 as 
demonstrated via immunocytochemistry. GD3 belongs to gangliosides that are normally 
present at high concentration in the brain and ubiquitous in the body but over-expressed in 
malignant gliomas (Berra, 1985; Gaini et al., 1988; Ohkawa et al., 2015) in which correlates 
with the degree of biological aggressiveness.  A study (Koochekpour, 1996) has shown that 
100% positive in immunoreactivity in GBM but only 70% in grade III gliomas. GD3 is 
clearly seen in the perivascular areas including cytoplasm and endothelial cells. This may 
suggests that GD3 expression is correlated well with the degree of malignancy and potential 
involvement in neovascularization.  
Neovascularization or angiogenesis is a hallmark in gliomas when GD3 was 
suggested to be a potent stimulator of VEGF release in human glioma cell lines and 
demonstrated to be highly expressed in hypervascularised areas of high grade gliomas 
(Koochekpour and Pilkington, 1996). However, acetylation of GD3 (addition of an acetyl 
group to the terminal sialic acid of GD3) by specific sialate -9-0-acetyl transferase renders 
apoptosis not to occur and reversal of it made the cells undergo apoptosis (Birks et al., 2011). 
It is possible that GD3 in these cells is either not being expressed or have been acetylated 
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thus resulted to GD3 negative cells detected in these glioblastoma cells. Therefore, in 
addition to the proposed non-apoptotic mechanisms that may have occurred (as discussed), 
acetylation or particularly the absence of GD3 in these glioblastoma cells may have resulted 
apoptosis not to take in place as demonstrated by Annexin V staining via flow cytometry. 
GD3 is a major ganglioside constituent of the embryonic brain that mediates migration as 
well as inducing apoptosis in the progenitor cells (Ogiso et al., 1991).  Increase of GD3 in a 
variety of cell lines has been shown to facilitate apoptosis to occur  which includes direct 
interaction with the mitochondrial permeability transition pore (MPTP), enhanced production 
of reactive oxygen species, suppression of the NFκ-B survival pathway, and promotion of 
CD95/Fas-mediated apoptosis (Colell et al., 2001; Chakrabandhu et al., 2008).  
Our results have also demonstrated that MMP-14 was highly expressed in one of the 
glioblastoma cell culture, MUTC, by two-fold from that detected in normal brain cells (Fig 
26, section 3.5.2 in results chapter). The other three primary brain tumour cells were either 
similar to MMP-14 measured in the normal brain cells or low in the expression of MMP-14 
suggesting that  they were not as invasive as MUTC. However, via invasion assay in vitro, 
MUTC cells that were found to show high MMP-14 in immunostaining (flow cytometry) 
were not invasive as compared to normal brain tumour cells. Moreover, MUTC level of 
invasion remained unaltered before and after treatment of curcumin. The remaining 
glioblastoma cells (MUBS, MUBP and MUP) expressed low level of MMP-14 as measured 
by flow cytometry, but in contrary, high level of invasion activity was detected in the in vitro 
invasion assay. Thus, to suggest that MMP-14 is inversely related to the invasion activity in 
cancer cells is somewhat contradict to what have reported in other studies. Overexpression of 
MMP-14 in human glioma samples was determined by several studies which include MMPs 
expression (including MMP-14) in both primary cells and established cell line of 
glioblastoma (Fillmore et al., 2001;Hagemann et al., 2010; Hagemann et al., 2012). Other 
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studies have shown that MMP-14 is expressed highly in tumour samples derived from higher 
grades of malignancy (Van Meter et al., 2001; Fillmore et al., 2001). MMP-14 mRNA level 
was significantly higher in malignant glioblastomas as detected via Northern blot and real-
time PCR analysis but it was not detectable in normal brain tissues (VanMeter et al., 2001; 
Nakada et al., 1999; Nakada et al., 2001; Nuttall et al., 2003). 
Membrane type matix metalloproteinase (MT1-MMP or also known as MMP-14) is 
involved in different pathophysiology of gliomas which include not only invasive property of 
the malignant gliomas but also angiogenesis activity of the tumour (Forsyth et al., 1999; 
Deyrugina, Soroceanu and Strongin, 2002; Deyrugina and Quigley, 2015).  A correlation 
between MMP-14 and MMP-2 has long been established when a previous study showed that 
U251MG glioma cells transfected with MT1-MMP resulted in cell surface expression of 
MT1-MMP and constitutive activation of MMP-2. MMP-14 transfectants also caused 
increased migration in spheroid outgrowth assays and this effect was enhanced on collagen 
than fibronectin and vitronectin (Deyrugina et al., 1997). Furthermore, it is well documented 
that high levels of MT-MMPs, such as MMP-14 are expressed by gliomas and promote 
MMP-2 activation hence playing a role in the regulation of invasiveness (Nakada et al., 2001; 
Hakulinen et al., 2008).  
Therefore, with respect to MMP-14 correlation with invasiveness of glioma, our 
immunostaining (flow cytometry) finding is not in agreement with the invasion activity 
detected via in vitro invasion assay.  The reason for this is not immediately apparent but can 
be the subject of future investigations. Lower passage of cell cultures may be used in future 
as it may contribute towards changes in the expression of MMP-14 when passaged 
continuously. A comparative study (Hagemann et al., 2010; Hagemann et al., 2012) between 
established cell line and primary cells suggested that there is a large variation in the MMPs 
expression which are changeable with duration of cell culture and are highly dependent of 
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cell culture conditions and cell-density. This complex microenvironment of GBM 
pathogenesis is still ambiguous, and it is appealing to speculate that depending on the 
environment, glioma cells will upregulate different MMP members to help achieve their 
growth. Such example is from a study on a glioma invasion which suggested that glioma cells 
exploit their astrocyte environment for the production and activation of MMP-2 which 
resulted to the increased ability of glioma cells to invade (Lee et al., 2003). Thus, it may not 
be MMP-14 as the only factor that responsible towards invasive characteristic of the 
glioblastoma cells studied seen in the invasion assay. 
Vascular endothelial growth factor (VEGF) pattern seen in this study is similar to the 
pattern of MMP-14 level of expression. Three of the glioblastoma cell cultures studied, 
except MUTC cells were low in the VEGF level compared to normal brain cells thus suggests 
that they are non-angiogenic. Perhaps, their angiogenic capacity may not solely depend or be 
attributed by the level of VEGF expression but other factor such as CD44 as discussed 
earlier. Not only responsible for angiogenesis, VEGF also have a role in mediating invasion 
activity in tumour cells. From our results on invasion assay in vitro, it is suggested that high 
invasive capacity measured in the three glioblastoma cells (before reduced by curcumin 
treatment) was due to the low level of VEGF that detected in the flow cytometry analysis. 
This finding is consistent with other studies when inhibition of VEGF signalling has been 
reported to increase the invasiveness and metastasis in some preclinical models (Rubenstein 
et al., 2000; Casanovas et al., 2005; Ebos et al., 2009; Paez-Ribes et al., 2009).The 
mechanism of the aggressiveness is speculative but participating factors could increase the 
expression of c-Met, the tyrosine kinase receptor for hepatocyte growth factor (HGF). These 
findings are supported by the recent discoveries made in glioblastoma and pancreatic cancer 
studies. 
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With respect to MUTC cells, our results showed that high level of VEGF was 
detected in flow cytometry analysis when low invasive capacity was measured using in vitro 
invasion assay. It has been reported that VEGF expression is strongly associated with tumour 
aggressiveness and early relapse which indicates poor prognosis and shorter survival of 
glioma patients (Bergers, 2003; Hardee, 2012). However, there is also a recent report that 
suggested that an overexpressed VEGF suppresses invasion in glioblastoma which provides 
some initial benefit for patients (McCarthy, 2012). Although this is specifically applied for 
patients with glioblastoma who express both mesenchymal-epithelial transition (MET) factor 
and Vascular Endothelial Growth Factor Receptor 2 (VEGFR2), this mechanism of 
suppression in invasion was also experienced in pancreatic cancers which not only slows 
tumour growth but also decreases invasion and metastasis by concurrent inhibition of c-Met 
and VEGF signalling (Sennino et al., 2012). However, it is not known whether MUTC cells 
express both factors (MET and VEGFR2) in order to have this benefit.  
In glioblastoma multiforme cells, it is understood that the balance of angiogenic 
growth factors is resulted from both activation of oncogenes and inactivation of tumour 
suppressors which then responsible for the up-regulation of pro-angiogenic pathways 
(Gatson, 2012).  It has been reviewed that solid tumour survival is dependent on 
angiogenesis which is new blood vessels formation where they gain nutrient and oxygen 
from and occurs in the presence of angiogenic factor such as vascular endothelial growth 
factor (Merzak, 1997). Thus it is suggested that, inhibition of VEGF in malignant glioma 
patients has withholds tumour recurrence together with impressive radiological responses 
and reduction in peritumoural oedema (Stupp, 2012).  Such inhibition is through the 
treatment with the anti-VEGF monoclonal antibody bevacizumab, which delays progression 
and prolongs survival of some patients but results in increased vascular co-option (an 
alternative way to obtain blood vessels through pre-existing vessels).  
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VEGF is an endothelial cell-specific mitogen that induces not only angiogenesis and 
permeabilization of blood vessels in vivo but also a central role in the regulation of 
vasculogenesis (Neufeld et al., 1999). Its normal functions include forming new blood vessels 
following injury and during embryonic development. However, deregulation of VEGF has 
been reviewed in many cancers which resulted to the development of solid tumours by 
promoting tumour angiogenesis and inhibition of VEGF signalling that abrogates the 
development of a wide variety of tumours. For  instance, it was reported previously (Neufeld, 
1999) that VEGF is abundantly expressed in glioma cells which reside along necrotic areas 
and this expression is potentiated in response to hypoxia, by activated oncogenes, and by a 
variety of cytokines. 
As demonstrated in this study, the invasive or angiogenic capacity of these 
glioblastoma cells investigated may not be attributed to one common factor as has been 
reported before, but perhaps an integration of many factors that overlapping in functions. 
MMP-14 that is well known for its contribution in promoting invasion may not be always the 
case as CD44 or NG2 are also have indirect roles in mediating invasion and angiogenesis of 
the cells. The network signalling transmitted by these factors in the microenvironment is 
made more complex by the addition of beta-1-integrin with a role that correlates with the 
invasive behaviour of glioma cells, VEGF that facilitates both angiogenesis and invasion and 
GD3 with a role in promoting apoptosis.  
The reliability of flow cytometry technique against Enzyme-Linked ImmunoSorbent 
Assay (ELISA) in detecting antigen’s expressions could be arguable as both have pros and 
cons in their system. This study used flow cytometry technique as part of collaboration with 
Cancer Research UK as well as a continuity and expansion to previous studies (Rooprai et al., 
2001; Rooprai, Christidou and Pilkington, 2003; Rooprai et al., 2007; Abdullah Thani et al., 
2012). Indeed, flow cytometry technique has been chosen to be the standard analysis but for 
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different potential therapeutic agent being studied. Flow cytometry provides thousands of 
cells thus consistency is reliable hence resulting to data that are only cell based. ELISA, 
which gives a single optical density, requires less cell numbers thus provides more replicates 
for each assay. Indeed, both techniques are equally manageable but a selection is important 
thus flow cyometry was chosen over ELISA.  
 
Heterogeneity of glioblastoma cells contributes to sophisticated expression of markers and 
varied population doubling time 
In this study, our result in cell morphology showed that, compared to normal brain cells, the 
human glioblastoma cells were heterogenous with different subtypes of varying shapes and 
sizes seen in a population of cells. It is suggested that the heterogeneity of the astrocytes may 
be greater than previously thought and this will become evident as molecular markers 
become more sophisticated. This is likely to impact on ideas about how astrocytes are 
involved in both health (normal astrocytes) and disease (glioblastoma which is astrocyte 
origin) (Nedergaard, Ransom and Goldman, 2003).  The morphology of normal human brain 
cells is more homogenous in nature compared to that of malignant gliomas. CC2565, which is 
a normal human astrocytic cell line, has clearly depicted more the unicellular morphology of 
the brain cells. As seen in the photomicrograph (Figure 16A) in the result chapter, the 
morphology of CC2565 cells was identical in one population of cells and uniform in the 
shape and size of the cells. Further sub-culturing of CC2565 may have developed increased 
homogeneity of cell populations which was also observed in a study of glioblastoma cells 
(Parker and Pilkington, 2006). 
However, unlike normal brain cells, glioblastoma cells showed variability in cell 
morphology (fig 15, section 3.1). It was also demonstrated that astrocytic gliomas exhibited 
not just heterogeneity as seen in the morphology, but also the molecular heterogeneity. This 
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molecular heterogeneity provides potential targets for developing molecular targeted 
therapies (Huang, et al., 2009). Such information has an impact on the glioma management. 
These include consequences that are reflected in the in vitro phenotype such as in the growth 
rate and sensitivity towards chemotherapeutics (Yung and Shapiro, 1982) and the therapeutic 
resistance of the tumours to treatment which partly contributed by distinct intratumoural 
cellular heterogeneity (Hamerlik, Rich and Lathia, 2013).  
Glioblastomas are extremely malignant neoplasms which have a high mitotic rate, 
often comprising pleomorphic astrocytic cells with marked nuclear atypia and necrosis 
(Pilkington, 2001). Indeed, Glioblastoma Multiforme was named due to its extreme 
variability in cell morphology and it shows a great variety from patient to patient (Salcman et 
al, 1995).The word “multiforme” derives from the tumour’s varied morphological features 
and heterogenous population of cell that present within a single tumour bed. This term 
represents the histopathologic description of lesions with a high degree of cellular and 
nuclear polymorphism. Moreover, cells size and shape in glioblastomas are ranged from 
small, undifferentiated with hyperchromatic nuclei and numerous multinucleated giant cells 
which coexist with areas of high cellular uniformity (Kleihues, 2000; Kleihues et al., 2007; 
Ohgaki and Kleihues 2013). In addition, pseudopallisades are associated with necrosis and 
constantly being a significant feature in GBM (Salcman et al, 1995; Rong et al., 2006). It also 
distinguishes GBM from lower grade astrocytomas, signalled a transition to more aggressive 
behaviour of brain tumour hence incorporated in the pathologic definition (Wippold et al., 
2006). Indeed, glioblastoma is heterogenous in characteristic compared to other tumours and 
numerous studies have demonstrated that cells within a glioma differ not only in morphology 
but also in their genetics and biological behaviour. For example, it was demonstrated that 
over-expressions of epidermal growth factor receptor (EGFR) in heterogenous tumour of 
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glioblastoma activated interclonal communication which resulted to an enhancement of the 
tumour growth (Bonavia et al., 2011). 
The heterogeneity seen in these glioblastoma cells likely reflects the individuality of 
the tumours of origin and genotypes as well as the capacity for a range of phenotypic 
expression of the cells. In addition, the biopsy reports of these four primary brain tumour 
cells were different from each other in their histological sections review. Although all four 
showed typical features of glioblastomamultiforme, i.e. vascular proliferation or necrosis 
with mitoses and nuclear pleomorphism, the other histological differences noted may 
contribute to the variation of cytological features and patterns in each primary brain tumour 
cell cultures. These variations reported include chromosome 1p19q deletion, the presence of 
some occasional giant cells and addition of gemistocytic astrocytes (see biopsy reports in 
appendix). Unfortunately, with regards to the pathology reports obtained from King’s College 
Hospital (the origin of the GBM cells, biopsy-derived), no other information was given 
(unless written in the report). Moreover, it is now impossible to get additional information as 
it may not have been necessary to have the data routinely at King’s College Hospital at the 
time. Additional information such as EGFR, PDGFR etc. was not available previously (at 
time the reports were given) but may be added in future for the purpose of research.  
Taken together, the difference noted in the morphology between normal brain and 
glioblastoma cells studied may suggests that there is a relation between the heterogeneity 
seen with the findings seen in the cell kinetics studied (population doubling time (PDT) 
assay) and variation in the antigenic expressions determined. Our population doubling time 
results showed that all four primary brain tumour cell cultures studied had relatively longer 
population doubling times, up to 208 hours but normal brain cells took only 40 hours to 
double in number (Fig 16). Unlike primary brain tumour cell cultures that are heterogenous, 
homogenous established glioma cell lines that have been investigated which include U373 
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and IPSB-18 had shorter population doubling time of 48 and 16 hours, respectively 
(unpublished data). As a result, the heterogeneity seen in these primary brain tumour cell 
cultures may explain the increased population doubling time compared to normal brain cells. 
In a population of cells, a particular cell that harbours with it different phenotype and 
genotype may have different capacity of growth and proliferation rates. Hence, several 
subpopulations of cells that exist in a tumour exhibit a range of doubling times. Furthermore, 
it is suggested that, as the cells are passaged, lingering cells with the highest growth capacity 
predominantly influence the PDT in each primary brain tumour cell cultures studied.  
From our results, it is observed that the biological behaviour of these malignant 
glioma cells investigated are not straightforward but difficult to interpret not only because the 
pattern of antigens expressions in each of them are varied but also overlapping in functions to 
the cells, i.e. invasion, angiogenesis or induction of apoptosis. Primary cells derived from 
different patients can behave differently in culture conditions and this is likely to depend on 
many intrinsic factors such as genetics and age of individuals from whom the tissue was 
derived. MUBP cells were found to be invasive and had a significant level of CD44 and Beta-
1-integrin. These cells showed little or no angiogenic activity and had low levels of VEGF 
compared to the normal brain cells. It is likely that MUBP invasive activity has 
overshadowed the angiogenesis event due to strong expressions of both beta-1-integrin and 
CD44. However, MUBS and MUP cells which were also either low or similar to the VEGF 
level in the normal brain cells demonstrated increased angiogenic activity. It is possible that 
the angiogenic activity occurred in these glioma cells was not promoted by VEGF but was 
instead a consequence of high level of CD44. Significant invasive capacity was also 
measured in these cell cultures (MUBS and MUP). This activity was possibly enhanced by a 
combination of high CD44 and NG2 level that were observed. Moreover, high expression of 
CD44 that was exhibited in MUP cells may responsible for the invasive potential due to the 
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prominent staining seen compared to the normal brain cells. As a result, the levels of invasion 
in these two glioblastoma cells were higher than that measured in MUBP or MUTC cells. The 
latter two cultures were low in NG2 expression.  
MUTC cells expressed higher amounts of MMP-14 compared to the other cell 
cultures. As described earlier MMP-14 (mt-MMP-1) expression is associated with invasive 
cells. However, in this case it is possible that the high level of VEGF that measured in the 
cells may neutralize this effect. As discussed earlier, over-expression of VEGF, suppresses 
invasion in glioma-expressing MET and VEGFR2 hence reduced in the protease level such as 
MMP-14 in the cells. Although this is not yet known for sure, there is a possibility that both 
factors may have been expressed in MUTC cells which warrants further investigation.  
Conclusions  
Taken together, glioblastomas as with other cancers are the results of an accumulation of 
genetic alterations, leading to the activation of oncogenes and/or the inactivation of tumour 
suppressor genes. Thus, in this study, these malignant gliomas may have their messenger 
RNAs (mRNAs) translated into proteins from the abnormal or altered genes, leading to 
aberrant expressions of some critical proteins.   
As seen in this study, the complexity of mixed antigenic expressions yet overlapping 
in functions in the tumour cells indirectly suggests that not a single but an integrated role of 
antigens are responsible for a specific functions in tumourigenecity of the cells. Indeed, other 
findings from other assays of different antigen expression, invasion and angiogenesis are of 
relevance. One marker might indicate one specific biological behaviour of the cells but this is 
not always the case in the complex microenvironment of glioblastoma when it is a 
heterogenous network and dysregulated in cell signalling, as with other cancers. Although 
curcumin is potentially cytotoxic to these glioblastoma cells which has also experienced by 
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the established cell line (Abdullah Thani et al., 2012), it has not induced apoptosis to occur, 
suggesting curcumin killed the cells via non-apoptotic pathway hence warrant further 
analysis on elucidating the possible pathway involved. Nevertheless, regardless the aberrant 
expression of antigens studied in relevance to invasion and angiogenesis, curcumin was 
found to have the potential in inhibiting both angiogenesis and invasion activity in these 
primary glioblastoma cells.  
To our knowledge, there are no studies that have investigated the potential therapeutic 
mechanism of lycopene (or LycoRed) in gliomas. All previous research either focused on 
animal studies or other types of human cancer. Although the therapeutic potential of LycoRed 
was not demonstrated in this study, further studies of this may be worthwhile. Thus, 
regardless of the findings that LycoRed did not kill the glioblastoma cells studied, it is 
tempting to know if it has the capability in reducing invasive capacity or inhibiting 
angiogenesis of the glioma cells. Indeed, a potential mechanism of lycopene in cancers has 
been documented not only for its well-known anti-oxidant property but also for its effects in 
modulating growth factors in cell signalling (insulin growth factor (IGF); platelet derived 
growth factor (PDGF); VEGF), and altering cell cycle progression in prostate cancer (Lo et 
al., 2007; Ford et al., 2011). Previous studies have also shown that lycopene has a therapeutic 
effect on breast and prostate cancers (Dorgan et al., 1998; Giovannucci, 1999; Kirsh et al., 
2006). Thus further studies of the potential therapeutic properties of Lycopene in 
glioblastoma may be worthwhile. 
Further studies of importance 
Treating primary brain tumours has unique challenges such as its difficult access to the 
tumour site and heterogeneity of tumour response from one malignant glioma case to the 
next. Hence a larger scale involving different analyses is required to fully evaluate the 
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potential of both lycoRed and curcumin in the prevention and treatment of glioblastoma. An 
example is a cell cycle arrest study using flow cytometry analysis which involves DNA 
replication and cell separation that consists of four distinct phases; G1 (growth and 
preparation of cells for DNA synthesis), S (DNA synthesis), G2 (preparation for mitosis) and 
M (mitosis) phases. The main regulatory molecules in the cell cycle phase are cyclins and 
cyclin dependent kinases (CDKs) which play major roles in verifying (checkpoint) that every 
requirement has been met before the cell cycle is allowed to proceed to the next step, in 
which deregulated in cancer cells.  
One approach is a single time point measurement of cells when it is based on 
measurement of DNA content of the cells following cell staining with fluorescent dye such as 
PI or 4’6’-diamino-2-phenylindole (DAPI), with the addition of ribonucleic acid polymerase 
A (RNase A) as to remove RNAs from the cells thus preventing from creating artefacts that 
would distort the results. As a result, the fluorescence intensity of the stained cells reveals 
distribution of cells in three major phases of the cycle (G1 vs S vs G2/M) and makes it 
possible to detect apoptotic cells with fractional DNA content (Pozarowski and 
Darzynkiewicz, 2004). Cell cycle assay is also related to the expression of cyclin D, cyclin E, 
cyclin A, orcyclin B1 vs DNA content. This allows one to distinguish, for example, G0 from 
G1 cells, identify mitotic cells, or relate expression of other intracellular proteins to the cell 
cycle position. Another approach relies on the detection of 5'-bromo-2'-deoxyuridine (BrdU) 
incorporation to label the DNA-replicating cells. Such examples have involved cell cycle 
analysis in cancer studies associated with flavonoids as the agents of treatment. A study 
demonstrated that treatment with resveratrol led to G1 phase cell cycle arrest in bladder 
cancer cells by downregulation of cyclin D1, cyclin dependent kinase 4, activation of p21 and 
retinoblastoma protein (Rb) that phosphorylated (Bai et al., 2010).  
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Another flavonoid study on quercetin demonstrated that the viability of cervical 
cancer was suppressed by quercetin in a dose dependent manner with cell cycle that arrested 
at G2/M phase (Priyadarsini et al., 2010). Therefore, cell cycle analysis via flow cytometry 
would confirm the non-apoptotic event seen in our Annexin V results thus leading to the 
identification of possible modulation or activation either pro- or anti-apoptotic molecules that 
might have occurred. 
Another approach in targeting apoptosis occurrence is via cleaved caspase 3 assay via 
flow cytometry technique. Indeed, modulating apoptosis via caspase family of proteins is one 
obvious target and commonly emphasized in apoptosis analysis. Caspases (cysteine-aspartic 
acid-specific proteases) are one of the molecular players involved in programmed cell death. 
Activation of caspases from its inactive state (inactive zymogen) via transcatalytic cleavage 
and followed by assembly of the product post cleavage is considered to be the point of 
detection. Caspase 3 is a well-characterised effector in apoptosis. Most caspase-3 substrates’ 
recognition site is DEVD (the single-letter code for amino acid is used) where cleavage 
occurs after the second D (Thornberry et al., 1997). This polypeptide (DEVD) is linked to 
rhodamine-110 (a fluorescent). The non-fluorescent bis-substituted peptide derivatives of 
rhodamine 110 are intracellularly cleaved to green fluorescent monosubstituted rhodamine 
110 and free rhodamine 110. This green fluorescent is measured in intact cells (as these 
substrates are cell-permeable) upon excitation with 488nm laser light of the flow cytometry 
(Ormerod et al., 2005). 
To expand the research of curcumin or LycoRed therapeutic effects on glioblastoma, 
an additional to cell cycle assay would be western blotting (WB), an assay at the protein 
level, which is commonly in association with real time polymerase chain reaction (RT-PCR) 
analysis. It is well established and straightforward in the interpretation. Western blotting 
allows the proteins in a complex sample such as in solid tumour of a glioblastoma (30 µg 
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lysates) to be separated according to molecular weight and visualized within a gel matrix 
and/or, once separated, transferred onto a supporting membrane, where they may be probed 
for the binding of antibodies or lectins. A glioma study using established cell lines has 
demonstrated the expressions of EGFR and matrix metalloproteinases which suggested being 
responsible as causative factors in mediating glioma malignancy (VanMeter et al., 2004). 
Another quantitative assay would be Real Time-Polymerase Chain Reaction (RT-PCR) when 
the expression of mRNA of each factor studied would be able to be identified at the 
molecular level as detected in another glioma study (Hagemann et al., 2010). In relation with 
WB and other protein detection assays, with RT-PCR, the factors that suggested having roles 
in the progression of gliomas may be determined at early stage thus assisting in elucidating 
the prevention and therapeutic potential of either curcumin or LycoRed.  
In recent years, epigenetic alterations in glioblastoma multiforme have been a great 
interest in diagnosing the potential prognostic and response factors towards treatment. 
Alterations in the chromatin structure and/or DNA methylation without changes in the DNA 
sequence (Henikoff and Matzke, 1997), epigenetic mechanism in normal cells regulates many 
cellular processes such as cell differentiation and memory formation. However, disruption of 
epigenetic processes can lead to altered gene function and malignant cellular transformation. 
In the state of diseases such as cancers, epigenetic modifications comprises of DNA 
methylation, post-translational histone modifications (acetylation, methylation, 
phosphorylation, ubiquitination, sumoylation) and regulation of gene expression by non-
coding (nc) RNA including microRNA (Stilling and Fischer, 2011; Choudhuri, 2011). 
Epigenetic alterations in glioblastoma have involved many genes such as O6-methylguanine 
methyltransferase (MGMT) and mutL homolog 1(MLH1) that function in DNA repair, 
p14ARF (p14), cyclin dependent kinase inhibitor 2B (p15/CDKN2B) and retinoblastoma 1 
(RB1) that play roles in cell cycle regulation.  For an instance, DNA methylation of MGMT 
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is frequent in glioblastoma multiforme when it is associated with increased number of 
mutations and poor outcome hence considered a biomarker of poor prognosis (Komine et al., 
2003). In contrast, it has been reported that GBM patients with methylated MGMT respond 
more positively to temozolomide (TMZ) than patients with unmethylated MGMT (Hegi et 
al., 2005; Balana et al., 2008). In the unmethylated MGMT, the DNA repair enzyme 
(MGMT) removes methyl groups from the O6-position of guanine and the expression of 
MGMT is therefore thought to inhibit the cytotoxic effect of TMZ. A recent study (Costa et 
al., 2010) has reported that there is no association between MGMT promoter methylation and 
the outcome of GBM treated with TMZ hence additional robust and consistent studies are 
warranted to clarify this information particularly to use MGMT status in clinical decisions.  
The initiation and progression of cancer, is now realized to involve epigenetic 
abnormalities along with genetic alterations which can substitute for genetic variation later in 
tumour progression. Therefore, it is important not only to find the key molecular targets that 
responsible for the initiation of tumourigenesis but also to identify whether curcumin or 
lycopene may act as inhibitors towards histone deacetylases and histone methyltransferases in 
improving the current poor prognosis of GBM. These may be facilitated by Histone 
Methyltransferase and Deacetylase Assays involve the incubation of histone reaction 
mixtures with curcumin or lycoRed concentrations which then resolved on 15% SDS-PAGE, 
and subjected to fluorography followed by autoradiography. This has been demonstrated in a 
cervical cancer cells when histone modifying enzyme (p300/CBP) was inhibited by 3-fold at 
100µM of curcumin (Blasubramanyam, et al., 2004). It has also been shown that exposure of 
human hepatoma cells to curcumin led to a significant decrease of histone acetylation at a 
range of 50-100 µM of curcumin (Kang et al., 2005). No study has investigated the effect of 
lycopene (lycoRed) on histone acetylation. However, there are studies that have demonstrated 
a role for lycopene inducing cell cycle arrest through certain CDKs that decreased in 
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expression. Inactivated CDKs deactivated Rb phosphorylation which resulted to inhibition in 
histone acetylation and transcription of genes (Karas et al., 2000; Nahum et al., 2001; Hwang 
and Bowen, 2004).  
With combination of these assays for future studies together with other relevant 
available assays, the potential therapeutic benefits of curcumin or LycoRed on GBM may be 
fully discovered and our limitations in understanding on complexities of glioblastoma 
multiforme may be improved. 
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